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Chapter 1: General introduction
Osteoarthritis – epidemiology
Osteoarthritis (OA) is one of the most disabling diseases in the Western world. The majority of individuals over the age of 65 have radiographic and/or clinical evidence of OA (1), which can affect hands, knees, hip and the spine. Symptoms include pain, stiffness of the joints, impaired mobility as well as signs of 
inflammation (2). Although OA pathology is very rarely a direct cause of death, the impact on quality of life is of particular importance. Hip and knee OA are ranked as the 11th highest contributor to global disability and the years lived with disabilities (YLDs) of OA, a parameter for the quality of life, accounts for 2.2% of total YLDs worldwide (3). The primary etiology of the disease remains 
unknown, however, several risk factors have been identified of which age is the most important one. Other risk factors include abnormal loading, obesity and genetic predisposition (4, 5). Due to the growing obesity epidemic as well as the increasing age, OA incidence is likely to rise considerably in the years to come (6). Current therapies for OA consist mainly of increasing mobility and controlling pain, while for end-stage OA patients health practitioners often revert to joint replacement (7). 
Osteoarthritis – pathogenesis 
Important pathophysiological characteristics of OA are, osteophyte formation, synovial thickening and foremost cartilage damage or even loss of cartilage (Figure 1). The progressive loss of articular cartilage leads to direct contact of bone on bone resulting in chronic joint pain and movement disabilities. Healthy articular cartilage can absorb stress and provides a smooth surface for low-friction movement of the joint. To do this, the articular cartilage consists of a 
unique extracellular matrix, mainly consisting of collagen type II fibers and the proteoglycan aggrecan. In this matrix, chondrocytes are embedded which balance the cartilage matrix turnover by anabolic and catabolic actions (8). One view on the cause of osteoarthritis is a failure by the chondrocytes to maintain the balance between anabolism and catabolism. A shift towards increased catabolism by 
chondrocytes can lead to release of pro-inflammatory factors: cytokines, damage associated molecular patterns (DAMPs)) and/or catabolic enzymes like matrix metalloproteineases (MMPs) or ADAMTSs (a disintegrin and metalloprotease 
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with thrombospondin motif) causing enhanced matrix degradation. Two major catabolic players thought to be involved in cartilage erosion during OA are MMP-13 and ADAMTS-5 (9, 10).
 
Other important structural changes in OA include increased subchondral plate thickness and formation of new cartilage and bone at the joint margins (osteophytes) and at tendons and ligaments (enthesophytes) (1, 11). Osteophytes or enthesophytes are cartilage-lined bony outgrowths that cause pain and limit movement in OA. Osteophytes are thought to arise from mesenchymal stem 
cells present in synovial lining and periosteum and are highly TGF-β and BMP-
2 dependent (12, 13). Their development resembles endochondral ossification 
with phases of chondrogenesis, chondrocyte hypertrophy and calcification of the cartilage matrix (11, 14).
Synovial activation in osteoarthritis
Although the main focus of OA research has been on the articular cartilage and the therein residing chondrocytes, recent evidence points to the involvement of multiple tissues in the pathophysiology of OA. Pathological changes in surrounding tissue such as the synovium, bone, ligaments, subchondral bone or even musculature and meniscus have prompted clinicians and researchers to 
Figure 1: Pathophysiological changes in OA. On the left a healthy joint is depicted, whereas on the right a joint with osteoarthritis, with synovial thickening, cartilage damage and loss and osteophyte formation 
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view OA as a “whole joint” disease (15). One major focus is on the involvement of 
synovial inflammation or activation in OA (16). The synovium, the lining tissue of the joint capsule, consists of the intima layer containing type A macrophage-
like cells and type B fibroblast-like cells and a much thicker subintima layer containing loose collagenous tissue and blood vessels. The synovium produces lubricating substances for the joint cavity and nourishes the cartilage. During OA, the intima can become thickened containing mainly monocytes/macrophages expressing an activated phenotype. Up to 50% of OA patients exhibit synovial activation as assessed by arthroscopy (17) and presence of synovitis, measured by MRI, can predict cartilage loss (18). It is thus becoming clear that OA is not 
one single disease and that synovial inflammation might be used as parameter to classify OA phenotypes (19). A schematic representation of three major hallmarks of OA, cartilage damage/loss, osteophyte formation and synovial activation or thickening, is depicted in Figure 1.
Macrophages in osteoarthritis
On histology, OA synovium shows hyperplasia of the lining and inflammatory 
infiltrate, mainly consisting of fibroblasts and macrophages (20, 21). Fibroblasts, long thought passive, have demonstrated capabilities of stimulating innate 
immune reactions in the synovium. Synovial fibroblasts express several Toll-like receptors (TLRs) and quickly upregulate cytokines and MMPs when stimulated with LPS (22). Macrophages have been shown to be of pivotal importance in OA. They are main producers of cytokines like IL-6 and IL-8 and enzymes MMP-1 and -3 (20). Moreover, depletion of synovial macrophages during experimental OA severely reduces cartilage damage and osteophyte formation (23, 24). 
Macrophages can be crudely divided into two sub-types; the pro-inflammatory 
M1-macrophage and the alternatively activated and less inflammatory M2-macrophage (25, 26). Presence of both subtypes has been proposed during synovitis and OA, however, their exact effect on OA pathogenesis remains enigmatic (27, 28). 
Mediators of synovial activation in osteoarthritis
As a result of the synovial activation during OA, multiple mediators of innate 
immunity are released in the synovial fluid by macrophages, like adipokines and prostaglandins/leukotrines (29-31). Also the complement system has recently 
15
Chapter 1
been implicated in OA. The synovium of OA patients expresses high levels of several complement components and experimental OA studies with knockout mice show crucial roles of complement component (C)5, C6 and CD59a in OA development (32). Multiple studies have also reported elevated presence of 
pro-inflammatory cytokines in OA synovial tissue or fluid, among which IL-1β 
and TNF-α are the most studied (reviewed in (33)). These cytokines can again induce their own secretion, or drive the production of several MMPs, eventually contributing to cartilage damage (34). However, the exact contribution that these cytokines have on OA pathology is still a matter of debate.
Triggers of synovial activation in osteoarthritis: a major role for DAMPs 
Apart from pro-inflammatory cytokines, the synovium can also be activated by DAMPs or alarmins. These factors can be released as a result of disruption of chondrocyte homeostasis and/or mechanical derangement. Several classes of 
DAMPs implicated in innate immunity are identified within the damaged OA 
joint, which could potentially contribute to synovial inflammation (Figure 2). 
Both extracellular as well as endogenous (formed within the cell) DAMPs have been described (35, 36). Examples of extracellular DAMPs are cartilage matrix 
breakdown products like biglycan, fibronectin, low molecular weight hyaluronic 
acid and tenascin C, which can stimulate cells via TLR2 (37). Joint inflammation may lead to vascular leakage and exudation of plasma proteins that can act as 
DAMPs as well. Recently it was found that plasma proteins α1-microglobulin 
and α2-macroglobulin are capable of inducing TLR4 dependent macrophage 
production of TNFα and IL-1β (38). Other extracellular molecules that can act 
as DAMPs are microscopic inorganic crystals like basic calcium phosphate (BCP) and calcium pyrophosphate dehydrate (CPPD). They are frequently observed 
in OA synovial fluids and tissues. At the time of joint replacement nearly all joints with severe OA show cartilage deposition of calcium-containing crystals (39). Apart from extracellular, also endogenous DAMPs are formed during OA. 
Examples of endogenous DAMPs are the high mobility group box 1 (HMGB1) that signals through RAGE (40), heat shock proteins (HSPs) and the family of S100-proteins (14, 41, 42). Endogenous DAMPs lead a double life, exhibiting different roles intracellularly versus extracellularly. When secreted after stimulation of 
cells by either stress, infection or inflammation, or released from necrotic cells, these endogenous DAMPs can activate (innate) immune cells through pattern recognition receptors (PRR) such as TLRs. They can also, depending on cell type 
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and their expression of PRR, stimulate cell differentiation, cell death or further 
secretion of pro-inflammatory mediators (36, 41).
S100A8 and S100A9
The S100-protein family currently consists of 21 known members. Its first members were originally discovered in the 1960s in brain tissue and they were named after their Solubility in 100% ammonium sulphate (43). Eleven family 
members so far have been identified as DAMPs or alarmins: S100B, S100P, S100A1, S100A2, S100A4, S100A7, S100A8, S100A9, S100A12, S100A13 and 
S100A15 (44-49). S100A8 and S100A9 (also: MRP8 and MRP14, respectively) are mainly produced by granulocytes, monocytes and activated macrophages, and 
can be induced in osteoclasts, endothelial cells, fibroblasts and chondrocytes (45, 
Figure 2: Effects of damage associated molecular patterns (DAMPs) in the OA joint
Overview of effects of DAMPs or alarmins on the OA joint, focusing on fibroblasts, macrophages and chondrocytes and their production of and stimulation by DAMPs.
17
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50, 51). In neutrophils, S100A8 and S100A9 can form up to 40% of the cytosolic protein content (52). S100A8/S100A9 exists in vivo mostly as heterodimer (also termed calprotectin), but homodimers of both S100A8 and S100A9 exist 
and tetramers of two heterodimers can form under the influence of calcium and 
zinc cations (53). There is discussion concerning the pro-inflammatory activity of the different forms of S100A8 and S100A9, however preliminary evidence suggests that the homodimers are the most potent forms (51). Recently, it was 
found that the S100A8/A9 heterodimer also shows strong pro-inflammatory properties which is lost after complexing into a tetramer (Thomas Vogl, Institute of Immunology, University of Münster, personal communication). S100A8/A9 can bind calcium, a common feature of all S100-proteins (54), and intracellularly they have been shown to regulate calcium homeostasis (55). Other intracellular functions of S100A8/A9 include roles in cytoskeleton organization (56-58), fatty acid metabolism (59) and proliferation and differentiation of keratinocytes (60). 
Extracellular roles of S100A8/A9
S100A8 and S100A9 can enter the extracellular space through necrosis. Although they do not possess leader signals for classical release via the Golgi-apparatus, active release has been shown for S100A8/A9 and is tubulin and protein kinase C 
dependent (61). Once released, S100A8 and S100A9 turn into pro-inflammatory danger signals and can stimulate a plethora of cell types. S100A8 induces the acute phase protein serum amyloid A3 (SAA3) in lung endothelial cells and alveolar macrophages (62). In human keratinocytes, S100A8 and S100A9 form 
a positive feedback loop with pro-inflammatory cytokines/chemokines like 
IL-8, -6, CXCL-1, -2 and TNFα (63). S100A8 increases TNFα and augments LPS signaling in bone marrow cells (64). More recently, S100A8 and/or S100A9 
have been shown to upregulate pro-inflammatory TNFα in astrocytes, as well 
as IL-1β in interferon gamma (IFNγ) primed monocytes (65, 66). S100A8 and S100A9 stimulation of murine immature dendritic cells upregulates activation markers CD86 and MHC-II and induces proliferation of CD4+ and CD8+ T-cells (67). S100A8/A9 also induce chemotaxis (reviewed in (68)). In endothelial cells they increase IL-8 and CXCL-1 and -2 and decrease integrity of endothelial monolayers, implying increased attraction and extravasation of leukocytes (69). S100A8 and S100A9 also induce chemotaxis of phagocytes to a pre-metastatic lung (62). 
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S100A8/A9 in arthritis
It is becoming clear that DAMPs or alarmins play key roles in various (auto)-
inflammatory diseases (reviewed by (41) and (70)). S100A8/A9 are found 
elevated in a host of inflammatory conditions, among which dermatomyositis, 
systemic lupus erythematosus, atherosclerosis, psoriasis and inflammatory bowel disease (71-76) and they have been postulated as biomarkers in a similarly 
large amount of (auto)inflammatory diseases (41, 77). Most attention however has been given to the relationship between S100A8 and S100A9 proteins and arthritis. Indeed, one of the earliest observations of S100A8 and S100A9 was in macrophages of RA patients (78). S100A8/A9 is upregulated in serum and 
synovial fluid of rheumatoid as well as in systemic onset juvenile idiopathic arthritis (SOJIA) and psoriatic arthritis. (36, 79, 80). Levels of S100A8/A9 in RA 
serum go up to 40 µg/ml and in RA synovial fluid up to a spectacular 60 µg/ml, implying local production of these DAMPs in the synovium (81). Moreover, serum levels of S100A8/A9 also correlate with disease activity in RA and psoriatic 
arthritis, better than the common inflammatory parameters erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) (80, 82). In SOJIA, despite 
extensively high serum levels of IL-1β, S100A8/A9 serum levels (and not CRP) can be used for diagnosis and to distinguish SOJIA from systemic infections. In addition, S100A8/A9 can also predict development of erosive RA (83). 
Mechanisms of S100A8/A9 in arthritis
Two 2008 papers by the van Lent group have shed some more light on the underlying mechanisms of action of S100A8 and S100A9 in experimental RA (51, 84). Antigen-induced arthritis  was elicited in S100A9-/- mice. These mice lack functional S100A8/A9 complexes and can be viewed as a functional S100A8 and S100A9 knockout (85, 86). Arthritic S100A9 -/- mice have reduced joint swelling, 
as measured by technetium-99 uptake, and reduced leukocyte infiltration. Moreover, proteoglycan depletion in the cartilage was heavily reduced in S100A9 -/- mice as well as activated MMPs and chondrocyte death. The direct role of S100A8/A9 in joint damage was further established by injection of recombinant S100A8 in knee joints of normal mice. Shortly (already one day) after injection, 
pro-inflammatory cytokines and catabolic enzymes like MMPs and ADAMTSs 
were significantly upregulated, resulting in proteoglycan depletion in the cartilage. The role of the chondrocyte in S100A8/A9 mediated joint damage was 
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further studied in vitro. Murine chondrocytes stimulated with S100A8 (most potent in mouse) induced expression of IL-6 and increased activation of MMPs and ADAMTSs in a concentration dependent manner. The association of S100A8/
A9 with cartilage and bone is further confirmed by Zreiqat et al. that showed expression of S100A8 and S100A9 in osteoclasts and hypertrophic chondrocytes 
(50). In a later study, the same group also confirmed inflammatory and catabolic actions of S100A8/A9 on chondrocytes by stimulating primary adult ovine 
articular chondrocytes. Moreover, they showed the first association of S100A8/A9 with OA, as S100A8 and S100A9 expression was observed in surgically induced mouse OA. 
Osteoarthritis therapy
To date, no agent has shown to have disease modifying effects on structural 
progression in OA. Studies targeting synovial inflammation in OA patients are showing moderate promise. Corticosteroid injections have been shown to reduce 
pain in OA on the short term, however there is no evidence of long term benefits 
(87). Biologicals inhibiting cytokines involved in OA pathology, like TNFα and 
IL-1β, only have limited success. A small open label study with monoclonal 
antibodies against TNFα (adalumimab) showed only very modest improvement and a large placebo-controlled trial in patients with knee OA receiving IL-1 receptor antagonist (RA) (anakinra) intra-articularly showed no improvement in the WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) (88, 89). Mesenchymal stem cells (MSCs) could also form an interesting avenue for therapy of OA. These cells combine their regenerative capacity with 
anti-inflammatory characteristics (90) and have been successfully used in 
inflammatory diseases among which autoimmune diabetes (91), experimental autoimmune encephalomyelitis (92, 93) and rheumatoid arthritis (94). MSCs can 
produce numerous anti-inflammatory mediators, like IL-10, IL-1RA, indoleamine 
2,3-dioxygenase (IDO), transforming growth factor (TGFβ), and prostaglandin E2 (PGE2) (95). Multipotent stem cells derived from adipose tissue, adipose-derived stem cells (ASCs), have comparable differentiation capacities as MSCs and also display immunosuppressive properties in vitro and in vivo (96). An in vitro study 
with human OA synoviocytes and chondrocytes suggests an anti-inflammatory mechanism for ASCs (97). As such, ASCs may be used therapeutically in rheumatic diseases (98).
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Outline and aims of the thesis
The general aim of this thesis was to broaden our knowledge on the role of synovial activation in OA, thereby focusing on DAMPs S100A8 and S100A9. Ultimately, we aimed to investigate ways to treat experimental osteoarthritis by tackling synovitis through inhibition of S100A8/S100A9 proteins or using anti-
inflammatory ASCs.
In the first part of this thesis (Chapter 2-6), we investigated the role of DAMPs S100A8 and S100A9 in experimental and human OA. We started (Chapter 2) by mapping S100A8 and S100A9 expression in two different OA models. In the collagenase induced OA (CIOA) model synovial activation is high and involved in the pathogenesis of the disease, while the DMM model (destabilization of the medial meniscus) has considerably lower synovitis. Then, we made use of S100A9-/- mice to study the role of S100A8 (functionally absent in these mice (85, 86)) and S100A9 in synovial activation and cartilage damage in CIOA and DMM. Furthermore, in this chapter we explored the expression of S100A8/A9 in human OA synovium and their correlation with damage in the Dutch CHECK cohort (Cohort Heup En Cohort Knie) of early symptomatic OA patients. Osteophyte formation is another important pathological hallmark of OA and the effect of DAMPs or alarmins on the development of osteophytes is poorly understood. Therefore in Chapter 3, we elucidated the role of DAMPs S100A8 and S100A9 in the development of osteophytes during OA. To do this, we again made use of the murine experimental OA models CIOA and DMM in the S100A9 -/- mice. To gain more insight in the mechanisms we thereafter investigated the role of S100A8/A9 in an in vitro chondrogenesis assay, as chondrogenesis is an important phase during osteophytosis. Finally, we connected S100A8/A9 levels in early symptomatic OA patients of the CHECK cohort with osteophyte development up till 5 years later.
Chondrocytes are important effector cells in OA and they balance anabolic and catabolic activity in the cartilage. Next, we investigated the up till now unknown 
contribution of DAMPs S100A8 and S100A9 on inflammatory and catabolic capacities of chondrocytes (Chapter 4). For this study we stimulated primary human OA chondrocytes with S100A8, S100A9 and S100A8/A9 complex and 
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analyzed expression and release of pro-inflammatory and catabolic mediators. We also sought to identify the receptor(s) responsible for these effects.
Besides chondrocytes, also macrophages play a vital part in the pathogenesis 
of OA, as they can initiate and sustain a pro-inflammatory and catabolic milieu. Macrophages are a heterogeneous population of cells that can be broadly divided 
into activatory M1 and inhibitory or anti-inflammatory M2 macrophages. In 
Chapter 5, we investigated the relationship between DAMPs S100A8 and S100A9 and M1 and M2 macrophages, by looking at the production and the stimulatory capacity of these DAMPs by the two subtypes of macrophages. Furthermore, we investigated the effect of S100A9 on total OA synovial explants, containing both 
macrophages and fibroblasts, and on OA fibroblasts alone.
In the final chapter of the first part (Chapter 6), we explored blocking DAMPs 
S100A8/A9 in OA for the first time. To achieve this, we used the quinoline 
derivative compound paquinimod (ABR-215757), that has been described to 
specifically inhibit the binding of S100A9 with its receptors RAGE and TLR4. We administered paquinimod in our experimental OA mouse models CIOA and DMM and analyzed OA pathology at the end stage. Moreover, we incubated synovial explants of end-stage OA patients with S100A9 and/or paquinimod and 
investigated the pro-inflammatory and catabolic effects.
In the second part (Chapters 7 and 8), we aimed to suppress synovial activation during experimental OA by local administration of adipose derived MSCs (ASCs). In Chapter 7, we investigated the effect of a single injection of ASCs into the knee joint during different time-points of both CIOA and DMM. We analyzed synovial activation, formation of new cartilage and bone (osteophytes) and cartilage 
damage in these experimental mouse models. Also, we identified the localization of the ASCs after injection in an OA model. Next, in Chapter 8, we zoomed in on the mechanisms behind the effects of ASCs on experimental OA. To do this, we isolated and analyzed the synovium and its mediators of mice treated with ASCs at different time points after OA induction and focused particularly on the role of S100A8 and S100A9 in the healing capacity of these ASCs.
In the final chapter (Chapter 9), we summarized and discussed the results of this thesis and offered perspective on how to move forward.
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Abstract
Objective: To investigate whether alarmins S100A8 and A9 are involved in mediating cartilage destruction during murine and human osteoarthritis (OA). 
Methods: Two different murine models of OA that differed in terms of synovial activation were compared. Cartilage destruction was measured histologically. Synovial biopsy and serum samples from OA patients were derived from the Cohort Hip and Cohort Knee (CHECK) patients with symptomatic early OA. Expression of mediators in the synovium was measured by reverse transcription–polymerase chain reaction analysis and immunolocalization
Results: In collagenase-induced OA, which showed marked synovial activation, 
interleukin-1 was expressed at significant levels only during the early stages of disease, whereas S100A8 and S100A9 expression remained high for a prolonged period of time (up to day 21 after induction). In S100A9-knockout mice, we found a major impact of S100A8 and S100A9 on synovial activation (62% inhibition) and OA cartilage destruction (45–73% inhibition) as compared to wild-type controls. In contrast, in the surgically induced destabilized medial meniscus model, in which synovial involvement is scant, we found no role of S100A8 and S100A9 in the focal OA cartilage destruction. Examination of arthroscopic synovial biopsy samples from patients in the early symptomatic OA CHECK cohort revealed substantial levels of S100A8 and S100A9 messenger RNA and 
protein, which correlated significantly with synovial lining thickness, cellularity in the subintima, and joint destruction. Levels of S100A8/A9 serum protein 
were significantly enhanced (19%) at baseline in patients who had pronounced progression of joint destruction after 2 years.
Conclusions: Our data suggest that the S100A8 and S100A9 proteins are crucially involved in synovial activation and cartilage destruction during OA and that high levels may predict joint destruction in humans with OA.
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Introduction
Breakdown of the cartilage matrix is one of the hallmarks of osteoarthritis (OA). Cartilage destruction is predominantly mediated by cytokines and enzymes (1-4). During osteoarthritis a clear pericellular activation of chondrocytes is observed expressing large amounts of neoepitopes induced by metalloproteinases which drive pericellular breakdown of the matrix eventually culminating in erosion (3). Pathology that develops during OA is driven by at least three different tissues: cartilage, subchondral bone and synovium (5-6). Although OA has been generally described as a disease of the cartilage, the synovium is considered to contribute to pathology during progression of the disease (7-11). A substantial group of OA patients (up to 50%) show activation of the synovium, not only during late phases but also in early stages of the disease (8). In earlier studies we showed that activated synovial lining macrophages are crucial in regulating synovial 
inflammation and subsequent cartilage destruction during experimental OA. Selective elimination of synovial lining macrophages prior to induction of collagenase-induced OA diminished synovial activation and almost completely inhibited cartilage destruction (12).
Activated macrophages which cover the inside of diarthrodial joints produce 
a plethora of mediators, among them cytokines like interleukin-1β (IL-1β) 
(2). Although IL-1β has been considered important in mediating cartilage destruction (2,13), its role in OA is still a matter of debate. The most prominent proteins released by activated macrophages are the calgranulins: myeloid related proteins MRP8 [S100A8] and MRP14 [S100A9] (14-15). These proteins belong to the group of Damage Associated Molecular Pattern proteins (DAMPs) which are crucial in innate immunity. Both proteins belong to the S100 family of calcium binding proteins which comprises 24 members. They are expressed as homodimers and heterodimer assemblies. S100A8 is generally co-expressed with S100A9 and the heterodimer S100A8/A9 is translocated to membrane and cytoskeletal structures upon activation (16). In mice, S100A8 forms the active part whereas S100A9 forms the regulating unit which binds to S100A8 thereby preventing its degradation. S100A8 stimulates macrophages via TLR4 signalling 
(17-18). When secreted, S100A8 exhibits pro-inflammatory functions leading to activation of endothelial cells and phagocytes.
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Homodimers S100A8 and A9 and the heterodimer accumulate in inflammatory 
fluids during arthritis (18-19) and their levels correlate significantly with severity of arthritis and predicted a 10 year radiographic progression in RA patients (20). In earlier studies we found that S100A8/S100A9 is crucial in mediating cartilage destruction during experimental arthritis (21). S100A8 and A9 have recently also been described in experimental osteoarthritis (22) and S100A8 appeared to be a potent stimulator of murine chondrocytes thereby inducing a catabolic phenotype (23). The goal of the present study was to investigate whether these proteins are involved in synovial activation and cartilage destruction in experimental osteoarthritis, using two murine models which differ in degree of synovial activation. In addition, we explored the clinical relevance of S100A8/A9 in synovial biopsies and serum from participants of the early OA symptomatic CHECK cohort.
Material and methods
Animals
Experimental osteoarthritis was elicited in male C57Bl/6 mice and S100A9-/- mice backcrossed to the C57BL/6 background for 12 generations. Myeloid cells of S100A9-/- also lack S100A8 at the protein level (24). 
Induction of experimental osteoarthritis 
Collagenase osteoarthritis (CIO) was induced by injecting 5 mg of bacterial Collagenase (Sigma Aldrich, Zwijndrecht, The Netherlands) two times at alternate days into knee joints of mice (C57BL/6) which causes disruption of the ligaments and local instability of the knee joint (25). DMM osteoarthritis was induced by transsection of the medial anterior meniscotibial ligament which leads to destabilization of the medial meniscus (DMM) (26). Experimental arthritis was induced by injection of 25 μg of streptococcal cell walls (SCW) into the murine knee joint (27).
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Histology of total knee joints 
Total knee joint sections of mice were fixed, dehydrated and embedded in 
paraffin. Sections (7 µM) were cut and stained with haematoxylin/eosin (H&E) or safranin-O. H&E-staining was used to score synovial activation as thickening of the intima lining layer (number of cell layers). Safranin-O staining was used to examine and score the OA-like cartilage changes, in which both severity and extent of the lesions were incorporated. The scoring method as described by 
Pritzker et al (28) was modified to make it more suitable for measuring murine cartilage pathology. In short, the OA score is the assessment of combined OA grade and stage. Grade represents OA depth progression into cartilage and includes six grades: 1-4 involve cartilage changes only;5 and 6 involve bone as well. The stage represents the horizontal extent of cartilage involvement irrespective of the underlying grade: thereby four stage stages are distinguished: 1:<10%, 2:0-<25%, 3:25-50%,4: >50%.
Immunohistochemical detection of S100A8/A9 protein
Whole knee joint sections were incubated for two hours with 10 mM citrate (pH 6.0) and thereafter incubated for 1 hour with the primary antibody directed against S100A8 or S100A9 (made in our own facilities). Rabbit IgG antibody was used as a control. After rinsing, sections were incubated for 30 minutes with biotinylated horseradish peroxidase-conjugated goat anti-rabbit IgG (Dako, Glostrup, Denmark). Development of the peroxidase staining was done with diaminobenzidine. Counterstaining was done with Mayer’s haematoxylin (Biochemica, Amsterdam, The Netherlands).
Isolation of murine synovial specimen
At various time-points after induction of osteoarthritis, synovial specimen were isolated as described previously (29). In short, joint capsule specimens were isolated on medial and lateral sides of the patella with a biopsy punch. Synovial 
specimen were snap frozen in liquid nitrogen and stored for RNA isolation.
Preparation of RNA and RT-PCR 
RNA was isolated from synovium using TRIzol reagent according to the 
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manufacturer’s protocol (Invitrogen Corp.). Five micrograms of total RNA was 
reverse transcribed, and cDNA aliquots were subjected to PCR. RT-PCR was normalized by the transcriptional levels of GAPDH. mRNA levels of various members of the S100 family (S100B, A2, A4, A6, A7, A8, A9 and A11) and 
cytokines/ chemokines (IL-1β, IL-6, TNFα, IL-10, KC and MIP-1α) were measured in synovial specimen at various time-points after induction of collagenase-
induced or DMM osteoarthritis and were quantified using the ABI/PRISM 7000 
Sequence Detection System. 
Patients and tissue preparation 
Synovial tissue was obtained from patients with OA (n=10) who were undergoing arthroplasty. Furthermore biopsies were taken arthroscopically from participants with knee pain (n=19) that entered the CHECK cohort. Biopsies were taken from various areas of the synovium to minimize bias taken 
from inflamed tissue rather than globally. Patients undergoing arthroplasty met 
the American College of Rheumatology classification criteria for OA (30). CHECK (Cohort Hip and Cohort Knee) is a prospective cohort study of 1002 individuals with early symptomatic OA of knee or hip (31). On entry, all participants had pain or stiffness of knee or hip, and were aged 45-65 years. They had not yet 
consulted their physician for these symptoms, or the first consultation was within 6 months before entry. Participants with any other pathological condition that could explain the symptoms were excluded (e.g.other rheumatic disease, previous hip or knee joint replacement, congenital dysplasia, osteochondritis dissecans, intra-articular fractures, septic arthritis, Perthes’ Disease, ligament or meniscus damage, plica syndrome, Baker’s cyst). Joint destruction was determined at baseline and 2 years after the start of the study, using the Kellgren & Lawrence score of radiographs. The sum of the Kellgren & Lawrence score for 
both hips and knee joints was calculated. Two patient groups were defined: [1] Non-progressors. Patients that showed neither joint abnormalities (Kellgren & Lawrence=0) at baseline nor after 2 years and [2] Progressors. Patients that did not show joint abnormalities at baseline, but did show joint damage using the 
Kellgren & Lawrence score after 2 years (K&L ≥ 1). 
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Immunolocalisation of S100A8 and S100A9 protein in synovium of early 
symptomatic OA patients
Tissues were fixed in 10% buffered formalin. Five micron sections were stained with rabbit-anti-human S100A8 and S100A9 (made in our own facilities) or isotype control and then incubated with biotinylated rabbit anti-goat antibody (Dako, Glostrup, Denmark). Sections were treated with streptavidine –peroxidase conjugate (Millipore, Amsterdam, The Netherlands), color was visualized with hematoxylin.
Measurement of S100A8/A9 in sera of early symptomatic OA patients
Serum was kept at –20°C and S100A8/A9 serum concentrations were determined by a sandwich enzyme linked immunosorbent assay (ELISA) system as described previously (32). For calibration different amounts (0.25–250 ng/ml) of the native complex of human S100A8/A9 were used, which were isolated from human granulocytes. The assay has a sensitivity of <0.5ng/ml and a linear range between 1 and 30 ng/ml. S100A8 and S100A9 form non-covalently associated complexes, which are detected by the sandwich ELISA system. Therefore the ELISA is calibrated with the native S100A8/A9 complex and the data are expressed as ng/ml S100A8/A9. The serum samples were coded, and the results represent the mean of duplicates of each of three dilutions within the linear range.
Statistical analysis
Data were statistically evaluated using the Mann Whitney U test and spearman correlation. Confounding by BMI was excluded by multiple regression analysis.
Ethical approvement of experiments
All animal experiments were approved by the local ethics commission of the Radboud University Nijmegen Medical Centre (RU-DEC 2008-162). The human study was approved by the medical ethics committees of all participating centers, and all participants gave their written informed consent before entering the study.
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Results
Clear synovial activation in collagenase-induced, but not destabilized 
medial meniscus–induced, OA
In a considerable number of OA patients synovial activation is observed, characterized by a thickened intima containing hypertrophic macrophages (33). We evaluated the course and degree of synovial activation at various time-points after induction of 2 models of instability related murine OA. In control murine knee joints the synovial intima is only one layer thick, comprising type A macrophage-
like and type B fibroblast-like cells (Figure 1B,C). In the collagenase-induced OA, a clear thickening of the intima was seen (Figure 1D,E), mainly consisting of hypertrophic F4/80 vesicular type A macrophage-like cells (Figure 1H versus control Figure 1I). Thickening of the intima lining layer containing 3-12 layers was observed throughout the 42 days observation period, reaching its maximum at day 14 (Figure 1A). In contrast, in the DMM model, synovial activation was much lower than in the collagenase-induced OA and reached its maximum at day 7 only expressing an intima layer of maximal 2-3 layers consisting of type A macrophages which showed a less pronounced hypertrophic character (Figure 1F,G). 
High and prolonged expression of S100A8 and S100A9 in the synovium in 
experimental collagenaseinduced OA
We next investigated whether synovia produce S100 proteins. RNA was isolated from synovia derived from collagenase-induced knee joints at several time-points (7, 21 and 42 days after induction). mRNA levels of most S100 proteins were strongly upregulated in synovium of collagenase-induced osteoarthritis when compared to control synovium, with S100A8 and A9 being the most upregulated. At day 7 and 21 expression of S100A8 was increased 24 and 32 fold and for S100A9 16 and 64 fold (Figure 2A). Interestingly mRNA levels of S100A9 increased during the course of OA up till day 21, whereas S100A8 levels remained at a high level from day 7 to day 21. In contrast, all other S100 members had returned to low levels at day 21. 
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In addition, mRNA levels of S100 members were measured in the synovium during the course of DMM in which less synovial activation was observed. In contrast to the levels found in CIO, DMM showed only minor increases except for S100A8 and S100A9 at day 7 (Figure 2B). 
Expression of S100A8 and S100A9 protein in synovium of both OA models was further investigated using immunolocalisation. Strong expression of S100A9 (and in lesser extent S100A8, data not shown) was found in intimal layers of collagenase-induced OA at day 7 (Figure 2C) and was still detectable at day 42 (Figure 2E). No staining of S100A8 or A9 was found in the intimal layer of OA knee joints of S100A9-/- mice at day 7 after induction (Figure 2D). In contrast to the prominent expression within knee joints with collagenase-induced OA, in the DMM model, expression of S100A8 and S100A9 was almost absent within the thin intimal lining layer at day 7 after induction (Figure 2F). Staining of S100A8 and -A9 protein was negative in synovial lining of normal mouse knee joints (data not shown).
Figure 1: Synovial activation is higher in collagenase-induced osteoarthritis (CIO)  when 
compared to destabilization medial meniscus (DMM) induced murine osteoarthritis. 
Synovial activation was defined as thickening of the intimal layer. In collagenase-induced osteoarthritis, synovial thickness (3-12 layers: D and E magnification 250 and 1000X ) reached 
its maximum at day 14 after induction and was significantly higher when compared to the lining thickness observed in DMM (1-3 layers: F and G magnification 250 and 1000X ) (A). In normal mouse knee joint, the intima lining layer is only one layer thick and consisting of 
flattened cells (B and C magnification 250 and 1000X). In the CIO, the intimal lining comprised large hypertrophic cells which particularly consisted of F4/80 positive macrophages (H and I 
control (with relevant first IgG). Data were evaluated using the Mann Whitney U test. Synovial activation CIO versus DMM *P<0.05.
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S100A8/A9 expression is prolonged during collagenase-induced OA, but 
not SCW-induced arthritisNext, expression of S100A8/A9 in the synovium of collagenase-induced 
osteoarthritis was compared with that in synovium of an acutely inflamed joint. Arthritis was induced by injection of 25 μg of SCW into the mouse knee joint. Total knee joint sections show that shortly after injection, cellularity of the synovium 
was significantly higher in arthritis when compared to osteoarthritis (data not shown). At day 7 after induction, thickness of the intimal layer was comparable between the two models (Figure 3A-B). In the SCW arthritic knee joint, S100A8/A9 mRNA levels were high shortly after injection but rapidly normalized and were not detected anymore at day 7 after injection (Figure 3C). In contrast, in the OA model, although showing comparable intimal thickness at day 7, S100A8/A9 levels remained high and even increased between 7 and 21 days. This suggests that within this OA model synovial intimal lining cells are activated for prolonged 
Figure 2: High and prolonged expression of S100A8/A9 during collagenase-induced 
osteoarthritis (CIO) but not destabilization medial meniscus (DMM) induced 
osteoarthritis.Expression of mRNA levels of various members of the S100 family in synovial activation obtained at various time-points after induction of CIO (A) or DMM (B). Note that mRNA expression of both S100A8 and S100A9 in synovium of CIO remains high up until day 21 whereas other members of the S100 family were low at that time-point. In the synovium 
of DMM, only S100A8 and S100A9 were high at day 7 but waned thereafter, reflecting the thickness of the lining layer. Values are the mean and SD and were compared to normal 
synovium. Total knee joint sections were stained with specific antibodies against S100A8 and S100A9. Strong expression of S100A9 (C) and S100A8 (not shown) was found in synovial lining at day 7 but also at day 42 although less pronounced (E). Staining of lining cells was absent in 
mice deficient for S100A8/A9 at day 7 after induction of CIO (D). S100A9 expression was also absent in the lining of knee joints at day 7 after induction of DMM (F). Original magnification 
of the photomicrographs X400.
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periods of time, probably through factors released from the affected cartilage during the course of OA.
Lack of prolonged expression of IL-1β in collagenase-induced OA
Apart from S100A8/A9, we determined expression of other pro-inflammatory cytokines/chemokines which might be involved in driving synovial activation. 
Pro-inflammatory cytokines/chemokines were hardly expressed (IL-6, TNFα, 
MIP1α and KC; 16,11,7 and 5 fold increase respectively) during collagenase-
induced osteoarthritis with the exception of IL-1β and its antagonist IL-1ra which were upregulated 65 and 99 times respectively. In contrast to S100A8 
and S100A9, expression of IL-1β was already markedly reduced at day 21. (IL-
1β between 7-9 times and S100A8 and S100A9 between 30-35 and 66-69 times higher when compared to normal synovium) (Figure. 4A).
Figure 3: S100A8/S100A9 is tightly regulated in streptococcal cell wall (SCW) induced 
arthritis but expressed for prolonged periods in collagenase-induced OA (CIO). Arthritis was induced by a single injection of 25 μg of SCW. Synovial activation was measured 
in inflamed knee joints as thickening (number of cell layers) of the synovial intimal lining layer. At day 7, synovial thickness in the SCW arthritis was comparable with that seen in CIO and representative photomicrographs are shown in A (=SCW arthritis at day 7) and B (=CIO at day 7). Note that expression of mRNA levels of S100A8 and S100A9 in the synovium of SCW arthritis was highest at day 1 and at day 7, despite a strongly thickened lining layer, had returned to basic levels. In contrast in synovia of CIO, levels remained high up till day 21 after induction (C). Data were evaluated using the Mann Whitney U test (*P<0.05). Photomicrograph 
magnification X 250.
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S100A8/A9 regulation of synovial activation during collagenase-induced 
OA
We next investigated the effect of S100A8/A9 in development of synovial lining thickness using S100A9-/- mice. S100A9-/- mice have a normal phenotype whereas S100A8-/- mice are not viable (34). S100A9-/- mice also lack S100A8 protein in their myeloid cells. S100A9-/- is thus functionally a double knockout, probably due to a high turnover of S100A8 in the absence of its binding partner S100A9 (17). When collagenase-induced-OA was elicited in knee joints of 
S100A9-/- mice, significantly less thickening of the synovial lining was observed when compared to WT mice. Synovial thickness was 62% lower at day 42 when compared to OA induced in WT controls (Figure 4B-C-D). 
Figure 4: High and prolonged expression of S100A8/A9 and decreased synovial 
thickening in S100A9 -/- mice during collagenase-induced OA Expression of mRNA levels of S100A8/S100A9 is higher and more prolonged than pro- and 
anti-inflammatory cytokines in activated synovium during collagenase-induced osteoarthritis (CIO) when compared to normal synovium (A). Note that apart from S100A8 and S100A9 also IL-1 and IL-1ra were highly expressed in the synovium at day 7 after OA induction but strongly decreased thereafter and were low at day 21.  Thickness of the synovial lining layer (number of cell layers) was determined in knee joints of S100A9-/- mice and their wild type controls (WT) at day 42 after induction of CIO (B). Note that synovial thickness was significantly lower in the OA synovium of S100A9-/- mice (B and C=day 42 CIO in WT and D=day 42 CIO in S100A9-/- mice). Knee joints were stained with anti-NITEGE antibodies which recognize neoepitopes generated by ADAMTS. Clear staining was observed in the lining of day 42 CIO in WT (E) which was absent in the synovial lining of the S100A9-/- (F). Bars show the mean and SD scores from 15 animals performed in two different experiments. Values were evaluated using the Mann 
Whitney U test (*P<0.05). Photomicrographs magnification X250 (D versus WT C) or X1000 (F versus WT E).
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Synovial lining cells express enzymes like ADAMTS which cleave proteoglycans thereby leaving NITEGE neoepitopes. At day 42 after OA induction, synovial intima lining cells stained strongly positive for NITEGE neoepitopes (Figure 4E) whereas no staining was observed within the intimal lining of S100A9-/- mice (Figure 4F). In contrast, in the DMM model, in which only low staining of S100A9 in the synovium was found, only minimal synovial thickness was observed which was not different between S100A9-/- and WT mice (data not shown). 
S100A8/A9 determination of cartilage destruction in collagenase-induced, 
but not destabilized medial meniscus–induced, OA
Subsequently, we explored whether S100A8/A9 mediates severe cartilage destruction during collagenase-induced osteoarthritis using histology. Cartilage destruction was measured using an arbitrary scale developed by Pritzker et al (28) and adapted by us for mice. Cartilage destruction was measured in various cartilage surfaces (medial and lateral femur and tibia) of the knee joint. Cartilage 
destruction was significantly lower in S100A9-/- in all surfaces (Figure 5A) and ranged from a 45% reduction in the lateral tibia to 73% reduction in the medial femur when compared to OA in WT. (Figure 5B-C). When DMM was induced in knee joints of WT mice, most cartilage matrix destruction at day 56 was observed in the medial tibia and femur whereas less destruction was observed 
at the lateral side (Figure 5D-E-F). Interestingly, no significant differences were measured between S100A9-/- and WT mice, suggesting that S100A8/A9 do not mediate cartilage destruction within this model.
Elevated expression of S100A8/A9 in synovial biopsy samples from OA 
patients
In synovial biopsies from early OA patients (n=19), high mRNA levels of S100A8 and A9 were measured when compared to “normal” synovium (obtained during an arthroscopic procedure in patients with suspected acute joint trauma). S100A8 and A9 levels were raised 11 and 10 fold respectively (Figure 6A). Joint pathology in knee joints of CHECK-patients was determined using the Kellgren 
Lawrence score (KL). Interestingly, levels of S100A8 mRNA were significantly enhanced by 4,5 fold in patients with a KL > 0 at the time of biopsy (Figure 6B) compared to those with a KL=0 (p=0.046).
Figure 5: S100A8/S100A9 regulate cartilage destruction during collagenase-induced 
osteoarthritis (CIO).Destruction was measured in cartilage layers of medial and lateral tibia and femur of the knee joint at day 42 after induction of CIO or at day 56 after induction of destabilization medial 
meniscus (DMM) osteoarthritis. In the CIO model, cartilage damage was significantly lower in all cartilage layers of the OA knee joints of S100A9-/- mice (A and C versus WT control B). In 
the DMM model no significant differences were observed (D and F versus WT control E). Bars show the mean and SD scores of 8 animals per group. Two independent experiments were 
performed. Values were evaluated using the Mann Whitney U test (*P<0.05). Magnification of 
the photomicrographs X 250).
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Protein expression of S100A8 and S100A9 was determined using immunohistochemistry. S100A8 was abundantly expressed in biopsies of early OA(n=19) (Figure 6C) as well as in synovium from late stage OA(n=10)(Figure 6D). Control irrelevant IgG was negative (data not shown). Similar expression was observed for S100A9 (data not shown) suggesting that these proteins are produced during prolonged periods throughout the osteoarthritic process. High S100A8 levels were particularly found within synovia containing a thickened intima. Positive staining was mainly found within CD68 positive macrophages in the lining layer, subintimal lining layer and surrounding the blood vessels (Figure 6D). The number of S100A8 and S100A9 positive cells varied between patients: 45-60% of total intima cells in early and between 50-60% of total intima cells in late synovial specimen. The intima lining thickness and subintima cellularity were determined and correlated to expression of S100A8 and S100A9 
protein. A significant positive correlation was found between S100A8 expression and intima lining thickness and subintima cellularity (Figure 6E) and a similar correlation was found for S100A9.
Synovial lining cells express enzymes like ADAMTS which cleave proteoglycans thereby leaving NITEGE neoepitopes. At day 42 after OA induction, synovial intima lining cells stained strongly positive for NITEGE neoepitopes (Figure 4E) whereas no staining was observed within the intimal lining of S100A9-/- mice (Figure 4F). In contrast, in the DMM model, in which only low staining of S100A9 in the synovium was found, only minimal synovial thickness was observed which was not different between S100A9-/- and WT mice (data not shown). 
S100A8/A9 determination of cartilage destruction in collagenase-induced, 
but not destabilized medial meniscus–induced, OA
Subsequently, we explored whether S100A8/A9 mediates severe cartilage destruction during collagenase-induced osteoarthritis using histology. Cartilage destruction was measured using an arbitrary scale developed by Pritzker et al (28) and adapted by us for mice. Cartilage destruction was measured in various cartilage surfaces (medial and lateral femur and tibia) of the knee joint. Cartilage 
destruction was significantly lower in S100A9-/- in all surfaces (Figure 5A) and ranged from a 45% reduction in the lateral tibia to 73% reduction in the medial femur when compared to OA in WT. (Figure 5B-C). When DMM was induced in knee joints of WT mice, most cartilage matrix destruction at day 56 was observed in the medial tibia and femur whereas less destruction was observed 
at the lateral side (Figure 5D-E-F). Interestingly, no significant differences were measured between S100A9-/- and WT mice, suggesting that S100A8/A9 do not mediate cartilage destruction within this model.
Elevated expression of S100A8/A9 in synovial biopsy samples from OA 
patients
In synovial biopsies from early OA patients (n=19), high mRNA levels of S100A8 and A9 were measured when compared to “normal” synovium (obtained during an arthroscopic procedure in patients with suspected acute joint trauma). S100A8 and A9 levels were raised 11 and 10 fold respectively (Figure 6A). Joint pathology in knee joints of CHECK-patients was determined using the Kellgren 
Lawrence score (KL). Interestingly, levels of S100A8 mRNA were significantly enhanced by 4,5 fold in patients with a KL > 0 at the time of biopsy (Figure 6B) compared to those with a KL=0 (p=0.046).
Figure 5: S100A8/S100A9 regulate cartilage destruction during collagenase-induced 
osteoarthritis (CIO).Destruction was measured in cartilage layers of medial and lateral tibia and femur of the knee joint at day 42 after induction of CIO or at day 56 after induction of destabilization medial 
meniscus (DMM) osteoarthritis. In the CIO model, cartilage damage was significantly lower in all cartilage layers of the OA knee joints of S100A9-/- mice (A and C versus WT control B). In 
the DMM model no significant differences were observed (D and F versus WT control E). Bars show the mean and SD scores of 8 animals per group. Two independent experiments were 
performed. Values were evaluated using the Mann Whitney U test (*P<0.05). Magnification of 
the photomicrographs X 250).
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S100A8/A9 prediction of early progression of joint destruction during 
human OA
To study whether S100A8/A9 levels are associated with progression of joint damage, S100A8/A9 was measured in sera from early symptomatic OA patients (CHECK cohort) at baseline using an ELISA. Joint destruction was determined at baseline and 2 years after the start of the study, using the Kellgren & Lawrence 
score of radiographs. Two patient groups were defined: [1] Non-progressors 
and [2] Progressors. No significant differences were found in demographic data 
like age and BMI between the groups. Strikingly, significantly higher serum levels of S100A8/A9 were found in the group of progressors compared to non-progressors (Figure 6F). The mean serum level in serum of non-progressors was 487 ng/ml (n=95), and in the progressor group 581 ng/ml (n=82), indicating a potential value for serum-levels as predictor for progression. 
Figure 6: S100A8 and S100A9 are highly expressed in biopsies of early and end stage 
human OA and mRNA levels of S100A8 predict joint damage at year 2. 
mRNA levels of both proteins were significantly elevated when compared to “normal” synovium (A). High expression of S100A8 correlated significantly with a positive Kellgren Lawrence score (B). In the synovial biopsies of early OA patients, both S100A8 (C) and S100A9 (data not shown) staining was found which was expressed by macrophages lying in the intima lining layer. Similar stainings were found in synovia of late OA patients (S100A8 staining in 
D and S100A9 (not shown)). Using irrelevant IgG no staining was found (data not shown). 
Original magnification photomicrographs X400. A significant correlation was found between S100A8/9 protein expression and synovium activation parameters (E). Furthermore, S100A8/A9 serum levels predict joint damage in human OA (F). Comparison of mean serum S100A8/S100A9 levels in patients without damage at base line, which do (82 patients) or do not show (95 patients) progression of joint damage (K&L) after two years. Data were evaluated using 
the Mann Whitney U test and significance is indicated by * (P<0.05). Confounding by BMI was excluded by multiple regression analysis.
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Discussion
In the present study we find that S100A8/S100A9 are pivotal proteins involved in mediating cartilage destruction during experimental collagenase-induced OA in which synovial activation is important for induction of joint pathology but not in the DMM model in which synovial activation is absent. Arthroscopic studies performed in joints of OA patients suggest that localized proliferation and 
inflammatory changes in the synovium occur in around 50% of OA patients (7-8). Macrophages are dominant cell types present in activated synovium of human OA although also B and T cells have been described (11 ). As in human OA, also in collagenase-induced osteoarthritis, macrophages form the predominant cell 
type in the inflamed synovium and no PMNs are observed during the chronic phase between day 7 and day 42.
S100A8/S100A9 appeared to be important in sustaining synovial activation during collagenase-induced OA as S100A9-/- mice whose peripheral myeloid cells also lack the S100A8 protein (24) show reduced synovial activation and cartilage destruction. Both mRNA as well as protein levels of S100A8 and A9 remained high for extended periods (up to 21 days after injection) in the synovium of collagenase-induced OA. S100A9 mRNA expression even increased between day 7 and day 21. This is in line with our human data which show that both biopsies from patients with early symptomatic as from patients with end stage OA express high levels of S100A8 and A9 protein suggesting a prolonged expression throughout the OA process. S100A8 and A9 have been shown to 
induce a specific inflammatory response in human microvascular endothelial cells, macrophages as well as osteo- and chondroblasts (35). Synovial activated macrophages are the source of S100A8/S100A9 in collagenase-induced OA.
Apart from regulating synovial inflammation, the macrophage has also been shown to mediate cartilage destruction. In earlier studies we found that removal of synovial macrophages prior to induction of experimental osteoarthritis almost completely blocked metalloproteinase-induced cartilage destruction 
and osteophyte formation (12,36). Synovial inflammation has been considered as a factor that most likely contributes to dysregulation of chondrocyte function favoring an imbalance between the catabolic and anabolic activities of the chondrocyte in remodeling the cartilage extracellular matrix (37). Earlier studies 
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showed that intra-articular injection of S100A8 into murine knee joints strongly stimulate both cytokine and MMP/ADAMTS expression in the intima layer (23). Fibroblast-like type B cells lying within the intimal layer produce proteoglycans and at the same time are high producers of ADAMTS (38) which may explain the presence of large amounts of NITEGE neoepitopes within the intimal layer of collagenase-induced OA. In contrast, stimulation of macrophages with S100A8 upregulated only cytokines but not MMP/ADAMTS suggesting that the contribution of macrophages to cartilage destruction may be through abundant release of catabolic cytokines and S100 species thereby further stimulating 
fibroblast-like type B cells to produce ADAMTS.
IL-1β, IL-6 and TNFα are all capable of inducing MMPs, aggrecanases and other 
catabolic factors (39). TNFα and IL-1β co-localized with MMP-1,-3,-9 and 13 in regions of matrix depletion in OA cartilage (40). There is a strong relationship 
between the increased levels of catabolic enzymes and inflammatory mediators like IL-1. IL-1 has earlier been shown to be crucial in mediating cartilage destruction in experimental murine arthritis (41). The role of IL-1 in driving OA pathology is however still a matter of debate (14). We found a two times downregulation of IL-1 in the synovium of the knee joint after a short initial 
phase of upregulation. IL-1β and its effects are probably inhibited by cytokines like IL-10 and IL-1ra which were highly expressed shortly after OA induction. IL-
1β drives cartilage destruction by stimulating MMP production in chondrocytes. However MMPs are secreted in a latent form and need an activation step in order to become activated. S100A8 protein may be involved in this by induction of MMP activating factors like oxygen radicals (23).
Interestingly when pro-inflammatory triggers like SCW fragments were injected into a normal mouse knee joint, only a short-lasting enhancement of S100A8 and S100A9 expression in the synovium was measured indicating that expression 
of both proteins is tightly controlled during acute inflammation. Expression of S100A8 and S100A9 for prolonged periods in synovium during collagenase-induced OA implies that the expression becomes reactivated, which may be driven by cartilage degradation products released during OA. Interestingly, whereas S100A8 and S100A9 levels remain high up till day 21, expression of cytokines like IL-1,TNF and IL-6 were already strongly decreased at this time-point. 
Although pathogenic triggers which are responsible for prolonged and specific up-regulation of S100A8/S100A9 in OA are not known, recent data point to a pro-
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inflammatory crosstalk between ECM metabolites and phagocyte-specific danger molecules. Elevated catabolic breakdown of the matrix by metalloproteinases leads to additional release of matrix products like byglycan, decorin and aspirin 
(42). Biglycan has recently been shown to activate the inflammasome within macrophages (43) and may reactivate macrophages forming a positive feedback loop with S100A8/S100A9. Interestingly, both molecules stimulate macrophages via TLR4 (44).
Apart from having an effect on synovial inflammation, S100 protein may have a direct effect on chondrocyte metabolism(23). Although homo- and heterodimers of S100A8 and S100A9 are negatively charged they may penetrate cartilage layers due to their small 20 kD size (45). In a recent study using human chondrocytes isolated from OA cartilage, we found that not only S100A8 but also S100A9 were 
potent stimulators of a catabolic phenotype reflected by a high release of MMP-1,-3 and-9 and an inhibition of matrix molecules, collagen type II and aggrecan (manuscript in press). MMP-3 is a crucial enzyme involved in cartilage destruction both during experimental arthritis (46) as well as during collagenase-induced osteoarthritis (13). 
The mechanism how S100A8 activates chondrocytes is not known. Various receptors have been described to be involved in S100A8 signaling like TLR4 (17,47), RAGE (48) and N-glycans (49). In previous studies, it was shown that S100A8 signaling in macrophages occurs via TLR4 (17). Using primary chondrocytes obtained from arthroplasties of OA patients, we recently found 
that stimulation by S100A8 and S100A9 was significantly inhibited by the TLR4 inhibitor TAK242 but not by inhibitors of RAGE or N-glycans (manuscript in press). 
In synovial fluids of OA patients abundant amounts of the S100A8/S100A9 (up to 
5-7 µg/ml) have been detected (50). Significantly elevated S100 concentrations, probably spillover of the joints, were also measured in sera of patients suspected 
from OA when compared to healthy controls. Interestingly significant higher levels were measured in those OA patients at baseline which had developed a 
clear cartilage destruction 2 years later. When a cut-off was defined at 600 ng/
ml, above which the level of S100A8/A9 was defined increased, and only patients 
with severe progression (delta K&L ≥3) were analyzed, a significantly higher number of patients with severe progression showed increased levels of S100A8/
A9 (chi square-test). The odds-ratio was 7.5 indicating a highly increased risk of severe progression when S100A8/A9 levels are increased (results not shown). 
48
Chapter 2
However, numbers of strong progressors were very low (n=8) and further research at later follow-up time points are planned to determine the value of these proteins as progression markers.
Synovial activation which is clearly present within a subpopulation of OA patients 
may explain the high levels of S100A8 and S100A9 found within synovial fluids but also the blood where they can easily be measured. As S100A8 and S100A9 levels remain high for prolonged periods and as they are important stimulators of cartilage destruction, these proteins may be effective biomarkers for predicting progressive cartilage destruction in OA.
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Abstract
Objective: Alarmins S100A8 and S100A9 are major products of activated macrophages regulating cartilage damage and synovial activation during murine and human osteoarthritis (OA). In the current study we investigated whether S100A8 and S100A9 are involved in osteophyte formation during experimental OA and if S100A8/A9 predicts osteophyte progression in early human OA.
Methods: OA was elicited in S100A9 -/- mice in two experimental models that differ in degree of synovial activation. Osteophyte size, S100A8, S100A9 and VDIPEN was measured histologically. Chondrogenesis was induced in murine mesenchymal stem cells in the presence of S100A8. Levels of S100A8/A9 were determined in plasma of early symptomatic OA participants of the CHECK cohort 
study and osteophytes measured after two and five years.
Results: Osteophyte size was drastically reduced in S100A9 -/- mice in ligaments and at medial femur and tibia on day 21 and 42 of collagenase-induced OA, in which synovial activation is high. In contrast, osteophyte size was not reduced in S100A9 -/- mice during destabilized medial meniscus OA, in which synovial activation is scant. S100A8 increased expression and activation of MMPs during micromass chondrogenesis, thereby possibly increasing cartilage matrix remodeling allowing for larger osteophytes. Interestingly, early symptomatic OA 
participants of the CHECK study with osteophyte progression after two and five years had elevated S100A8/A9 plasma levels at baseline, while CRP, ESR and COMP were not elevated at baseline.
Conclusion: S100A8/A9 aggravate osteophyte formation in experimental OA with high synovial activation and may be used to predict osteophyte progression in early symptomatic human OA.
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Introduction
Recently the view on osteoarthritis (OA) is shifting from a disease of only the 
cartilage to a whole joint disease. Synovial activation and pro-inflammatory mediators from the synovium play an important role in the pathogenesis of OA (1-4). An arthroscopic study suggests that synovial activation occurs in 50% of OA patients (5) and synovitis is associated and can predict cartilage pathology (6, 7). We previously showed that synovial macrophages are essential in regulating 
synovial inflammation and subsequent cartilage erosion during collagenase-induced OA (CIOA) (8). Important products from activated macrophages are the alarmins S100A8 and S100A9. These damage associated molecular patterns bind calcium and can also be released in huge amounts by neutrophils and monocytes 
(9, 10). S100A8/A9 is highly present in synovial fluid of both rheumatoid arthritis 
(RA) and OA patients (11) and in RA both serum and synovial fluid levels of S100A8/A9 correlate with radiological damage and disease activity (12, 13). We recently showed that S100A8 and S100A9 induce a catabolic phenotype in 
human OA chondrocytes by upregulating pro-inflammatory cytokines and MMP-1, -3, -9 and -13 via TLR-4 (14). Furthermore, we demonstrated that S100A9 -/- mice showed reduced cartilage damage and synovial activation during CIOA, but not in the surgically induced DMM (destabilized medial meniscus) OA (15). CIOA has considerably higher synovial activation compared to DMM, indicating the 
importance of S100A8/A9 in inflammatory OA. 
Osteophytes, important hallmarks of OA, are bony outgrowths lined by cartilage that limit joint movement and cause pain. While classic osteophytes originate from the periosteum, similar structures can also develop in ligaments and tendons, further also called osteophytes. Osteophytosis is initiated by mesenchymal stem cells (MSCs) that undergo condensation, chondrogenic differentiation and proliferation. Finally, the chondrocytes go into hypertrophy and blood vessels are formed which give access to osteoblasts and osteoclasts that transforms the 
structure into bone in a process highly resembling endochondral ossification 
(16). Earlier, our lab has shown that overexpression of both TGFβ1 and BMP-
2 induces osteophyte formation in the mouse knee joint, albeit with different 
dynamics (17, 18). Consequently, we have shown that osteophyte formation 
is highly dependent on synovial macrophages, potent producers of TGFβ-
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superfamily members (19).
In the current study, we aimed to unravel the role of S100A8/A9 in osteophyte formation in experimental OA models, focusing on the involvement of the synovium. Moreover, we investigated whether S100A8/A9 plasma levels predict osteophyte progression in participants of the Dutch CHECK cohort of early symptomatic OA.
Material and Methods
Animals and experimental OA models
Experimental OA was elicited in 12-14 weeks old male C57BL/6J (Janvier) and 
S100A9 -/- mice backcrossed to the C57BL/6 background for 12 generations. 
Mice were housed in groups of 10 animals in filter-top cages, and water and food were provided ad libitum.
Collagenase-induced osteoarthritis (CIOA) was performed by 2 times intra-articular injection of 1U of bacterial collagenase (Sigma-Aldrich), causing 
disruption of the ligaments and local instability of the knee joint (20). Destabilized medial meniscus (DMM) OA was induced by transection of the medial anterior meniscotibial ligament (21).
Histology
Total knee joints or micromasses were fixed in formalin and cut in 7 or 5 µm sections, respectively. Staining was done with Safranin-O (0.1% in water), counterstaining with Fast Green (0.1% in water). Osteophyte size was assessed in Safranin-O sections using the Leica Application Suite (LAS) image analysis software. Knee joint sections were also immunostained with anti-rabbit S100A8, S100A9 (own facilities) or VDIPEN, with rabbit IgG as isotype. Biotinylated 
horseradish peroxidase–conjugated goat antirabbit IgG (Dako) was used as 
secondary antibody, followed by avidin-streptavidin-peroxidase (Elite kit; Vector) 
and diaminobenzidine to develop peroxidase staining, enhanced with nickel for the VDIPEN staining. Counterstaining was done with Mayer’s hematoxylin 
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(Merck) for S100A8 and S100A9 and with Orange G (2%) for VDIPEN.
Micromass chondrogenesis
Chondrogenesis was studied by bringing the MSC cell line C3H10T1/2 in micromass pellets. 250.000 Cells were allowed to adhere in round-bottom 96-well plates for 3 hours after which they spontaneously form microspheres of cells. Micromasses were stimulated with chondrogenic medium (DMEM with 
50µg/ml vitamin C, 6.25µg/ml transferrin, 6.25ng/ml sodium selenite, 5.35µg/
ml linoleic acid, 10-7M dexamethasone, 6.25µg/ml insulin, 1.0mg/ml sodium 
pyruvate, 0.4mg/ml prolin, 2% BSA and 48 µg/ml gentamycin) two times a week 
for three weeks, supplemented with 5 ng/ml TGFβ1, 50 ng/ml BMP-2 and 5µg/ml recombinant murine S100A8.
Determination of mRNA expression with RT-qPCR
RNA was isolated from micromass cultures using TRI-reagent (Sigma-Aldrich), as described previously (22). RNA from murine synovial biopsies was isolated 
using the RNeasy-kit (Qiagen), after first disrupting synovial tissue with the 
MagNA Lyser (Roche). RNA was reverse transcribed to cDNA and RT-qPCR 
was performed with specific primers and the SYBR Green Master mix in the StepOnePlus real-time PCR system (Applied Biosystems) as described before (22). Expression levels are expressed as (-) delta Ct (dCt) values, normalized to 
the reference gene GAPDH. Primer-sequences can be found in the supplemental methods.
Measurements in early symptomatic OA cohort (CHECK)
Samples were obtained from the Cohort Heup and Cohort Knie (CHECK). On entry into the CHECK study (=baseline), all participants had pain or stiffness 
of the knee or hip, and all of them were aged between 45–65 years. They had 
not yet consulted their physician for these symptoms, or the first consultation occurred within 6 months before cohort entry. Participants with any other pathologic condition that could explain the symptoms were excluded. Right or 
left knee pain was assessed at baseline and S100A8/A9 was measured in plasma of 58 participants of the CHECK cohort. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and serum cartilage oligomeric matrix protein (COMP) 
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was measured in the same participants, as described before (23). Osteophytes of the tibiofemoral joints were made at baseline and after 2 and 5 years by a 
weight-bearing posteroanterior view, semi-flexed (7–10 degrees). Femoral medial and lateral osteophytes, and tibial medial and lateral osteophytes were scored on a 0-3 scale according to Altman et al. (24). Participants were categorized into osteophyte progressors and non-progressors: Progressors 
(n=34) were participants that had pain in left or right knee (or both) at baseline 
and consequently developed osteophytes or increased their osteophyte size after 
either 2 or 5 years in that particular knee on any of the 4 measured locations. 
Non-progressors (n=24) did have pain in the knee, but did not develop or 
increase osteophytes in that particular knee. All except two non-progressors also 
did not have osteophyte progression in the other knee. More information on the CHECK cohort can be found in the supplemental methods.
Additional methods
Methods on CAGA-luc (TGFβ-activity), S100A8/A9 ELISA as well as information on statistical analysis and ethics can be found in the supplement.
Results
Development of osteophytes during collagenase induced OA coincides with 
high synovial and serum S100A8/A9 protein levels
Recently, we have shown that S100A8/A9 drives cartilage destruction in collagenase-induced OA (CIOA) (15), a model with high synovial activation. Within this model we explored whether S100A8/A9 is associated with osteophyte 
formation. On day 7, 21 and 42 after induction of CIOA, we stained whole knee sections with Safranin-O (SafO) and immunostained for S100A8 and S100A9. 
After one week of CIOA, osteophytes started to develop, as evidenced by chondrogenesis particularly at the medial and lateral margins of the femur. However, no chondrogenesis was seen in the ligaments yet. Interestingly, very strong S100A9 expression at this time point was found in the synovial lining layer (Figure 1A). On day 21 of CIOA, bone deposition was observed in 
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the osteophytes as they increased in size. Furthermore, osteophytes started developing in the medial collateral ligament. S100A9 expression on day 21 was still high in the synovial lining layer (Figure 1B). On day 42, fully developed and large osteophytes were observed particularly at the medial side, but also at the lateral side. Although decreased compared to day 7 and 21, S100A9 was 
still expressed in the synovial lining layer on day 42 (Figure 1C). A naïve knee joint did not show any osteophytes and isotype staining for S100A9 was negative (Figure 1E). Immunostaining of S100A8 was comparable to S100A9 (not shown). S100A8/A9 protein levels in serum were high on both day 7 and day 21 (Figure 1D), and returned to control (non-OA) levels on day 42. Together, these results show that S100A8 and S100A9 are present during CIOA in the synovium during 
the first phases of osteophytosis.
Osteophyte size is drastically reduced in S100A9 -/- mice with collagenase 
induced OA
Next, we investigated whether S100A8/S100A9 could affect osteophyte 
development by inducing CIOA in knee joints of mice deficient for S100A9. The 
peripheral myeloid cells of these mice also lack S100A8 protein, while S100A8 protein was also hardly detectable in the joint (see supplementary Figure S1), 
which make them a functional double knockout (25). On day 7, both WT and S100A9 -/- mice showed small areas with chondrogenesis at the medial femur (Figure 2A). Interestingly, on day 21 osteophytes were greatly reduced in S100A9 -/- mice on the margin of the medial femur and tibia (56% and 67% reduction compared to WT, respectively) (Figure 2B) and even slightly more reduced on day 42 (65% and 68% reduction) (Figure 2C-D). Osteophytes at the cruciate 
ligament were also significantly smaller at day 21 (58% reduction) and a non-
significant reduction was observed in the medial collateral ligament (Figure 2B). Finally, we observed a dramatic reduction in osteophyte size at the medial collateral ligament on day 42 in S100A9 -/- mice (92% compared to WT) (Figure 2C-D). 
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Osteophyte size is not reduced in S100A9 -/- during experimental OA with 
low synovial activation
To investigate whether S100A8/A9 released by the activated synovium is important in the reduction of osteophyte size, we induced experimental OA in 
Figure 1: Time course of osteophyte development during collagenase induced OA (CIOA) 
and S100A8/A9 protein expression in synovium and serum. 
CIOA was elicited in C57/Bl6 mice and histology of total knees was taken on 7 (A), 21 (B) and 42 days (C) after induction. At the same days after CIOA induction, S100A8/A9 serum 
levels were measured with a specific ELISA (D). Paraffin-embedded sections were stained for proteoglycans with Safranin-O (A,B,C upper panels) and S100A8 (not shown) and S100A9 were immunostained in adjoining sections (A,B,C lower panels). A, On day 7, chondrogenesis in developing osteophytes was almost exclusively seen at the medial and lateral margins of the femur, while S100A9 expression was highly expressed in the synovial lining. B, On day 21, chondrogenesis was observed in medial collateral and cruciate ligaments, and at the margins of tibia and femur while S100A9 staining was observed in the synovial lining layer with similar intensity as on day 7.C, On day 42, bone development in about 50% of osteophytes in both ligaments and femur and tibia margins was observed, as osteophytes grew to larger size. Interestingly, S100A9 staining was still present in the synovial lining layer, although less intense. E Safranin-O staining of naive, non-OA mouse knee joint, showing no 
chondrogenesis/osteophyte formation. Specific RbIgG isotype staining of S100A9 in the right 
panel. Magnifications are either 50x or 200x for safranin-O and 400x for S100A9 stained sections. A,B,C n=10 mice/group, results are representative for 2 independent experiments. In 
D, average serum S100A8/A9 levels are shown of 4 independent experiments.
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S100A9 -/- mice by destabilization of the medial meniscus (DMM). In contrast 
to CIOA, synovial activation is very low during DMM (15). No significant changes in osteophyte size were found on day 56 of DMM, neither at the medial femur nor tibia, the locations to which osteophyte formation is mainly restricted to during DMM (Figure 3A-B). The results in the CIOA and DMM model suggest that S100A8/A9 from the synovium stimulates osteophyte development.
S100A8/A9 does not regulate growth factor levels and activation during 
collagenase induced OA
Earlier, our lab has shown that growth factors such as BMP-2 and TGFβ play a major role in the development of osteophytes during CIOA (17, 26). To investigate whether the reduced osteophyte size in S100A9 -/- mice during CIOA was due to a reduction in growth factors, we measured synovial mRNA expression on 7, 21 
and 42 days after induction of OA. No differences in mRNA expression for TGFβ-
Figure 2: Osteophyte size is drastically reduced in S100A9 -/- mice at day 21 and 42 of 
collagenase induced-OACIOA was elicited in S100A9 -/- mice and osteophyte size was measured with image analysis software at 7 (A), 21 (B) and 42 (C,D) days at lateral femur, medial femur and tibia and at medial and lateral collateral ligaments on Saf-O stained histological sections. A On day 7, osteophyte size was still small and only slightly reduced at the lateral femur, not on other locations. No chondrogenesis was yet observed inside the lateral and medial collateral ligaments. B On day 
21, osteophytes were larger and significantly reduced in the S100A9 -/- mice at medial femur and tibia, as well as inside the cruciate ligament. A trend towards smaller osteophyte size was observed inside the medial collateral ligament . C On day 42, osteophyte size was drastically reduced at again medial femur and tibia, as well as at the medial collateral ligament. D 
Photomicrographs (magnification 50x) of representative Saf-O stained sections of osteohpytes on day 42 of both WT and S100A9 -/- mice.
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family members TGFβ1, BMP-2 and BMP-6 were found between S100A9 -/- and 
WT (Figure 4A). Nor was there an effect on the activation of TGFβ, as measured with CAGA-luc in synovial washouts (Figure 4B). 
S100A8/A9 increase remodeling of the cartilage matrix during 
chondrogenesis by upregulating and activating MMPs
Chondrogenesis of MSCs is an early key feature of osteophyte development (16) and since S100A8/A9 expression was highest at early phases of CIOA (Figure 1), we studied the effect of S100A8 on chondrogenesis in more detail. Chondrogenesis was present in S100A8-supplemented micromasses, as shown by Saf-O staining of proteoglycans. However, the integrity of the S100A8-supplemented micromasses was completely lost as they seemed to collapse and protrusions appeared (Figure 5A). Measuring MMP mRNA levels in these micromasses, we found that particularly MMP-3 was greatly upregulated by adding S100A8 (96-fold), while 
chondrogenic markers collagen type II and aggrecan were not changed (Figure 5B). Moreover, we also found higher MMP activity as measured by an increase 
Figure 3: Osteophyte size is not 
reduced in S100A9 -/- mice with 
surgically induced DMM OADestabilized medial meniscus (DMM) OA was induced in S100A9 -/- mice and osteophyte size was measured on day 56. Osteophytes in the DMM model, 
which lacks synovial activation, develop almost exclusively at the margins of the medial tibia and femur. A, On day 56, osteophyte size at medial tibia and femur was unchanged in S100A9 -/- compared to WT. B, Photomicrographs 
(magnification 50x) of representative Saf-O stained sections of osteohpytes on day 56 of both WT and S100A9 -/- mice.
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in the neoepitope VDIPEN (27), which is specific for proteoglycans cleaved by MMPs (Figure 5C). These results indicate that S100A8 can activate MMPs during chondrogenesis. Finally, we analyzed MMP activation during chondrogenesis in vivo, at day 7 of CIOA. High expression of VDIPEN coincided with areas of high proteoglycan content in areas of emerging osteophytes (Figure 5D), suggesting that indeed MMP activation and activity is important in chondrogenesis during osteophyte formation.
S100A8/A9 predicts osteophyte progression in early human symptomatic 
OA 
Our current findings in the mouse prompted us to investigate whether S100A8/A9 levels could predict the progression of osteophytes in humans. For this we measured S100A8/A9 levels in plasma of participants in a sample of the CHECK cohort (n=58) of early symptomatic OA at baseline and scored osteophytes by 
Figure 4: S100A8/A9 do not alter 
growth factor and MMP expression 
nor TGFβ activation in the synovium 
during collagenase induced OA.CIOA was elicited in S100A9 -/- mice and synovial mRNA samples and synovial washouts were collected after 7, 21 and 42 days. A, mRNA levels of growth factors TGFβ1, BMP-2 and -6 and of matrix metalloproteinases (MMP)-3 and -13 
were measured with RT-qPCR and no differences were found between S100A9 -/- and WT mice on all time points, day 7, 21 and 42. B, TGFβ activation was measured in synovial washouts. No differences between S100A9 -/- and WT mice on synovial TGFβ activation as measured by luminescence using the TGFβ-responsive CAGA-luc assay.
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radiograph analysis at baseline and after 2 and 5 years (24). Progressors were 
defined as participants that had increased osteophyte score after 2 or 5 years 
after having had pain in that knee at baseline, while non-progressors did not 
increase their knee osteophyte score after 2 or 5 years, despite having knee pain at baseline. Progressors and non-progressors were matched for sex, age and body mass index. 
Demographic data shows no significant differences between progressors and non-progressors (supplementary Table S1). Interestingly, progressors already 
had elevated osteophyte scores at baseline (Table S1). Remarkably, we found 
significantly elevated S100A8/A9 levels in progressors (n=34) of osteophyte formation compared to non-progressors (n=24) (451 ng/ml vs. 254 ng/ml) 
Figure 5: S100A8 increases cartilage remodeling during micromass chondrogenesis by 
upregulating and activating MMPs.Chondrogenesis was induced in micromasses of murine mesenchymal stem cells (C3H10T1/2), in the presence of 5 ng/ml TGFβ1 and 50 ng/ml BMP-2, with or without (=control) 5 µg/ml recombinant S100A8. A, No chondrogenesis was observed after 21 days in conditions without TGFβ1/BMP-2 (A, left panels). Proper chondrogenesis was seen in the TGFβ1/BMP-2 stimulated micromasses as evidenced by Saf-O proteoglycan staining (A, bottom middle panels). S100A8 supplemented micromasses did show chondrogenesis, but showed protrusions or total collapse of micromasses (A, top middle panels). Detailed pictures (200x magnification) of chondrogenic area with/without S100A8 in top and bottom right panels. B, MMP-3, collagen type II and aggrecan mRNA levels were upregulated in micromasses stimulated with S100A8, with or without TGFβ1/BMP-2. C, MMP activation was upregulated in S100A8 stimulated 
micromasses, as evidenced by heightened immunostaining of the MMP-specific cartilage 
matrix breakdown neoepitope VDIPEN. D, On day 7 of CIOA, VDIPEN expression as measure of MMP activation (left panel) coincides with proteoglycan content (Safranin-O, right panel) in developing osteophytes.
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(Figure 6A). Furthermore, participants with S100A8/A9 plasma concentrations higher than 200 ng/ml had increased odds of developing osteophytes (odds ratio 
4.0; p=0.01, chi square), indicating an increased risk of osteophyte progression when S100A8/A9 levels are high. Moreover, we measured C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in these participants, common 
parameters for inflammation in arthritic disease, and found that this was not different between progressors and non-progressors (Figure 6B-C). Also cartilage 
oligomeric matrix protein (COMP), a widely used marker for cartilage damage, was not changed (Figure 6D). 
Discussion
In the current study we show that alarmins S100A8 and S100A9 aggravate osteophyte formation during experimental OA with high synovial activation. Moreover, S100A8/A9 can upregulate and activate MMPs thereby possibly enhancing remodeling during osteophytosis and allowing for larger osteophytes. 
Finally, we confirmed the relevance of S100A8/A9 during osteophyte formation in humans by showing that elevated S100A8/A9 plasma levels in people with early symptomatic OA at baseline have a predictive value for development of 
osteophytes after two or five years. 
Using S100A9 -/- mice first in CIOA, we have shown that S100A8 and S100A9 are important for the development of large osteophytes at both the bone margins as well as in ligaments. Since we have shown earlier that cartilage damage is reduced in S100A9 -/- mice during CIOA (15), S100A8/A9 could indirectly contribute to 
osteophyte size through cartilage damage and cartilage breakdown products. However, we clearly show that osteophyte formation already starts early during CIOA (day 7, Figure 1A), while the onset of cartilage damage occurs around day 14. Moreover, synovial activation occurs early during CIOA and is reduced in S100A9 -/- mice (15). As such, we cannot completely rule out that S100A8/A9 could have its effect on osteophyte formation indirectly via synovial activation. Osteophyte size was not reduced in S100A9 -/- mice during DMM OA. Considering the near absence of synovitis during DMM, this again points to an important role for synovial activation in osteophyte formation. Although we have shown low S100A8/A9 levels in the synovium during DMM (15) a role for S100A8/A9 inside 
the chondrocyte on osteophyte formation cannot be fully excluded. Zreiqat et al. showed expression of S100A8 and S100A9 in chondrocytes during DMM (28). However, we were unable to detect S100A8/A9 in supernatants of human OA and murine chondrocytes nor show S100A8 or S100A9 on Western Blot in chondrocyte cell-lysates (unpublished results), indicating a marginal role for these alarmins in chondrocytes.
These results together suggest that synovial activation and consequently factors 
released by macrophages/infiltrated monocytes, such as S100A8 and S100A9, could stimulate osteophyte formation. Intra-articular injection and adenoviral 
Figure 6: High plasma levels of S100A8/A9 predict knee osteophyte progression at 2 
or 5 years in an early symptomatic OA cohort.Plasma levels of S100A8/A9, serum levels of C-reactive protein (CRP) and cartilage oligomeric matrix protein (COMP), and erythrocyte sedimentation rate (ESR) were measured at baseline in 58 participants of the CHECK cohort. Osteophyte progression was measured by radiograph analysis. A, S100A8/A9 plasma levels are significantly upregulated at baseline in 
participants that developed knee osteophytes after 2 or 5 years after having had knee pain 
at baseline (=progressors, n=34) compared to participants that did not develop any knee 
osteophytes after 2 or 5 years, despite having knee pain at baseline (=non-progressors, n=24) 
B,C In contrast, standard markers for inflammation, ESR (B) and CRP (C) are not elevated at baseline in progressors compared to non-progressors. D Finally, COMP, a standard clinical 
marker for cartilage damage, was also not elevated in progressors at baseline. 
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Discussion
In the current study we show that alarmins S100A8 and S100A9 aggravate osteophyte formation during experimental OA with high synovial activation. Moreover, S100A8/A9 can upregulate and activate MMPs thereby possibly enhancing remodeling during osteophytosis and allowing for larger osteophytes. 
Finally, we confirmed the relevance of S100A8/A9 during osteophyte formation in humans by showing that elevated S100A8/A9 plasma levels in people with early symptomatic OA at baseline have a predictive value for development of 
osteophytes after two or five years. 
Using S100A9 -/- mice first in CIOA, we have shown that S100A8 and S100A9 are important for the development of large osteophytes at both the bone margins as well as in ligaments. Since we have shown earlier that cartilage damage is reduced in S100A9 -/- mice during CIOA (15), S100A8/A9 could indirectly contribute to 
osteophyte size through cartilage damage and cartilage breakdown products. However, we clearly show that osteophyte formation already starts early during CIOA (day 7, Figure 1A), while the onset of cartilage damage occurs around day 14. Moreover, synovial activation occurs early during CIOA and is reduced in S100A9 -/- mice (15). As such, we cannot completely rule out that S100A8/A9 could have its effect on osteophyte formation indirectly via synovial activation. Osteophyte size was not reduced in S100A9 -/- mice during DMM OA. Considering the near absence of synovitis during DMM, this again points to an important role for synovial activation in osteophyte formation. Although we have shown low S100A8/A9 levels in the synovium during DMM (15) a role for S100A8/A9 inside 
the chondrocyte on osteophyte formation cannot be fully excluded. Zreiqat et al. showed expression of S100A8 and S100A9 in chondrocytes during DMM (28). However, we were unable to detect S100A8/A9 in supernatants of human OA and murine chondrocytes nor show S100A8 or S100A9 on Western Blot in chondrocyte cell-lysates (unpublished results), indicating a marginal role for these alarmins in chondrocytes.
These results together suggest that synovial activation and consequently factors 
released by macrophages/infiltrated monocytes, such as S100A8 and S100A9, could stimulate osteophyte formation. Intra-articular injection and adenoviral 
Figure 6: High plasma levels of S100A8/A9 predict knee osteophyte progression at 2 
or 5 years in an early symptomatic OA cohort.Plasma levels of S100A8/A9, serum levels of C-reactive protein (CRP) and cartilage oligomeric matrix protein (COMP), and erythrocyte sedimentation rate (ESR) were measured at baseline in 58 participants of the CHECK cohort. Osteophyte progression was measured by radiograph analysis. A, S100A8/A9 plasma levels are significantly upregulated at baseline in 
participants that developed knee osteophytes after 2 or 5 years after having had knee pain 
at baseline (=progressors, n=34) compared to participants that did not develop any knee 
osteophytes after 2 or 5 years, despite having knee pain at baseline (=non-progressors, n=24) 
B,C In contrast, standard markers for inflammation, ESR (B) and CRP (C) are not elevated at baseline in progressors compared to non-progressors. D Finally, COMP, a standard clinical 
marker for cartilage damage, was also not elevated in progressors at baseline. 
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overexpression of both TGFβ1 and BMP-2 induces osteophyte formation in the 
mouse (17, 18, 29). In the current study, we could not find changes on synovial 
mRNA expression of TGFβ1 and BMP-2 nor levels of active TGFβ in S100A9 -/- 
during CIOA. TGFβ-levels however, are already high during CIOA and S100A8/A9 
could be working as an enhancer to increase osteophyte size through catabolic actions. 
Our lab has extensively shown that S100A8 and S100A9 are capable of upregulating 
and activating MMPs in chondrocytes (14, 30). From developmental knock-out studies in mice it is clear that MMPs are essential for proper endochondral 
ossification, a process similar to osteophyte formation (31, 32) and MMP-3 is strongly expressed within adult human osteophytic bone (33). In line with this, we showed in the present study that S100A8 could upregulate MMP-3 mRNA and activate MMPs in differentiating chondrocytes derived from murine MSCs. Moreover, we showed that VDIPEN expression and thus MMP activation is elevated in vivo during CIOA in the same areas in which chondrogenesis occurs. This supports the view that S100A8 and S100A9 can increase osteophyte size 
through activation of MMPs. By breaking down the cartilage matrix, MMPs 
could make it possible for chondrocytes to proliferate further and form larger osteophytes. These results together indicate that (MMP-mediated) catabolic rather than anabolic mechanisms are responsible for the proposed effects of S100A8/A9 on osteophyte formation.
CHECK has as main goal to identify factors important for the (early) onset and development of OA. Studies using the CHECK cohort of early symptomatic OA 
participants already identified several biomarkers and diagnostic tools for early OA (34, 35). Especially early diagnosis could vastly improve OA therapeutics, since it has proven almost impossible to reverse structural deformities in the later stages of the disease and clinicians often revert to total joint replacement. 
We found that plasma S100A8/A9 is significantly higher in CHECK participants 
that develop osteophytes, but remarkably this is not the case for CRP, ESR and COMP. Plasma S100A8/A9 higher than 200ng/ml also indicate a 4 times higher 
risk of developing osteophytes at later stages. Recently, we also showed a 
thickened intima lining of the synovium of CHECK participants that correlated with S100A8/A9 expression on immunohistochemistry. Also, we showed that high serum S100A8/A9 levels correlate with the development of cartilage damage in symptomatic OA patients (15). This study further increases the value 
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of measuring S100A8/A9 at an early stage of OA as possible predictor of both cartilage damage and osteophyte formation, although the number of participants (n=58) needs to increase to be able to assess proper prognostic value of S100A8/A9.
Taken together the current study shows that S100A8 and S100A9, as important products of activated macrophages during synovial activation in OA, could 
increase osteophyte size during experimental OA with synovial inflammation. S100A8/A9 can upregulate and activate MMPs that aid in the remodeling of the cartilage matrix, allowing for osteophytes to increase in size. Finally, we showed 
that S100A8/A9 may prove an interesting biomarker to not only predict cartilage damage, but also osteophyte progression during human OA.
Acknowledgements
The authors would like to thank Terry Jorna, Laurie de Kroon, Birgitte Walgreen 
and Monique Helsen for their excellent technical assistance and Janet Wesseling for cooperation in the CHECK cohort.
This study was supported by 7th Framework Programme MIAMI from the European Commission, Dutch Arthritis Foundation (RF 07-2-301 and 12-2-405) 
and the Osteoimmune training network. The funding sources indicated above had no role in study design, in collection, analysis or interpretation of data, nor in writing the manuscript or decision to submit the manuscript.
70
Chapter 3
Supplemental data
Supplemental Methods
RT-qPCR primer sequences
Primer sequences for target genes for RT-qPCR spanned exon-exon 
transitions and were as follows: TGFβ1; FW: GCAGTGGCTGAACCAAGGA, 
RV: AAGAGCAGTGAGCGCTGAATC. BMP-2; FW: CGCAGCTTCCATCACGAA, 
RV: GCCGGGCCGTTTTCC. BMP-6; FW: GATGGCAGGACTGGATCATTG, RV: 
AGGAACACTCTCCATCACAGTAGTTG. MMP-2; FW: CATGCGGAAGCCAAGATGT, 
RV: AGGTGTGTAACCAATGATCCTGTATGT. MMP-3; FW: 
TGAAGCCACCAACATCAGGA, RV: TGGAGCTGATGCATAAGCCC. MMP-9; FW: 
GGAACTCACACGACATCTTCCA, RV: GAAACTCACACGCCAGAAGAATTT. MMP-13; FW: AGACCTTGTGTTTGCAGAGCACTAC, RV: CTTCAGGATTCCCGCAAGAG. 
Measurement of TGFβ activity
TGFβ activity was determined by adding 1:5 dilution of synovial washouts of 
CIOA mice (36) overnight to 3T3 fibroblasts transduced with adenoviral CAGA-
luciferase (CAGA-luc) with a multiplicity of infection (MOI) of 10 (10 plaque-forming units) per cell, after which luminescence was measured. The plasmid 
was kindly provided by Dr. Ten Dijke (Department of Molecular Cell Biology, Leiden University Medical Center, The Netherlands). The CAGA-boxes in the 
vector are transcribed by Smad3/4 through active TGFβ, resulting in luciferase activity (37).
Measurement of S100A8/A9 protein
S100A8/A9 concentrations were determined in serum of mice with experimental 
OA or plasma of human CHECK samples and in synovial washouts of murine knee 
joints by a sandwich enzyme-linked immunosorbent assay (ELISA) specifically for either murine or human S100A8/A9 as described previously (38).
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CHECK cohort
CHECK is a Dutch prospective cohort study of a total of 1,002 individuals with 
early symptomatic OA of the knee or hip (39). The CHECK cohort was initiated by the Dutch Arthritis Association and performed at Erasmus Medical Centre Rotterdam, Kennemer Gasthuis Haarlem, Leiden University Medical Centre, Maastricht University Medical Centre, Martini Hospital Groningen/Allied Health Care Centre for Rheumatology and Rehabilitation Groningen, Medical Spectrum 
Twente Enschede, Ziekenhuisgroep Twente Almelo, Reade/Jan van Breemen 
Research Institute and VU Medical Center Amsterdam, St. Maartenskliniek Nijmegen, University Medical Centre Utrecht, and Wilhelmina Hospital Assen.
Statistical analysis
Statistical differences were calculated using an unpaired t-test unless stated otherwise with Graph Pad Prism 5 (GraphPad Software). Differences were called 
significant with P-value < 0.05 (*), < 0.01 (**) or <0.0005(***).
Ethics
All animal experiments were approved by the local ethics committee of the Radboud University Nijmegen Medical Centre. The human study was approved by the medical ethics committees of all participating centers, and all participants gave their written informed consent before entering the study.
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Supplemental Tables and Figures
Table S1: Demographic data participants CHECK cohortDemographic parameters were not different between progressors (n=34) and non-progressors 
(n=24). BMI, Body Mass Index; BL, baseline. Total osteophyte score calculated by taking average 
osteophyte scores (0-3) of 4 locations per knee (medial and lateral tibia/femur) left and right. 
P-values were determined using Mann-Whitney test. ns=non-significant *=P<0.05
Figure S1: S100A8 protein is very sparsely expressed in the joint of S100A9 knockout 
mice.
Paraffin-embedded sections of S100A9 knockout (A) and WT mice (C57Bl/6J) on day 21 of collagenase-induced OA (B) were stained with specific anti-rabbit S100A8. A, S100A8 proteinwas sparsely expressed only in the bone marrow, not in other cells. B, S100A8 protein is abundantly expressed in synovial lining, bone marrow and growth-plate mostly.
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Abstract
Objective: S100A8 and S100A9 are two Ca2+-binding proteins classified as damage-associated molecular patterns or alarmins that are found in high amounts in the 
synovial fluid of osteoarthritis (OA) patients. The purpose of this study was to investigate whether S100A8 and/or S100A9 can interact with chondrocytes from OA patients to increase catabolic mediators.
Methods: Using immunohistochemistry, we stained for S100A8 and S100A9 
protein, matrix metalloproteinases (MMPs), and a cartilage-breakdown epitope 
specific for MMPs (VDIPEN) in cartilage from OA donors. Isolated chondrocytes or explants from OA and non-OA donors were stimulated with S100A8 and/or 
S100A9. Messenger RNA and protein levels of MMPs, cytokines, and cartilage matrix molecules were determined with quantitative reverse transcription–polymerase chain reaction and Luminex techniques, respectively. For receptor 
blocking studies, specific inhibitors for Toll-like receptor 4 (TLR-4), receptor for 
advanced glycation end products (RAGE), and carboxylated glycans were used.
Results: In cartilage from OA patients, the expression of S100A8 and S100A9 protein close to chondrocytes was associated with proteoglycan depletion and expression of MMP-1, MMP-3, and VDIPEN. Stimulation of chondrocytes with 
S100A8 and S100A9 caused a strong up-regulation of catabolic markers (MMPs 1, 
3, 9, and 13, interleukin-6 (IL-6), IL-8, and monocytes chemotactic protein 1) and 
down-regulation of anabolic markers (aggrecan and type II collagen), thereby 
favoring cartilage breakdown. Blocking TLR-4, but not carboxylated glycans or 
RAGE, inhibited the S100 effect. The catabolic S100 effect was significantly more pronounced in chondrocytes from OA patients as compared to those from non-OA patients, possibly due to higher TLR-4 expression.
Conclusion: S100A8 and S100A9 have a catabolic effect on human chondrocytes that is TLR-4 dependent. OA chondrocytes are more sensitive than normal chondrocytes to S100 stimulation. 
80
Chapter 4
Introduction
During osteoarthritis (OA) the erosion of cartilage is an important cause of pain and disability in the joint. Cartilage damage associated with OA is mainly 
caused by a shift in the balance between resorptive (or catabolic) and synthetic 
(or anabolic) capacities of chondrocytes. Catabolic activities of OA chondrocytes are characterized by elevated release of cartilage degrading enzymes, such as 
matrix metalloproteinases (MMPs), while anabolic activity of chondrocytes 
results in aggrecan and collagen type II production (1). Although OA is generally considered as a disease of the cartilage, recent evidence is accumulating that 
synovial activation and pro-inflammatory mediators released after synovial 
activation might contribute to induction of cartilage damage in OA (2-4). Arthroscopic studies suggest that synovial activation occurs in 50% of OA 
patients and that it is associated with more severe cartilage damage (5). In 
line with this, pro-inflammatory mediators released by synovial macrophages 
or fibroblasts contribute to cartilage damage, although the involvement of for 
example interleukin-1 (IL-1), tumor necrosis factor α (TNF-α) and IL-6  is still a 
matter of debate (6;7).
Apart from cytokines, damage associated molecular patterns (DAMPs), also termed alarmins, are released after activation of the synovium. Major members 
of the DAMP-family are the calcium binding proteins S100A8 (also: Myeloid 
Related Protein (MRP) 8) and its binding partner S100A9 (also: MRP14) (8-10). 
They belong to the S100-family comprising at least 20 proteins (11) and are released in large amounts by neutrophils, monocytes and activated macrophages 
(12). S100A8 and S100A9 exist as homodimers and can form S100A8/S100A9 
heterodimer complexes. They can bind to Toll-like receptor 4 (TLR4) (13), but 
associations with the receptor for advanced glycation end products (RAGE) and 
carboxylated glycans have also been described (14;15). 
In rheumatoid arthritis (RA), the S100A8/A9 heterodimer accumulates in huge 
amounts (up to 50 µg/ml) in synovial fluid and its levels strongly correlate with 
disease activity and radiological damage (8;16). Studies on serum levels of the 
S100A8/S100A9 heterodimer in RA confirm this correlation and highly support 
the diagnostic capacity of S100A8/S100A9 as a biomarker in RA (17;18). More 
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recently, we demonstrated that in arthritic mice deficient for S100A9 (in which 
myeloid cells lack S100A8 protein) cartilage destruction was almost absent and 
joint inflammation significantly reduced (19).
The role of S100A8 and S100A9 in OA is still enigmatic and evidence of its involvement mainly comes from the effects of S100A8 and S100A9 on chondrocytes in vitro. On murine and ovine chondrocytes S100A8 and S100A9 
upregulate several MMPs (14;20). And one study shows the presence of S100A8 and S100A9 in murine chondrocytes during destabilization of the medial 
meniscus (DMM) OA (20). 
In the present study, we investigated whether S100A8 and/or S100A9 is present 
in human OA cartilage and whether it is associated with cartilage breakdown. Moreover, we used human chondrocytes to explore the in vitro capacity of S100A8, S100A9 and/or the S100A8/S100A9 complex to induce a more catabolic chondrocyte. Finally, we investigated possible receptors and whether there is a difference in sensitivity between OA and normal chondrocytes. In short, our results indicate that S100A8 and S100A9 are associated with cartilage 
breakdown in human OA tissue and that they stimulate chondrocytes from 
OA patients to produce more catabolic factors (MMPs and cytokines) and less 
anabolic factors (collagen type II and aggrecan). Furthermore, the net catabolic 
effect was dependent on TLR4 and significantly higher in OA chondrocytes compared to normal chondrocytes.
Materials and Methods
S100A8/A9 proteins
Recombinant human S100A8, S100A9 and S100A8/A9 heterodimer complex 
with no LPS contamination were expressed and purified as previously described 
(21;22). Protein preparations were tested using the Limulus amoebocyte cell 
lysate (BioWhittaker, Walkersville, MD), and lipopolysaccharide (LPS) content 
was undetectable (sensitivity 0.7 ± 0.5 pg LPS/µg protein), indicating that the maximal possible contamination of the S100 protein preparations was <1.2 pg 
LPS/µg protein. S100A8 and S100A9 lost their activity while heat-inactivating 
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at 80°C for 30 minutes. LPS activity was not changed at that temperature (13). 
Tissue acquisition and chondrocyte cell culture
Human cartilage was collected from patients with OA undergoing total knee or 
hip arthroplasty or from age-matched non-OA patients suffering a femoral neck fracture of the hip. After collection, either cartilage explants of approximately 2 
x 2 mm were cut and cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
F12 (Gibco, Invitrogen, Breda, The Netherlands) supplemented with 10% fetal 
calf serum (FCS), or chondrocytes were isolated. For isolation, cartilage was 
incubated overnight with 2 mg/ml collagenase B (Roche, Mannheim, Germany) in serum-free DMEM F12 medium. The next day, the cells were washed and seeded on 24-well plates at 4x105 cells/well in DMEM F12 medium supplemented with 10% FCS. Plates were maintained for 5-7 days prior to stimulations. The Medical Ethics Committee of Radboud University Nijmegen Medical Centre approved the study protocol.
Stimulation of chondrocytes and cartilage explants
Monolayer chondrocyte cultures were stimulated with recombinant human 
S100A8, S100A9 and the S100A8/A9 complex at 1 μg/ml (unless stated 
otherwise) and 10 ng/ml human recombinant IL-1β (R&D Systems, Minneapolis, 
MN) for 24 hours. Optimal concentrations for S100 stimulations were determined 
by stimulating OA chondrocytes with 0.2, 1 and 5 µg/ml S100A8 and S100A9 
and measuring IL-6, MMP3 and -13 mRNA levels with quantitative reverse 
transcriptase PCR (RT-qPCR). In the blocking studies against TLR4, RAGE and carboxylated glycans, chondrocytes were pre-incubated for 30 minutes with 
specific blockers before stimulation with S100-proteins or IL-1β. For TLR4, 1 
µM of the small molecule inhibitor TAK242 was used (23) (CLI-095, InvivoGen, 
San Diego, CA), for RAGE a blocking anti-human RAGE antibody, 10 µg/ml (R&D 
Systems (MAB11451), Minneapolis, MN) and for carboxylated glycans 10 µg/
ml of the monoclonal antibody GB3.1 was used (24) (kind gift of G. Srikrishna 
and H. Freeze, Sanford Children’s Health Research Center, La Jolla, CA). In all 
stimulations with S100A8 and/or S100A9 and IL-1β, 10 μg/ml polymixin B was 
added (Sigma, Deisenhofen, Germany).Cartilage explants were maintained in culture for 1 day after collection, then stimulated for 24 hours with the same 
concentrations of S100 proteins and IL-1β as described above.
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Quantitative detection of messenger RNA (mRNA) levels using RT-qPCR
RNA was isolated from chondrocytes with 1 ml of TRI-reagent (Sigma-Aldrich, 
Zwijndrecht, The Netherlands). Specific mRNA levels for cytokines and 
chemokines (IL-6, IL-8, MCP-1, IL-1β, TNFα), MMPs (MMP-1, MMP-3, MMP-
9, MMP-13), aggrecan and collagen type II were detected using the ABI Prism 
7000 Sequence Detection System (PE Applied Biosystems, Foster City, CA). 
Briefly, 1 μg of total RNA was used for RT-PCR. mRNA was reverse transcribed 
to complementary DNA (cDNA) using oligo(dT) primers, and 1/20 of the cDNA was used in 1 PCR reaction. PCR was performed in SYBR Green Master Mix using 
the following amplification protocol: 2 minutes at 50°C followed by 40 cycles 
of 15 seconds at 95°C and 1 minute at 60°C, with data collection in the last 30 
seconds. mRNA for human genes was amplified using specific primers (Biolegio, 
Malden, The Netherlands) at a final concentration of 300 nmoles/liter. Relative 
quantification of the PCR signals was calculated by comparing the threshold 
cycle (Ct) value of the different genes, correcting for GAPDH content (dCt) and 
finally correcting for unstimulated conditions (ddCt).
Protein measurement using Luminex technology
To determine protein levels of MMPs (MMP-1, MMP-3, MMP-9, MMP-13) and 
cytokines/chemokines (IL-6, IL-8 and MCP-1) in chondrocyte culture medium, Luminex multianalyte technology on the Bio-Plex system was used in combination 
with multiplex MMP/cytokine kits (Milliplex from Millipore, Amsterdam, The 
Netherlands). Protein levels were measured in 25 μl of culture medium, diluted 
1:5. The sensitivity of the multiplex kit was <5 pg/ml.
Immunohistochemical detection of VDIPEN, S100 and MMPs in paraffin 
sections
Formalin-fixed specimen of cartilage from either OA or non-OA were paraffin 
embedded and 7 μm thick sections were cut. Serial sections were digested 
with proteinase-free chondroitinase ABC (0.25 units/ml) (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) to remove the glycosaminoglycan side chains. For VDIPEN, cartilage sections were incubated with rabbit anti-VDIPEN, for S100A8 and S100A9 goat polyclonal antibody anti-human S100A8 and S100A9, 
for MMP3 goat polyclonal anti-human MMP3 (all Santa Cruz Biotechnology, 
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Santa Cruz, CA) and for MMP1 goat polyclonal anti-human MMP1 (R&D Systems, 
Minneapolis, MN). The primary antibody was detected using biotinylated rabbit anti-goat, except for VDIPEN for which we used biotinylated goat anti-rabbit 
IgG and subsequently stained using avidin–streptavidin–peroxidase (Elite 
kit; Vector, Burlingame, CA). Orange G (2%) was used for counterstaining the 
VDIPEN sections, Mayer’s hematoxylin (Merck, Darmstadt, Germany) for S100A8 and S100A9 and Toluidine Blue for MMP1 and MMP3. 
Statistical analysis
Statistical differences were calculated with either paired t-test or Mann Whitney 
U test, as indicated, using Graph Pad Prism 5 (GraphPad Software,  La Jolla, CA). 
Differences were called significant with P-values < 0.05.
Results
Localization of S100A8 and S100A9 proteins in human OA cartilage and 
association with proteoglycan depletion and MMP expression
Alarmins S100A8 and S100A9 are found in high concentration (up to 5 µg/ml) 
in the synovial fluid of OA patients, possibly reflecting synovial activation (8). We analyzed whether S100A8 and S100A9 are found in human OA cartilage. For 
this, cartilage specimens obtained following hip or knee arthroplasty of several 
OA patients (n=8) were embedded in paraffin and sliced into 7 μm thick serial sections. When stained with antibodies against S100A8 and S100A9, we found that S100A8 is abundantly present close to the majority of the chondrocytes 
(>75%) in the superficial layer of the cartilage (Figure 1A). Identical staining 
was found for S100A9 (data not shown). When comparing S100 localization with 
safranin O staining (Figure 1B) we observed that S100A8 and S100A9 were only found in areas with PG loss. We also found staining of the MMP-induced neo-
epitope VDIPEN in the same areas as S100A8 and S100A9 expression (Figure 1C). Finally, MMP1 and MMP3 were also detected in the majority of the chondrocytes 
(>75%) in the superficial layer (Figure 1D-E), their expression pattern coinciding with that of S100A8 and S100A9. These results suggest that S100A8 and S100A9 proteins are expressed in similar areas of OA cartilage in which there is PG loss 
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and MMP mediated cartilage destruction. 
S100A8 and S100A9 stimulate breakdown of human cartilage matrix in 
situ through matrix metalloproteinases
Next, we wondered whether chondrocytes could be stimulated by S100 proteins 
in intact cartilage. Small proteins like S100A8 and S100A9 (homodimeric size 
24 kD) have been shown to easily penetrate intact cartilage and stimulate 
chondrocytes (25). When we stimulated cartilage explants with 1 µg/ml S100A8 
and S100A9, mRNA levels of MMP1, -9 and -13 and IL-6 were significantly 
upregulated compared to non-stimulated controls (Figure 2A). Moreover, on 
mRNA level S100A8 significantly downregulated aggrecan and collagen type II 
(Figure 2B).We concluded that S100A8 and S100A9 can have a catabolic effect on chondrocytes in situ in OA cartilage.
Figure 1 – Expression of S100A8 and several cartilage breakdown markers in 
adjoining sections of human articular cartilage from OA patients as measured  by 
immunolocalisation. 
OA cartilage was embedded in paraffin and sliced into 7µm thick serial sections. S100A8 is 
clearly seen close to the majority of (>75%) of the chondrocytes in the superficial layer of 
the cartilage (A). Expression of S100A9 shows the same pattern (not shown). Safranin-O 
staining of proteoglycans is observed in the deep layers (B). There is no proteoglycan 
staining in the superficial layer where we found S100A8 and S100A9 expression in A. VDIPEN staining as measure of MMP activation is also found in the same areas as S100A8 
and S100A9 in A (C). Isotype staining (top-right inset) is negative. MMP1 and MMP3 is also 
seen in the majority of (>75%) of the chondrocytes in the superficial layer of the cartilage 
(D-E). Isotype staining for MMP1, MMP3 and S100A8 is negative (F). Magnifications are depicted in the bottom right corner. Staining patterns are representative for 8 OA donors.
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S100A8 and S100A9 suppression of the anabolic function of human OA 
chondrocytes
To investigate the effects of S100A8 and S100A9 on human chondrocytes in 
more detail, we isolated chondrocytes from OA patients (n=8), cultured them 
for 5-7 days and stimulated them for 24 hours with 1 µg/ml S100A8, S100A9 and the S100A8/A9 complex. This concentration is also physiologically relevant, 
since S100A8/S100A9 levels in OA synovial fluid range from a few to 10 µg/
ml (8).We first studied the effect of the S100-proteins on the anabolic function 
of the chondrocyte. S100A8 and S100A9 significantly inhibited both aggrecan 
and collagen type II mRNA (S100A8 1.6 and 1.2 ddCt; S100A9 1.4 and 1.6 ddCt 
respectively) (Figure 3A). The inhibiting effect of S100A8 and S100A9 was 
compared with that of IL-1β, the most potent inhibitor for aggrecan and collagen 
type II synthesis. Although less potent than IL-1β, S100A8 and S100A9 effects 
were still 70 and 61% of the IL-1β effect for aggrecan and 26 and 35%  for collagen type II.Our results indicate that S100A8 and S100A9 have a substantial suppressive effect on cartilage matrix synthesis by chondrocytes from OA patients. 
Figure 2 – S100A8 and S100A9 have a catabolic effect on human cartilage 
explants as seen by upregulation of MMP-1, -9, -13 and IL-6 mRNA expression and 
downregulation of aggrecan and collagen type II mRNA expression.
Cartilage explants (approximately 2x2 mm) were excised from cartilage derived from 
patients undergoing total hip arthroplasty following a femoral neck fracture (n=6). 
Explants were kept in culture for 24 hours before 24 hour stimulation with 1 μg/ml human recombinant S100A8, S100A9 or S100A8/A9 heterodimer and subsequent measurement of mRNA expression by qPCR. Catabolic enzymes MMP1, -9 and -13 and pro-
inflammatory cytokine IL-6 are upregulated by S100A8 and S100A9, but not the S100A8/
S100A9 heterodimer (A). Cartilage matrix components aggrecan and collagen type II are 
downregulated by S100A8 (B).* = P < 0.05 ** = P < 0.01 *** = P < 0.005 stimulated versus non-stimulated explants by paired t-test.
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Up-regulation of MMPs 1, 3, 9, and 13 following stimulation of human OA 
chondrocytes with S100A8 and S100A9
In addition, we studied the effect of S100A8, S100A9 and its heterodimeric complex on the catabolic functions of the chondrocyte, which are largely mediated by MMPs. We focused on MMP-1, -3, -9 and -13 since they are all 
upregulated during OA (26). In previous studies we have shown that murine S100A8 but not S100A9 strongly upregulate MMPs in a murine chondrocyte cell 
line (14).S100A8 and S100A9 significantly upregulated MMP1, MMP3, MMP9 and MMP13 at the mRNA level. For S100A8 2.0, 2.0, 1.5 and 1.0 ddCt respectively, 
for S100A9 even more: 3.0, 2.6, 2.5 and 2.2 ddCt respectively (Figure 3B). The 
upregulation of MMPs was between 12 and 30% of the effect of IL-1β (a strong 
inducer of MMPs) for S100A8 and 24 to 62% for S100A9.Whether MMP proteins were released by chondrocytes after stimulation with S100A8 and S100A9 was further investigated using a Luminex-based protein assay. MMP1, -3 and -13 
protein levels in the culture medium were significantly elevated by S100A8 (2.1, 
3.0 and 3.3 fold respectively) and even more by S100A9 (2.6, 3.1 and 3.9 fold 
respectively) (Figure 3C and 3D). Compared to IL-1β, the effect of S100A8 on 
MMP1, -3 and -13 protein level was 55, 28 and 30% respectively and 63, 29 and 
26% for S100A9.In conclusion, S100A8 and S100A9 stimulation of OA chondrocytes upregulates MMP expression on mRNA and protein level.
Up-regulation of IL-1β, IL-6, IL-8, and MCP-1 following stimulation of human 
OA chondrocytes with S100A8 and S100A9
Apart from MMPs, catabolic effects of chondrocytes are mediated through several 
cytokines and chemokines. At the mRNA level, S100A8 and S100A9 upregulated 
IL-1β and IL-6 but not TNFα (S100A8: 4.3, 3.4 and 0.4 ddCt; S100A9: 5.2, 4.4 and 
0.5 ddCt respectively) (Figure 4A). Measurement of the corresponding protein levels in the culture supernatant showed that S100A8 and S100A9 strongly 
upregulated secretion of IL-6 by chondrocytes (23.7 and 34.4 fold respectively) 
(Figure 4B). However, IL-1β and TNFα protein levels were below the detection 
limit (data not shown). The chemokine IL-8, which earlier has been shown to 
induce hypertrophy in human articular chondrocytes (27), was significantly 
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upregulated upon stimulation with S100A8 and S100A9. At the mRNA level, IL-8 
was upregulated by S100A8 (3.9 ddCt) and S100A9 (5.3 ddCt) (Figure 4C). In line 
with mRNA data, secreted IL-8 protein level was also elevated (20.4 and 79.0 fold 
for S100A8 and S100A9 respectively) (Figure 4D). MCP-1, a chemokine involved 
in migration of macrophages, was significantly upregulated at the mRNA level by 
S100A8 and S100A9 (1.7 and 2.3 cycles respectively) (Figure 4C), as well as at 
the protein level in the culture supernatant (6.7 and 8.7 fold respectively) (Figure 
4D).
Taken together, our results indicate that S100A8 and S100A9 stimulate OA 
chondrocytes to produce increased levels of pro-inflammatory cytokines and 
chemokines. In sharp contrast to the strong stimulating effects of S100A8 and S100A9 homodimers, the heterodimeric S100A8/S100A9 complex did not show 
any significant effect on either MMPs (Figure 3) or cytokines and chemokines 
(Figure 4), neither on mRNA nor at the protein level. 
Figure 3 – S100A8 and S100A9 suppress mRNA levels of aggrecan and collagen type 
II and stimulate MMPs on mRNA level and on protein level in chondrocytes from OA 
patients. 
After isolation from articular OA cartilage (n=8), chondrocytes were stimulated for 24 hours with 1 μg/ml S100A8, S100A9 or S100A8/A9 complex. 10 ng/ml IL-1β served as 
positive control. mRNA levels were measured with qPCR (A, B) and MMP1, -3 and -13 total protein level was determined in culture supernatants with a Luminex-based protein 
immunoassay  (C, D). * = P < 0.05 ** = P < 0.01 *** = P < 0.005 stimulated versus non-
stimulated (medium control) chondrocytes by paired t-test.
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Catabolic effect of S100A9 on OA chondrocytes via TLR-4
Various receptors like TLR4, RAGE and carboxylated glycans have been proposed to be involved in S100A8/A9 signaling. To investigate the involvement of these receptors, we stimulated human chondrocytes from several OA donors with 
S100A9 in the presence or absence of specific blockers. For TLR4 we used an 
intracellular small molecule inhibitor (TAK242), and for both RAGE and the carboxylated glycans a neutralizing antibody. We used S100A9 as stimulator, as it proved to be the most potent form in the previous experiments. Interestingly, 
blocking TLR4 with TAK242 almost completely suppressed S100A9 mediated 
elevation of MMP3 (79% inhibition), cytokine IL-6 (83% inhibition), chemokine 
MCP-1 (79% inhibition) and collagen type II (86% inhibition) (Figure 5A). 
The upregulation of MMP1, -9 and -13 by S100A9 was also blocked by adding 
TAK242, yet to a lesser extent (60%, 69%, 52%). However, the inhibition was 
comparable to that of the LPS effect (data not shown), suggesting that perhaps 
higher concentrations of TAK242 are necessary for complete inhibition. In 
Figure 4 – S100A8 and S100A9 stimulate mRNA expression and protein release of 
several cytokines and chemokines in chondrocytes from OA patients.
After isolation from articular OA cartilage (n=8), chondrocytes were stimulated for 24 hours with 1 μg/ml S100A8, S100A9 or S100A8/A9 complex. mRNA levels of cytokines IL-1β, IL-6 and TNFα (A) and chemokines IL-8 and MCP-1 (C) were measured with qPCR. 
In the culture medium protein levels of IL-6 (B) and IL-8 and MCP-1 (D) were determined using a Luminex-based immunoassay. Protein levels of IL-1β and TNFα were undetectable 
in the culture medium. * = P < 0.05 ** = P < 0.01 *** = P < 0.005 stimulated versus non-stimulated chondrocytes by paired t-test.
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contrast, blocking of RAGE did not change S100A9-stimulated expression of 
MMPs, collagen type II or cytokines (Figure 5B), nor did blocking carboxylated 
glycans (Figure 5C). These data suggest that TLR4 is a candidate receptor for S100A8 and S100A9 signaling in human chondrocytes.
Significantly higher catabolic effect of S100A8 and S100A9 on OA 
chondrocytes than non-OA chondrocytes
To explore if chondrocytes from OA patients are more sensitive to S100A8 and S100A9, we compared the anabolic and catabolic effects of S100A8 and S100A9 on OA chondrocytes with those on non-OA chondrocytes. For this, we isolated 
chondrocytes from age-matched donors (n=4) without a history of OA that 
had suffered a femoral neck fracture. Interestingly, we found that inhibition of 
aggrecan mRNA by S100A8 and S100A9 was significantly higher in chondrocytes 
from OA patients compared to non-OA (1.4 and 1.0 ddCt difference respectively) 
(Figure 6A). S100A8 and S100A9 stimulation of non-OA chondrocytes induced 
Figure 5 – The catabolic effect of 
S100A9 on OA chondrocytes is 
mediated through TLR4, not RAGE or 
carboxylated glycancs. 
The effect of blocking TLR4 (A), RAGE 
(B) and carboxylated glycans (C) on S100A9 stimulation of OA chondrocytes 
(n=3). After isolation from articular cartilage, chondrocytes were stimulated for 24 hours with 1 μg/ml S100A9, with or without 30 minute pre-incubation 
with a specific blocker. (TAK242 for 
TLR4, anti-human RAGE blocking antibody for RAGE and GB3.1 antibody 
for carboxylated glycans). Transcript levels were measured with qPCR.
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a minor increase in mRNA level of MMP1, -3, -9 and -13 and IL-6 (data not 
shown). When comparing the effects of S100A8 and S100A9 on OA and normal 
chondrocytes, MMP3 was upregulated significantly higher in OA chondrocytes 
(1.3 and 1.3 ddCt difference respectively) (Figure 6B). Although MMP1, -9 and 
-13 and IL-6 mRNA levels were somewhat higher in OA chondrocytes, this did 
not reach statistical significance. Since we showed that TLR4 is important for S100 signaling in human OA chondrocytes, we next wondered if differences in the level of TLR4 expression could account for the heightened sensitivity for S100 in OA chondrocytes. When comparing TLR4 mRNA levels in unstimulated 
chondrocytes between OA (n=8) and non-OA donors (n=4), we found that TLR4 
mRNA is higher in OA chondrocytes, compared to non-OA (Figure 6C). These data suggest that TLR4 is upregulated on OA chondrocytes compared to non-OA chondrocytes possibly explaining why the catabolic effect of S100A8 and S100A9 is greater on OA chondrocytes than on non-OA chondrocytes. 
Figure 6 – The catabolic effect of S100A8 
and S100A9 on human chondrocytes 
is significantly higher in OA-derived 
chondrocytes, compared to non-OA and 
possibly mediated through TLR4. 
Cartilage from OA donors (n=8) and age-
matched non-OA (“normal”) donors (n=4) was collected after a hip-replacing operation 
following a femoral neck fracture. mRNA 
levels  for the anabolic marker aggrecan (A) 
and the catabolic marker MMP3 (B) after S100A8, S100A9, S100A8/A9 stimulation were measured with qPCR. TLR4 mRNA levels were measured in unstimulated OA or non-
OA chondrocytes. dCt values (corrected for 
GAPDH) are represented as relative expression 
(=2-dCt) (C).  * = P < 0.05 ** = P < 0.01 *** = P < 0.005 normal versus OA chondrocytes by Mann Whitney U test
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Discussion
In the present study we show that S100A8 and S100A9 can elicit a TLR4-
dependent catabolic effect in human chondrocytes which is significantly elevated under OA conditions. 
S100A8 and S100A9 are mostly associated with inflammation as they 
are implicated in numerous inflammatory diseases (RA, systemic lupus 
erythematosus (SLE), and psoriasis (28;29)). In RA, S100A8 and S100A9 
proteins are produced in large amounts by infiltrating myeloid cells and their 
concentration can reach up to 50 µg/ml in RA synovial fluid (8). Although it is generally accepted that OA is a disease of the cartilage, evidence is accumulating 
that synovitis also plays a significant role in OA (30). Histologically, OA patients 
of all severity grades show thickening of the synovial lining as well as increased 
inflammatory cell infiltration (31;32). The histological changes in OA are 
accompanied by an increase in inflammatory mediators in the synovium. OA 
synovium expresses significant amounts of the cytokines IL-1β, TNF and IL-6 as 
well as the chemokines IL-8 and MCP-1 (32-34). Among the most abundantly 
produced proteins in OA synovial fluid are the S100A8 and S100A9 proteins 
reaching concentrations up to 10 µg/ml (8). We now show that S100A8 and 
S100A9 strongly upregulate IL-6 , IL-8 and MCP-1 on mRNA and protein level 
in OA chondrocytes and IL-1β on mRNA level. Release of IL-8 by chondrocytes may attract granulocytes to the cartilage surface promoting cartilage destruction and increasing S100 production. IL-8 can further deteriorate cartilage integrity by causing chondrocyte hypertrophy through upregulation of collagen type X 
(35). MCP-1, which was also significantly upregulated by S100A8 and S100A9, is 
a major chemokine for monocytes/macrophages and may attract these S100A8/S100A9 producing cells towards the synovial compartment and cartilage surface. Together, the elevated production of IL-8 and MCP-1 might cause an increased 
inflammatory cell-influx and more S100A8/A9 production thereby possibly 
creating a positive feedback loop of inflammation and cartilage degradation.
Next to an effect on inflammation, we also found that S100A8 and S100A9 
stimulate production of several MMPs (MMP1, -3, -9 and -13) by OA chondrocytes, 
both at the mRNA as well as the protein level. To our knowledge, this is the first 
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study in human chondrocytes that shows upregulation of MMPs by S100A8 and 
S100A9. Previous studies performed in the mouse show that S100A9 knock-
out mice, whose myeloid cells are deficient for S100A8 protein, are protected 
against severe cartilage destruction during an antigen induced arthritis (19). Interestingly, S100A8 but not S100A9 stimulated MMP expression in an 
immortalized murine chondrocyte cell line (14). We now find, using human S100 
proteins and human primary chondrocytes, that also S100A9 is a significant 
stimulator of MMP production. This is in line with earlier findings in primary ovine chondrocytes in which both S100A8 and S100A9 upregulated several 
MMPs at the mRNA level (20). The lack of effect of S100A9 in mouse could be due to the use of an immortalized murine chondrocyte line that expresses different receptors. Studies are now in progress in which primary murine chondrocytes are used for S100 stimulation. Apart from a stimulating effect on MMPs, we show that S100A8 and S100A9 downregulate the expression of the anabolic factors aggrecan and collagen type II in OA chondrocytes. This is also in line with earlier 
studies performed in ovine chondrocytes (20). Taken together, we demonstrated that S100A8 and S100A9 elicit a net catabolic response in OA chondrocytes. 
In contrast to the homodimers S100A8 and S100A9, the S100A8/S100A9 
heterodimer only had minor effects in the current study. The lack of activity of the S100A8/A9 complex may be dependent on the species and/or cell-type. In human 
endothelial cells, the S100A8/S100A9 heterodimer increased the inflammatory 
response (36). Sunahori et al. showed that the heterodimeric complex and the S100A9 homodimer were equally active on human monocytes and macrophages 
by increasing production of pro-inflammatory cytokines (8). A recent study by our lab showed that in the mouse only S100 homodimers stimulated the expression 
of activatory Fcγ receptors in macrophages (37). No effect of the S100A8/S100A9 
heterodimer was found in murine nor ovine chondrocytes on pro-inflammatory 
cytokines and MMPs (14;20). This is in line with our results that show that the heterodimer is inactive on human primary chondrocytes. An explanation for the inactivity of the heterodimer might be that coupling of S100A8 to S100A9 shield the sites needed for receptor binding. Although not conclusively shown 
for S100A8 and S100A9 but known for other S100 proteins, the heterodimers 
may also require post-translational modification for proper functioning. S100A4 
required sumoylation to upregulate MMP13 (38) and transamidation of S100A11 
skewed chondrocytes towards a catabolic phenotype (39).
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The receptor(s) responsible for S100A8 and S100A9 signaling in chondrocytes is still under debate. Up till now various receptors have been implicated in S100A8 and/or S100A9 signaling, e.g. TLR4, RAGE and carboxylated glycans. In 
the present study we show that blockade of TLR4, but not RAGE or carboxylated 
glycans, inhibited the effect of S100A9 on MMPs and IL-6 production, suggesting that in human chondrocytes TLR4 is a major receptor for S100A8 and S100A9 signaling. TLR4 is present in primary chondrocytes and is strongly stimulated 
by TLR ligands like LPS (40). TLR4 is the major receptor for S100A8 and S100A9 
in other cell types, like macrophages. Vogl et al. showed that upregulation of 
NFκB by S100A8 is TLR4-dependent (13). Further study, performed in our lab, 
demonstrated that the upregulation of Fcγ receptors by S100A8 was completely 
absent in TLR4 knock-out macrophages (37). A few studies report the interaction 
of S100A8 and/or S100A9 with RAGE (41;42) but not in chondrocytes. Signaling through RAGE has only been showed for other S100 family members, most notably 
S100A11 and S100A4 (27;43). Combining these two observations, it is unlikely that RAGE plays a role in the signaling of S100A8 and S100A9 in chondrocytes. 
Carboxylated glycans mediate transendothelial leukocyte migration by S100A8/
A9 (44). Contrasting the results shown in the current study, earlier studies in our lab show that carboxylated glycans are also important in S100A8 signaling 
in a murine chondrocyte cell-line (14). However, immortalization of this cell-line caused low expression levels of TLR4 and internalization of this receptor, 
possibly making carboxylated glycans the preferred S100-receptor. Finally, we show that TLR4 has a higher expression in isolated chondrocytes from OA 
patients than from non-OA patients. While this contradicts with findings from 
Zhang et al. (45), their study focused on intact femoral heads instead of isolated and cultured chondrocytes. 
Coinciding with our results, chondrocytes from OA patients are more sensitive to S100A8 and S100A9 signaling, adding to the evidence that TLR4 is important 
in S100 signaling in primary human chondrocytes. Possibly, pro-inflammatory factors released by the activated synovium during OA may be responsible for upregulation of TLR4 and a higher sensitivity to TLR4-ligands such as S100A8 and S100A9.
Taken together, we conclude that it is very likely that TLR4 is the preferred receptor for S100A8 and S100A9 both in monocytes and macrophages as well 
as in the chondrocyte. The role of S100A8 and S100A9 in inflammation has 
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been established in recent years. However, its role in cartilage destruction is just starting to get unraveled. Cartilage damage is the most important feature in OA, 
with synovitis playing an increasingly significant role in the pathophysiology. 
This study links the effects of S100A8 and S100A9 as one of the most upregulated 
proteins during synovial activation to cartilage damage in OA and solidifies the potential of S100A8 and S100A9 as mediators of cartilage destruction in OA.
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Abstract
Background: Alarmins S100A8/A9 have been shown to regulate synovial activation, cartilage damage and osteophyte formation in osteoarthritis (OA). In the current study we investigated the effect of S100A9 on OA synovium, M1- and 
M2-macrophages and OA fibroblasts.
Methods: End stage OA synovial explants, OA fibroblasts and human monocyte-derived M1- and M2-macrophages were stimulated with S100A9 and mRNA and 
protein levels of pro-inflammatory cytokines and MMPs were measured using RT-qPCR and Luminex. 
Results: S100A9 upregulated pro-inflammatory cytokines IL-1β, -6, -8 and TNFα 
and MMP-9 in OA synovial explants ex vivo. However, in OA fibroblasts S100A9 
had no significant effects on these mediators. S100A8/A9 mRNA and secreted protein was higher in M1- compared to M2-macrophages. Additional stimulation 
of M1-macrophages with S100A9 induced pro-inflammatory mediators IL-1β, -6, 
-8 on mRNA and IL-6 , -8 and TNFα on protein level and MMP-1 and -3 on mRNA. 
In M2-macrophages, S100A9 also upregulated these cytokines, yet to a lesser extent than in M1-macrophages. The mRNA level of TLR4 , the main receptor 
for S100A8/A9, was significantly lower in OA fibroblasts than in M1- and M2-macrophages
Conclusion: Alarmin S100A9 strongly upregulates pro-inflammatory and catabolic mediators in OA synovium and in both M1- and M2-macrophages, but 
not fibroblasts.
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Introduction
Synovial inflammation is found in a large subgroup of osteoarthritis (OA) patients and it is believed to contribute to OA pathology (1, 2). The synovial intima layer 
consists of mainly two cell-types: the macrophage-like (type A) and fibroblast-
like synoviocytes (type B). Although there are fewer synovial macrophages present in OA compared to rheumatoid arthritis (RA), they are crucial for the 
production of pro-inflammatory cytokines (such as IL-6 and IL-8) and cartilage 
matrix degrading enzymes, matrix metalloproteinases (MMP)-1 and -3 (3). Previous studies in our lab have shown that selective depletion of synovial macrophages during experimental OA largely reduces cartilage damage and 
osteophyte formation, two major hallmarks of OA (4, 5). Analogous to the Th1/Th2 nomenclature, classically activated and alternatively activated macrophages 
can be categorized as M1 and M2 macrophages respectively (6, 7). M1 
macrophages can produce numerous pro-inflammatory cytokines such as TNFα 
and IL-1β and express MHC class II and CD86 receptors, while M2 macrophages 
produce anti-inflammatory cytokines IL-10 and IL-1RA and express scavenger 
receptor CD163 and mannose receptor (CD206) (7, 8). 
Activation of the synovium during OA induces release of large amounts of 
alarmins S100A8 and S100A9 which can be easily measured in synovial fluid as 
well as in serum (9, 10). S100A8/A9 proteins are pro-inflammatory mediators 
produced by myeloid cells like monocytes and activated macrophages and have been shown to stimulate cells via TLR4. S100A8/A9 proteins exist as homodimers 
and heterodimers. The pro-inflammatory activity is particularly mediated by the 
homodimeric forms of S100A8 and S100A9. Earlier, we found that mice deficient for S100A9 (that also have no functional S100A8 protein) are largely protected against cartilage damage and synovial activation during collagenase induced OA 
(10), while also development of osteophytes was considerable less (Chapter 3). Furthermore, we showed that S100A8/A9 levels in the serum are elevated in early symptomatic OA patients and that high levels of these alarmins predict more cartilage damage and larger osteophytes at later stages in the disease 
(10)(Chapter 3). Earlier, we found that murine S100A8 induces release of TNFα in murine phagocytes (11) and human S100A8 and S100A9 were both able to 
induce a catabolic and pro-inflammatory phenotype in human OA chondrocytes, 
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in both cell-types via TLR-4 (12).
In the current study we analyzed S100A8/A9 production in M1- and M2-macrophages. Then we investigated the effects of S100A9 on the total cell 
population of human OA synovium and additionally zoomed in to specific effects 
of S100A9 on OA fibroblasts and macrophage subsets M1 and M2.
Materials and Methods
Human OA synovium
Permission of patients and the local ethics commission was obtained prior to harvesting of study samples. Human OA synovium was obtained from patients 
undergoing total knee or hip joint replacement surgery. Control synovium from 
patients with acute knee joint trauma was obtained at the time of arthroscopic examination.
Micro-array analysis
Preparation of complementary DNA and subsequent microarray analysis was 
done as described before (13). In short, generation of biotinylated complementary 
RNA, hybridization, and subsequent staining of MOE 430_2 oligonucleotide arrays (Affymetrix) was performed according to the Affymetrix Expression 
Analysis Technical Manual for 1-cycle amplification. Arrays were scanned using a laser scanner (GeneChip Scanner; Affymetrix) and analyzed using Affymetrix GeneChip Operating Software, version 1.4. Array normalization, expression value calculation, and clustering analysis were performed using DNA-Chip Analyzer 
(dChip) software, version 1.3 (online at www.dchip.org).
Immunohistochemistry and stimulations of human OA synovium
Synovium pieces of approximately 2x2 mm were cut from synovium obtained anonymously from end-stage OA patients undergoing arthroplasty. Pieces were 
randomized and 3 pieces/well were stimulated in quadruple for 24h with 1 µg/ml recombinant human (rh) S100A9 (developed in our labs (14)), other pieces 
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were fixed in formalin and afterwards embedded in paraffin. Tissue sections of 
7 µm were cut, de-paraffinized and stained with mouse anti-human CD68 (clone 
KP1, Dako) and mouse anti-human CD163 (clone 10D6, Abcam).
Differentiation and stimulation of human M1- and M2-macrophages
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers after density gradient centrifugation of heparinized blood with Ficoll. 
Monocytes were isolated by magnetic-activated cell sorting (MACS) with specific CD14+ magnetic beads (Miltenyi Biotec). Monocytes were differentiated into M1 
and M2 macrophages by adding 50 ng/ml rhGM-CSF or 20 ng/ml rhM-CSF (both 
R&D Systems), respectively, for 6 days with changing of the medium halfway. M1 
and M2 macrophages were stimulated for 24h with 1 µg/ml rhS100A9 or 1 ng/
ml rhIL-1β, after which cells were lysed in TRI-reagent (Sigma) for RNA isolation or collected in phosphate buffered saline (PBS) with 1% bovine serum albumin 
(BSA) for flow cytometry. Supernatants were collected and stored at -20 °C to be measured for protein release by Luminex.
RNA isolation and RT-qPCR
RNA was isolated from OA fibroblasts and M1-M2 macrophages using TRI-
reagent (Sigma-Aldrich), as described previously (15). OA synovium pieces 
were disrupted first with the MagNA Lyser (Roche) 5 times for 20 seconds at 
6500 rpm and then RNA was isolated using the RNeasy-kit (Qiagen) according to the manufacturers protocol. RNA was reverse transcribed to cDNA and RT-
qPCR was performed with specific primers and the SYBR Green Master mix in the StepOnePlus real-time PCR system (Applied Biosystems) as described before 
(15). Expression levels are expressed as minus delta Ct (ΔCt) values, normalized to the reference gene GAPDH.
Multiplex cytokine and matrix metalloproteinase protein measurement 
with Luminex
To determine protein levels of MMPs (MMP-1, MMP-3, MMP-9, MMP-13) and 
cytokines/chemokines (IL-6, IL-8 and TNFα) in culture medium, Luminex multianalyte technology on the Bio-Plex 100 system (Bio-Rad) was used in 
combination with multiplex MMP/cytokine kits (Milliplex from Millipore), 
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according to the Milliplex protocol. 
S100A8/A9 proteins and ELISA
Recombinant human S100A9 were expressed and purified as previously described (14). Protein preparations were tested using the Limulus amoebocyte cell 
lysate (BioWhittaker), and lipopolysaccharide (LPS) content was undetectable 
(sensitivity 0.7 ± 0.5 pg LPS/µg protein), indicating that the maximal possible 
contamination of the S100 protein preparations was <1.2 pg LPS/µg protein. 
S100A9 lost activity while heat-inactivating at 80°C for 30 minutes. LPS activity was not changed at that temperature (11). S100A8/A9 concentrations were determined in supernatants of CD14+ monocytes and M1- and M2-macrophages 
by a sandwich enzyme-linked immunosorbent assay (ELISA) specifically for 
human S100A8/A9 as described previously (16).
Isolation and stimulation of human OA synovial fibroblasts
Human synovial fibroblasts originated from OA patients undergoing arthroplasty 
of knee or hip. OA synovium was isolated and tissue samples of approximately 
2x2 mm were cultured for several weeks until adherent cells appeared. Adherent 
cells were considered fibroblasts on morphology. Non-adherent cells and tissue 
fragments were discarded. Fibroblasts were stimulated with 1 µg/ml S100A9 
or with 1 ng/ml IL-1β for 24 hours. After stimulation, cells were lysed in TRI-
reagent (Sigma) for mRNA measurement and supernatants were stored at -20°C for protein measurement.
Flow cytometry
S100A9-stimulated M2 macrophages were dissolved in PBS with 1% BSA and 
incubated with mouse anti-human CD163 (MAB1607, R&D Systems) followed 
by goat anti-mouse coupled with fluorescein isothiocyanate (FITC) (626312, 
Life Technologies) or with mouse anti-human CD206-FITC labelled (321104, Biolegend) only. Fluorescence was measured at 488 nm with the FACS Calibur (BD Bioscience) and analyzed using FlowJo software (TreeStar).
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Statistics
Statistical differences were calculated with Students t-test, using Graph Pad 
Prism 5 (GraphPad Software). Differences were called significant with P-values 
< 0.05. Statistical analysis for array-based gene expression was performed using 
dChip software. The t statistic was computed as (mean1 - mean2)/√(SE(mean1)2 + SE(mean2)2); its value is calculated based on the t distribution, and the degree 
of freedom is set according to Welch modified two sample t test (17).
Results
Presence of M1 and M2 macrophages and expression of S100A8/A9 in OA 
synovium
Previously, we described that S100A8 and S100A9 mRNA were increased in OA synovium compared to normal synovium from patients in which acute joint trauma was suspected (11- and 10-fold, (10)). Synovial macrophages in 
OA express an activated phenotype but there is little known about their exact activation status (M1 versus M2). Now, we investigated gene expression of M1- 
and M2-markers in OA synovium using micro-array. For that, we used whole synovium explants from end-stage OA patients and healthy controls. Classical 
M2 markers CD163 and CD206 were present in total OA synovium, as well as 
anti-inflammatory M2 mediators IL-10 and IL-1RA (Table 1). CD206 and IL-10 
were significantly upregulated in OA synovium (2.18 and 2.32 fold compared 
to healthy) while CD163 and IL-1RA were not significantly changed. M1 
markers CD86, CD64 and TLR4 were also present in OA synovium, with CD86 
being the only one significantly upregulated (1.8 fold) compared to healthy synovium (Table 1). These results indicate elevated presence of both M1 and 
M2 markers in OA synovium. Next, we confirmed the micro-array results with 
immunohistochemistry on paraffin-embedded sections of human OA synovium. 
We stained consecutive sections with CD68, a general macrophage marker and 
CD163, a specific M2 marker. CD68 was highly expressed in the synovial lining layer (Figure 1). Interestingly, in the same area there was also clear expression of 
CD163 (Figure 1). This suggests that there is a mixture of M2 and other possible 
more M1-like macrophages within the OA synovial lining layer.
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Fold change compared 
to healthy control
p-value Significance after 
correction for 
multiple testing
M2-markers
CD163 1,43 (-) 0,30 n.s.
CD206 2,18 (+) 0,02 *IL-10 2,32 (+) 0,01 *IL-1RA 2,1 (+) 0,04 n.s.
M1-markers
CD86 1,8 (+) 0,03 *
CD64 (FcγRI) 1,73 (+) 0,36 n.s.TLR4 1,67 (+) 0,05 n.s.
S100A8/A9 is expressed and secreted in high amounts by M1-macrophages 
and to a lesser extent by M2-macrophages
When entering the inflamed OA joint monocytes can differentiate into various 
macrophage phenotypes like pro-inflammatory M1 or anti-inflammatory M2, 
depending on the type of cytokines they meet within the synovium. While it 
is known that monocytes and activated macrophages produce and release 
S100A8/A9, nothing is known about the relative contribution of M1- and M2-macrophages. To investigate this, we differentiated human CD14+ monocytes into M1- or M2-macrophages and measured S100A8 and S100A9 mRNA levels 
and secreted S100A8/A9 protein and took along monocytes as positive control. 
Both S100A8 and S100A9 mRNA were significantly higher expressed in M1-
macrophages compared to M2 (65.1 and 2.4-fold respectively) (Figure 2). In line 
with that, M1 macrophages produced significantly higher amounts of S100A8/
Table 1: Micro-array analysis of several M1- and M2-macrophage markers in OA 
synoviumSynovial RNA was isolated from end-stage OA patients undergoing arthroplasty of hip or 
knee and from healthy controls. Subsequent microarray analysis was performed on MOE 
430_2 oligonucleotide array (Affymetrix). M1-macrophage markers CD86, CD64 (FcγRI) 
and TLR4 and M2-macrophage markers CD163, CD206, IL-10 and IL-1RA were compared 
to healthy synovium. Both M1- and M2-macrophage markers were all expressed in OA 
synovium. Of M2-markers, CD206 and IL-10 were significantly upregulated compared to 
healthy synovium, while of M1-markers only CD86 was significantly upregulated.
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A9 protein compared to M2 (164% increase), and similar amounts of S100A8/A9 protein compared to monocytes (Figure 2).
S100A9 has pro-inflammatory effects on total OA synovium
S100A8 and S100A9 stimulate macrophages via TLR4 releasing additional S100 
proteins and DAMPS, thereby forming a positive feedback-loop. Here, we studied whether S100A9 could stimulate OA synovium. We used S100A9 only, since we have shown before that it is the most potent human form and S100A8 and S100A9 
show similar effects (12). Explants of whole OA synovium, containing fibroblasts and M1/M2 macrophages were stimulated ex vivo with human S100A9 and IL-
1β as a positive control for 24h. S100A9 significantly induced mRNA expression 
of pro-inflammatory genes IL-1β, IL-6, IL-8 and TNFα (4.6, 2.7, 2.3 and 1.3 cycles 
compared to medium, respectively) and of catabolic MMP-9 (1.6 cycles), not of 
MMP-1, -3 and -13. (Figure 3A). Also, protein release of IL-6, IL-8 and TNFα was upregulated by S100A9 (9-, 14- and 22-fold increase respectively), while IL-
1β protein could not be detected. S100A9 did not significantly change protein 
release of MMP-1, -3 and -9 (1.6-, 1.8- and 1.1-fold increase respectively). MMP-
13 could not be detected in the supernatant (Figure 3B). 
Figure 1: Expression of different macrophage markers in OA synovium
Synovial explants of end-stage OA patients undergoing arthroplasty of hip or knee were 
embedded in paraffin and tissue sections of 7 µm were cut.  Consecutive sections were 
stained with specific antibodies against human CD68 (a common macrophage marker) 
or human CD163, a specific M2-macrophage marker or isotype IgG. Clear and abundant 
expression of CD68 was observed in mainly the lining layer of the OA synovium. CD163 was also clearly expressed in the lining layer of the synovium, suggesting presence of M2-macrophages.
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Figure 2: S100A8/A9 is expressed and released highly by M1-macrophages and to a 
lesser extent by M2-macrophagesHuman monocytes were differentiated into M1- or M2-macrophages and mRNA expression and protein release of S100A8 and S100A9 were measured, also in the undifferentiated 
monocytes. S100A8 and S100A9 mRNA expression was significantly higher in M1- compared to M2-macrophages, while S100A9 mRNA expression in monocytes were even higher as in M1-macrophages. M1-macrophages release similar amounts of S100A8/A9 
protein compared to monocytes yet significantly higher than M2-macrophages. N=11 
donors. Every dot represent a separate donor. * = P<0.05, ** = P<0.01, *** = P<0.005 as measured by Students t-test.
Figure 3: S100A9 increases pro-inflammatory mediators in OA synoviumWhole OA synovium from end-stage OA patients undergoing arthroplasty of hip or 
knee was stimulated ex vivo with S100A9 and IL-1β as a positive control. A. S100A9 
significantly induced mRNA expression of pro-inflammatory genes IL-1β, IL-6, IL-8 and TNFα  and of MMP-9, not of MMP-1, -3 and -13. B. Protein release of IL-6, IL-8 and TNFα was upregulated by S100A9, while IL-1β protein could not be detected. S100A9 did not 
significantly change protein release of MMP-1, -3 and -9. N=8 donors, although in some 
cytokine or MMP levels were below detection level. Every dot represent a separate donor. 
* = P<0.05, ** = P<0.01, *** = P<0.005 as measured by Students t-test. med=medium, 
A9=S100A9, IL1=IL-1β
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S100A9 has no effects on OA fibroblasts
Next, we investigated whether synovial fibroblasts may significantly contribute to 
S100A9 upregulation of pro-inflammatory and catabolic factors in OA synovium. Fibroblasts were isolated from end-stage OA synovium by letting cells grow out 
and adhere to the plate for 1-2 weeks. Then we stimulated the fibroblasts with 
S100A9 (with IL-1β as positive control) for 24h, isolated mRNA and collected supernatants for protein measurement. No effect of S100A9 on mRNA expression 
of IL-1β, IL-6 and IL-8, nor on MMP-1 and -3 could be observed, while IL-1β 
strongly upregulated these genes in OA fibroblasts (Figure 4A). On protein level, 
S100A9 slightly upregulated IL-8 protein release, yet not significantly (2.4-fold 
increase), but not IL-6 (1.2-fold increase), while TNFα and IL-1β could not be detected (Figure 4B). 
Figure 4: S100A9 has no significant effects on OA fibroblasts
OA fibroblasts were isolated from end-stage OA patients undergoing arthroplasty of 
hip or knee and stimulated with S100A9 and IL-1β as a positive control. A. On mRNA 
level, S100A9 did not change expression of cytokines IL-1β, IL-6 and IL-8, nor of MMP-1 
and -3, while TNFα and MMP-9 and -13 were below detection level. In contrast, IL-1β 
significantly upregulated IL-1β, IL-6 and IL-8, and MMP-1 and -3. B. S100A9 also did not 
increase release of cytokines IL-6 and IL-8 by OA fibroblasts. IL-1β, TNFα, MMP-1, -3 and 
-9 could not be detected on protein level. N=5 donors, although in some cytokine or MMP 
levels were below detection level. Every dot represent a separate donor. * = P<0.05, ** = 
P<0.01, *** = P<0.005 as measured by Students t-test. med=medium, A9=S100A9, IL1=IL-1β
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S100A9 has pro-inflammatory and catabolic effects on M1-macrophages 
Next, we studied S100 stimulation of macrophages exhibiting different phenotypes. We differentiated human CD14+ monocytes into M1 or M2 macrophages and stimulated them with S100A9 for 24h, followed by measuring mRNA expression and protein release in the supernatant. S100A9 stimulation 
of M1 macrophages significantly upregulated mRNA levels of pro-inflammatory 
cytokines IL-1β, IL-6 and IL-8 (6.2, 3.8 and 4.4 cycles compared to medium, 
respectively), but not that of TNFα (0.1 cycles). Moreover, MMP-1 and -3 mRNA 
were also significantly upregulated (3.4 and 2.9 cycles compared to medium, 
respectively) (Figure 5A). On protein level, IL-6, IL-8 and TNFα were highly 
upregulated by S100A9 (90-, 33- and 167-fold increase), while IL-1β, MMP-1, -3 
and -9 could not be detected on protein level (Figure 5B).
S100A9 has pro-inflammatory effects on regulatory M2-macrophages
Interestingly, S100A9 stimulation of the anti-inflammatory M2-macrophage also 
increased mRNA levels of IL-1β, IL-6 and IL-8 (5.0, 2.3 and 3.0 cycles compared 
to medium, respectively) but not TNFα (-0.2 cycles) (Figure 6A). Cytokine 
upregulation in M2 was slightly lower (1.2, 1.5 and 1.4 cycles respectively) than 
in M1-macrophages. In contrast to M1-macrophages, MMP-1 and MMP-3 mRNA 
were not upregulated in M2 (Figure 6A). On protein level, S100A9 also elevated 
release of pro-inflammatory cytokines IL-6, IL-8 and TNFα (41-, 67-, and 290-fold increase), although to considerably lower absolute amounts in M2 than in 
M1 macrophages (Figure 6B). Again, MMP-1, -3, and -9 protein levels were below detection level. We also measured mRNA expression of M1 and M2 receptors 
after S100A9 stimulation. Both M1 and M2 receptor markers CD86 / FcγR1 and 
CD163 / CD206 were not changed at the mRNA level, although a non-significant 
trend towards reduction of CD206 was observed (Figure 6C). Next, expression of 
M2 markers CD206 and CD163 was measured using flow cytometry. Expression 
of CD206 was significantly down-regulated by S100A9, both on the total 
percentage of positive cells as on the mean fluorescence intensity (MFI). Protein 
expression of CD163, another classical M2-marker, was however not affected by 
S100A9 stimulation of M2 macrophages (Figure 6D). Finally, we investigated why S100A9 stimulation may be more potent on macrophage subtypes M1 and M2 
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than on fibroblasts. As TLR-4 has earlier been shown to be the main receptor for signaling S100A8/A9 (11, 12, 18), we measured basal mRNA expression of TLR-
4 on OA fibroblasts, M1- and M2-macrophages. TLR-4 mRNA was significantly 
higher in both M1- and M2-macrophages, compared to fibroblasts (2.5 and 
3.5 cycles, respectively), while there was no significant difference in TLR-4 
expression between M1- and M2-macrophages (Figure 6E).
Figure 5: S100A9 increases pro-inflammatory and catabolic mediators in M1-
macrophagesHuman CD14+ monocytes were differentiated into M1-macrophages with GM-CSF and stimulated with S100A9 for 24h, followed by measuring mRNA expression (A) and protein release (B). A. S100A9 significantly upregulated mRNA expression of pro-inflammatory 
cytokines IL-1β, IL-6 and IL-8, not TNFα. Also mRNA of MMP-1 and -3 were upregulated by S100A9. B. On protein level, S100A9 significantly upregulated cytokine release of IL-6 
and TNFα. IL-8 protein release was increased by S100A9, however this did not reach 
significance. IL-1β, MMP-1, -3 and -9 could not be detected on protein level. N=5 donors in A, n=8 in B, although in some cytokine or MMP levels were below detection level. Every 
dot represent a separate donor. * = P<0.05, ** = P<0.01, *** = P<0.005 as measured by Students t-test.
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Figure 6: S100A9 has pro-inflammatory effects on M2-macrophagesHuman CD14+ monocytes were differentiated into M2-macrophages with M-CSF and stimulated with S100A9 for 24h, followed by measuring mRNA expression (A-C), protein release (B) or protein expression on the membrane (D). A. S100A9 significantly 
upregulated mRNA expression of pro-inflammatory cytokines IL-1β, IL-6 and IL-8, not TNFα, in M2-macrophages. mRNA expression of MMP-1 and -3 were not upregulated by S100A9 in M2-macrophages. B. On protein level, S100A9 significantly upregulated 
cytokine release of IL-6, IL-8 and TNFα by M2-macrophages, although the absolute levels reached were lower as by M1-macrophages. C. S100A9 stimulation of M2-macrophages 
did not significantly change  mRNA expression of M1- and M2-macrophage markers CD86, FCγRI (CD64), CD163 and CD206. D. As measured by flow cytometry, S100A9 stimulation 
of M2-macrophages downregulated M2-marker CD206 on Median Fluorescence Intensity 
(MFI) and total percentage of positive cells. M2-marker CD163 was not changed on the membrane of M2-macrophages by S100A9 stimulation. E. mRNA levels of TLR4, described 
receptor for S100A9, was higher in M1- and M2-macrophages compared to OA fibroblasts. 
N=8 donors in A and C, n=10 in B, n=3 in D and variable in E. Every dot represent a 
separate donor. * = P<0.05, ** = P<0.01, *** = P<0.005 as measured by Students t-test. 
med=medium, A9=S100A9
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Discussion
In the current study we show that alarmins S100A8/A9 can upregulate pro-
inflammatory and catabolic mediators in OA synovium ex vivo. Moreover, 
S100A9 can induce pro-inflammatory and catabolic mediators not only in pro-
inflammatory M1 type macrophages, but interestingly also in regulatory M2 macrophages, inducing an intermediate M1/M2 macrophage phenotype.
In this study micro-array analysis of OA synovium showed presence of both M1- 
and M2-macrophage markers, while we could confirm the expression of the M2 
marker CD163 in OA synovium using immunohistochemistry. CD86 and CD206 
can also be expressed by other immune cells like dendritic cells and B-cells. However, involvement and presence of these cells in OA is very low. Moreover, 
Fahy et al. recently showed combined presence of CD86 (M1 marker) and 
CD206 (M2 marker) in OA synovium by histology (19). In spondyloarthritis and rheumatoid arthritis both types are equally present as well (20). Together with our data, this suggests presence of both M1- and M2-macrophages in arthritic synovium. 
From several studies it seems clear that macrophages in OA exhibit an activated 
phenotype, producing amongst others IL-6, IL-8 and vascular endothelial growth factor (VEGF). Moreover, OA synovial cell cultures depleted of macrophages no 
longer produce IL-1β and TNFα (3, 21) suggesting that the macrophage is the 
major cell type regulating the release of pro-inflammatory factors in OA synovial 
activation. From experimental OA models we know that synovial inflammation 
and IL-1β, TNFα and IL-6 are high only at the start of OA, while waning at later time-points (10). In contrast, S100A8 and S100A9 stay high during the course of 
the model. Seen in this light, M1-macrophages could well be dominant in the first 
phase, while M2-macrophages take over in the end stages of the disease. Both cell phenotypes however can produce S100A8 and S100A9 and become strongly activated after addition of these proteins as we have shown in the current study. 
By this mechanism, S100A8 and S100A9 can perpetuate synovial inflammation throughout the disease course of OA.
In our study, we show that S100A8 and S100A9 are preferentially expressed and 
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produced by M1-macrophages, even as high as monocytes, known to be potent producers of S100 (22). In line with our results, a recent mouse study by Dessing et al. shows that also murine bone-marrow derived M1-macrophages express more S100A8 and S100A9 mRNA than M2. Moreover, they show that S100A9 -/- bone marrow cells preferentially differentiate into arginase-1 positive M2-
type macrophages, suggesting absence of S100-proteins skews macrophages to 
an M2-phenotype (23). 
We also show that S100A9 acts most potently on M1-macrophages, but is also a strong stimulator yet slightly less potent, of M2-macrophages, while there is no 
significant effect of S100A9 on synovial fibroblasts. This difference in potency might be due to the expression levels of TLR4, as we show by qPCR. In line with 
this, we showed earlier that upregulation of TNFα in monocytes by S100A8 is 
TLR4-dependent (11) and that upregulation of Fcγ receptors by S100A8 was completely absent in TLR4 -/- macrophages (24). Moreover, we demonstrated that TLR4 also mediated S100A8/A9 effects in both chondrocytes and osteoclasts (12, 18). Some studies report the interaction of S100A8 and/or S100A9 with 
RAGE (25), yet signaling through RAGE is only reported for other S100 family 
members S100A11 and S100A4 (26, 27). TLR4 expression in synovial fibroblasts however is not completely absent, and S100A8/A9 could still have some effects. This could be due to the different signaling pathways of TLR4. Recently, we found 
that TLR4 signaling in fibroblasts is specifically TGFβ-activated kinase (TAK1) 
independent (28), while TAK1 is a key regulator of TLR mediated activation of 
NFκB and mitogen activated protein kinase (MAPK) pathways in macrophages. 
Moreover, S100A8 and S100A9 have been shown to act via the TAK1-NFκB pathway (29). Possibly, TLR4 signaling through the MyD88-TAK1 dependent 
pathway might be less dominant or even ablated in fibroblasts.
Interestingly we found that stimulation of M2-macrophages with S100A9 
upregulated pro-inflammatory cytokines and down-regulated M2 marker 
CD206, while CD163, another well-known M2 marker, was not changed. Earlier 
studies show that skewing of M2- to M1-type myeloid-derived cells can be 
induced with LPS, which also acts via TLR4 (30). Another factor that has been 
described to skew M2 towards M1 is oxidized low-density lipoprotein (LDL) 
inducing pro-inflammatory cytokines IL-6, -8 and MCP-1 in M2-macrophages 
(31). Interestingly, we showed earlier that (oxidized) LDL increases S100A8 
expression in synovial macrophages (15), suggesting that the effect of (oxidized) 
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LDL runs via S100A8/A9. M1 and M2 are macrophage phenotypes at the opposite sides of a spectrum, with multiple intermediate stages. The group of Schultze differentiated human M1 and M2 macrophages with GM-CSF and M-CSF (similar to our approach) and consequently stimulated these with 28 different stimuli. When analyzing the transcriptome, they found that macrophages have the ability 
to respond specifically and differently to each stimulus (32). Apparently, also 
S100A9 skews the M2-macrophage towards a yet undefined pro-inflammatory macrophage. 
Taken together, our study indicates that S100A8/A9 can induce and perpetuate 
a pro-inflammatory loop in OA synovium via M1-macrophages and to a lesser extent M2-macrophages. Considering the long-time expression of S100A8/A9 in the synovium during OA, targeting these proteins could be an interesting option for future therapies of OA.
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Abstract
Objectives: Alarmins S100A8/A9 regulate pathology in experimental osteoarthritis (OA). Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. We investigated the effect of paquinimod on experimental OA and human OA synovium.
Materials and Methods: Two OA mouse models differing in level of synovial activation were treated with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod.
Results: Paquinimod treatment of collagenase-induced OA (CIOA) resulted in 
significantly reduced synovial thickening (57%), osteophyte size at the medial 
femur (66%) and cruciate ligaments (67%) and cartilage damage at the medial 
tibia (47%) and femur (75%). In contrast, paquinimod did not reduce cartilage damage and reduced osteophyte size only slightly in DMM (destabilization of the medial meniscus), an OA model with considerably lower synovial activation compared to CIOA. In human OA synovium, paquinimod blocked pro-
inflammatory (IL-6, IL-8, TNFα) and catabolic (MMP-1 and -3) factors induced by S100A9. 
Conclusions: Paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and can block pathological effects of S100A9 in OA synovium ex vivo.
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Introduction
Osteoarthritis (OA), one of the ten most disabling diseases in developed countries, has no effective therapy to date. Although historically considered a disease of the cartilage only, it is now clear that other tissues like the synovium also play an important role in the pathophysiology of OA (1). Synovial activation is present 
in at least 50% of OA patients (2) and several pro-inflammatory mediators have been shown to be involved in OA pathology (3, 4), among which alarmins S100A8 and S100A9. In recent studies, we have shown that S100A8/A9 is high in serum and synovium of OA patients and predictive for cartilage damage and osteophyte 
formation (Chapter 3 and (5)). S100A9 -/- mice show reduced joint pathology in collagenase-induced OA (CIOA), a model with considerable synovitis. However, 
no effect of the absence of S100A9 was seen in the surgical, non-inflammatory 
DMM model (destabilization of the medial meniscus) (5). S100A8 and S100A9 are endogenous ligands for TLR-4 (6) and blocking this interaction in OA 
chondrocytes reduces the catabolic effects of these alarmins (7). Quinoline-3-
carboxamide paquinimod (ABR-215757) is effective in experimental lupus and encephalomyelitis and proven to be safe and well tolerated in SLE patients (8, 
9). Paquinimod binds with high affinity to both human and mouse S100A9 and 
specifically blocks the interaction of S100A9 to its receptors TLR-4 and RAGE (10). 
In the current study we investigated the effect of the S100A9-blocking compound paquinimod on experimental osteoarthritis with different degrees of synovial activation. Furthermore, we tested the in vitro effects of paquinimod on human OA synovial tissue.
Material and Methods
Human OA synovium preparation and stimulation
Human synovium was obtained anonymously from OA patients undergoing arthroplasty. Synovium pieces (2x2 mm)  were randomized and 3 pieces/
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well were cultured and stimulated in quadruplo for 24h with 1µg/ml human 
S100A9, 350 µM paquinimod or both (30 minutes pre-incubated). Thereafter, 
synovium pieces were weighed and fixed in formalin and embedded in paraffin 
for histological analysis with hematoxylin-eosin (HE) staining and with a specific mouse anti-human CD68 (clone KP1, Dako). OA synovium supernatant was collected for protein measurement on the Bio-Plex 100 Luminex system (Bio-rad).
Animals and animal models
Experimental OA was elicited in 12-14 weeks old male C57BL/6J (Janvier) and 
S100A9-/- in a C57BL/6 background. Mice were housed in groups of 10 animals 
in filter-top cages, and water and food were provided ad libitum. Collagenase-
induced osteoarthritis (CIOA) was performed by 2x 1U collagenase (C0773, Sigma) injection into the knee-joint (11). Destabilized medial meniscus (DMM) OA was induced by transection of the medial anterior meniscotibial ligament (12). All animal experiments were approved by the local authority Animal Care and Use Committee and local ethics committee (RU-DEC 2012-232) and were 
performed by personnel certified by the Dutch Ministry of WVC.
Paquinimod preparation and administration
Paquinimod (ABR-215757) was synthesized by Active Biotech AB and 
administered in the drinking water of mice to a final concentration of 3,75 mg/kg. Normal tap water in which the paquinimod was dissolved served as control.
Histological analysis
Total knee joints were fixed in formalin, embedded in paraffin and cut in 7 µm sections. Osteophyte size was assessed in Safranin-O/Fast Green stained sections using the Leica Application Suite (LAS) image analysis software. Cartilage damage was measured blinded using an arbitrary score based on the OARSI scoring 
method by Pritzker et al. (13). Briefly, lateral and medial tibia and femur were 
scored for the grade of cartilage destruction (0-5) and the extent of damaged cartilage surface (0-6). These scores were multiplied and added together for 
5 sections to form the total OA cartilage score. Synovial thickening/activation 
was scored on HE stained paraffin sections using an arbitrary score from 0-3 as 
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previously described (14).
Statistical analysis
Statistical differences were calculated with student t-test or Mann Whitney U as 
indicated using Graph Pad Prism 5 (GraphPad Software).
Results
Paquinimod reduces synovial activation, osteophyte formation and 
cartilage damage in collagenase induced OA
We treated experimental OA with high (CIOA) and low synovial activation (DMM model) with paquinimod, administered via the drinking water. Treatment started 4 days prior to induction of either model and was refreshed twice a week. Paquinimod was well tolerated and caused no apparent side effects in both models. Control- and paquinimod-treated animals did not differ in weight when 
measured on day 11 (weight increase control vs. paquinimod in CIOA 105% 
vs. 106%, in DMM 114% vs. 114%) nor on day 42 (weight increase control vs. 
paquinimod in CIOA 117% vs. 117%, in DMM 117% vs. 115%) (data not shown), indicating that drinking behavior was not affected. 
CIOA was treated with paquinimod and on day 42 we measured synovial thickening, osteophyte formation and cartilage damage, three important 
hallmarks of OA pathology. Synovial thickening was significantly reduced by 
paquinimod-treatment at the medial side of the patella-femur region (57%) 
(Figure 1A). Osteophyte size was significantly reduced at the medial femur (66%) 
and cruciate ligament (67%) (Figure 1B). A trend towards reduction was also observed in the medial collateral ligament and in total osteophyte size, but this 
did not reach significance. Finally, cartilage damage was significantly reduced by 
paquinimod treatment of CIOA at both medial tibia and femur (47% and 75% 
respectively) and in the total joint score (47% reduction) (Figure 1C).
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Figure 1: Treatment of collagenase induced OA with paquinimod significantly 
reduced synovial thickening, osteophyte formation and cartilage damage.Collagenase-induced osteoarthritis (CIOA) was induced by two times collagenase injection 
into the knee joint of C57BL/6J mice, an experimental OA model with high synovial 
activation. We treated the mice starting four days prior to induction of OA with 3,75 mg/kg paquinimod and assessed OA pathology on day 42. A. Synovial thickening, scored on an arbitrary scale from 0-3 on hematoxylin/eosin (HE) stained histological slides, was 
significantly reduced by paquinimod at the medial side of the femur. B. Osteophyte size was measured with image analysis software on Safranin-O/Fast Green stained histological slides. Paquinimod reduced osteophyte size on day 42 of CIOA at the medial femur and cruciate ligament, while a trend towards reduction was observed at the medial collateral ligament and in the total medial and lateral osteophyte size. med=medial, col=collateral, lig=ligament, fem=femur, tib=tibia, cruc=cruciate, lat=lateral C. Cartilage damage was 
assessed on Safranin-O/Fast Green stained histological slides with the modified Pritzker 
OARSI score. Paquinimod significantly reduced cartilage damage on day 42 of CIOA at the 
medial tibia and femur and in the total joint. * = P<0.05, ** = P<0.01 as measured by Mann Whitney test (A) or student t-test (in B, C).
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Paquinimod has marginal effects in DMM 
Paquinimod treatment of DMM OA, in which synovial activation is scant, did not reduce osteophyte size in neither medial tibia nor femur (Figure 2A). Cartilage 
damage was significantly reduced by paquinimod treatment only at the medial 
femur (64%), but not at the medial tibia where most damage occurs in DMM (Figure 2B).
Paquinimod reduces pro-inflammatory/catabolic effects in vitro in 
macrophages and OA synovial tissue
To test paquinimod in a human OA setting, we investigated the effect of the compound on synovial specimen obtained after joint replacement of end-stage OA patients. Macroscopically, we excluded non-synovial tissue like cartilage, 
tendon and fat and we could confirm this on histology using HE staining. We 
Figure 2: Paquinimod does not reduce osteophyte size and only marginally reduces 
cartilage damage in surgically induced experimental OA.
DMM (destabilization of the medial meniscus) was surgically induced in C57BL/6J 
mice and treatment with 3,75 mg/kg paquinimod was started four days prior. Synovial activation in the DMM model is low and cartilage damage and osteophyte formation occur mostly at the medial femur and tibia. Osteophyte size and cartilage damage were assessed 
on day 56 A. Paquinimod did not reduce osteophyte size on day 56 of DMM at medial tibia or femur, as measured with image analysis software on Safranin-O/Fast Green stained histological slides. B. Cartilage damage was assessed on Safranin-O/Fast Green stained 
histological slides with the modified Pritzker OARSI score. Paquinimod significantly 
reduced cartilage damage at the medial femur on day 56 of DMM, however not at the medial tibia where most damage occurs. * = P<0.05 measured by student t-test.
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stained for CD68 demonstrating presence of macrophages (Figure 3A). Then 
we incubated OA synovium with human S100A9 (15) and/or paquinimod, and measured the protein release. Addition of paquinimod alone did not have 
an effect on pro-inflammatory cytokines TNFα, IL-6 and IL-8 nor on matrix 
metalloproteinases (MMP)-1, -3 and -9 (IL-1β and MMP-13 were not detectable) 
(Figure 3B). S100A9 alone clearly upregulated IL-6, IL-8 and TNFα protein levels in OA synovia compared to medium control (9-fold, 12-fold and 20-fold 
increase respectively), and addition of paquinimod significantly inhibited this 
upregulation for IL-6 (35% reduction) and IL-8 (38% reduction), but not TNFα 
(Figure 3C). S100A9 significantly upregulated MMP-1 and MMP-3 (up to 2,5 fold) 
and this catabolic effect could be partially inhibited by adding paquinimod (39% 
and 64% reduction, respectively). No effects were found on MMP-9 (Figure 3D). 
Discussion
In the current study we show that the S100A9 inhibitor paquinimod reduces pathology in experimental OA that is characterized by high synovial activation. Furthermore, we show that paquinimod can reduce induction of pro-
inflammatory and catabolic mediators by S100A9 in human OA synovium.
We showed earlier that paquinimod binds S100A9, but not S100A8, using 
photoaffinity labelling and surface plasmon resonance (SPR) (10). Furthermore, we found that S100A9-/- mice showed reduction of synovial thickening, 
osteophyte formation and cartilage damage during CIOA (5). Therefore, the 
beneficial effects of paquinimod on experimental OA are probably due to a 
specific inhibition of functional S100A9. We recently showed that the effects of paquinimod on encephalomyelitis run via Ly6Chi monocytes (9), providing another possible mechanism for the observed effects on OA pathology.  In recent years, researchers and clinicians have given more focus to the role of 
inflammation in OA and it is believed that synovial inflammation might be one of the parameters to classify different phenotypes of OA patients (16). We found that the effect of paquinimod was largest in an OA model with high synovial activation (CIOA), compared to low (DMM).
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Figure 3: Paquinimod reduces induction of pro-inflammatory and catabolic 
mediators by S100A9 in human OA synoviumSynovia were collected from end-stage OA patients undergoing arthroplasty, characterized 
and stimulated for 24 hours with 1µg/ml S100A9 and/or 350 µM paquinimod. A. Paraffin-embedded histological sections were stained with hematoxylin/eosin and showed 
synovial tissue with thickened lining and blood vessels. Staining with specific human CD68 antibodies revealed abundant presence of CD68+ macrophages, mostly in the lining 
layer. Isotype IgG staining was negative. (Magnification 400x) B. Treatment of OA synovia 
with 350 µM paquinimod did not affect production of pro-inflammatory mediators TNFα, IL-6 and IL-8, nor of catabolic MMP-1, -3 and -9 (IL-1β and MMP-13 were not detectable). Every dot represents one donor. med=medium, paq=paquinimod C. S100A9 upregulated release of IL-6, -8 and TNFα by synovial specimen and addition of paquinimod significantly inhibited this upregulation for IL-6 and -8, while a clear trend towards inhibition was observed for TNFα. D. S100A9 upregulated release of MMP-1 and -3 by OA synovia and 
this effect was significantly inhibited by addition of paquinimod. MMP-9 release was not affected by S100A9 with or without paquinimod. In C and D every line represents one 
donor. Measurements were done in 7 donors in total, although in some cytokine or MMP levels were below detection level. * = P<0.05, ** = P<0.01 as measured by students t-test.
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In translation of this study to the clinic, one could imagine that targeting S100A9 by paquinimod would especially be suitable for treating patients with considerable synovial activation and high S100A8/A9 levels. Levels of S100A8/
A9 in serum could be used as marker to assess synovial inflammation, as they 
have been described as inflammatory markers in various forms of arthritis like 
rheumatoid arthritis, juvenile idiopathic arthritis and gout (17-19). Recently, we described presence of S100A8/A9 in serum of early symptomatic OA patients 
correlating with joint damage and osteophyte size (Chapter 3 and (5)). We now 
show that paquinimod is able to block production of pro-inflammatory and catabolic mediators induced by S100A9 in human OA synovium, in which CD68+ macrophages are present. This suggests that effects of paquinimod ex vivo run via synovial macrophages. We have shown earlier that macrophages are crucial in mediating OA pathology as selective removal of macrophages prior to CIOA 
effectively reduces synovial activation, fibrosis, osteophyte formation and MMP-induced cartilage damage (20, 21). 
Taken together, our study indicates that paquinimod may be a promising 
compound to targeting joint destruction, inflammation and osteophyte formation in OA patients with high synovial activation and expressing high levels of S100A8/A9.
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Abstract
Objective: In experimental collagenase-induced osteoarthritis (OA) in the mouse, synovial lining macrophages are crucial in mediating joint destruction. It was recently shown that adipose-derived stem cells (ASCs) express immunosuppressive characteristics. This study was undertaken to explore the effect of intraarticular injection of ASCs on synovial lining thickness and its relation to joint pathology in experimental mouse OA.
Methods: ASCs were isolated from fat surrounding the inguinal lymph nodes and cultured for 2 weeks. Experimental OA was induced by injection of collagenase into the knee joints of C57BL/6 mice. OA phenotypes were measured within 8 weeks after induction. Histologic analysis was performed, and synovial thickening, enthesophyte formation, and cartilage destruction were measured in the knee joint.
Results: ASCs were injected into the knee joints of mice 7 days after the induction 
of collagenase-induced OA. On day 1, green fluorescent protein–labeled ASCs were attached to the lining layer in close contact with macrophages. Thickening of the synovial lining, formation of enthesophytes associated with medial collateral ligaments, and formation of enthesophytes associated with cruciate ligaments 
were significantly inhibited on day 42 after ASC treatment, by 31%, 89%, and 
44%, respectively. Destruction of cartilage was inhibited on day 14 (65%) and 
day 42 (35%). In contrast to early treatment, injection of ASCs on day 14 after OA 
induction showed no significant effect on synovial activation or joint pathology on day 42.
Conclusion: These findings indicate that a single injection of ASCs into the knee joints of mice with early-stage collagenase-induced OA inhibits synovial thickening, formation of enthesophytes associated with ligaments, and cartilage destruction.
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Introduction
Although it is generally accepted that osteoarthritis (OA) is a disease of the cartilage,  other tissues like subchondral bone and synovium are thought to be involved in mediating joint destruction within this disease. Clinically, patients with OA have a variable degree of synovitis, as was demonstrated by high levels 
of interleukin (IL)-1β, tumor necrosis factor (TNF)α and complement factors (1, 2). A substantial subpopulation of patients with early symptomatic OA shows an increase in synovial lining layer thickness (3). Synovial biopsies of OA patients show hyperplasia and an increased number of lining cells that mainly consist of CD68+ macrophages. Macrophages within these OA biopsies exhibit an activated 
phenotype and produce pro-inflammatory cytokines like IL-1β, TNFα, vascular endothelial growth factor (VEGF) and S100-damage-associated molecular patterns (DAMPs) (3, 4), suggesting that these cells may play an important role in OA pathology (5).
Synovial lining macrophages are crucial in joint destruction in experimental collagenase-induced osteoarthritis (CIOA) in mice. In a previous study we found that selective elimination of lining macrophages from the mouse knee joint prior to induction of CIOA, strongly inhibited synovial thickness, development of cartilage destruction and new cartilage/bone, indicating that synovial macrophages mediate joint destruction within this model(6). Synovial macrophages are an important source of both catabolic and anabolic factors which contribute to either cartilage destruction or formation of osteophytes (7). 
Mesenchymal stem cells (MSCs) which reside in various tissues of the body have recently been shown to exhibit immunosuppressive characteristics. Although it has generally been accepted that the primary effect of stem cell treatment occurs 
through tissue specific differentiation (8,9) new data suggest that the therapeutic potential of these cells might be related to their paracrine effect(10,11). Several studies showed that MSCs can modulate the functions of cells of the adaptive immune system, like T and B cells(12). Other studies have shown that these stem 
cells are also able to induce expression of anti-inflammatory mediators, like IL-10 and IL-12p40, in macrophages(13,14). Multiple factors secreted by MSCs that 
exert an immunosuppressive effect have been identified, e.g. IL-10, IL-1 receptor 
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antagonist (IL-1RA), indoleamine 2,3-dioxygenase (IDO), transforming growth 
factor(TGF)β and prostaglandin E2 (PGE2)(15). Although several contradictory 
results have been published, there is ample evidence that inflammatory molecules may provide the licensing signal for MSCs to deliver the immunosuppressive signals, including PGE2(10, 16, 17).
Adipose tissues are well known for their key role in energy balance and metabolic disorders. Recently it appeared that adipose tissue hosts multipotent stem cells. 
These cells named adipose-derived stem cells (ASCs) can easily be purified after digestion of fat and selection by adhesion onto plastic from the very heterogeneous crude stromal fraction. ASCs share numerous properties with bone marrow-
derived MSCs(18). In adipose tissue ASCs represent around 5% of nucleated cells in the normal vascular fraction which is much higher than in the adult 
human bone marrow where MSCs represent only 0.01-0.0001% of the nucleated cells. Both types are able to differentiate towards adipogenic, osteoblastic and chondrogenic phenotype. Moreover they display immunosuppressive properties 
in vitro as well as in vivo (19). Because of their immunosuppressive phenotype 
ASCs may be used to decrease local inflammation during rheumatic diseases(20). 
In the present study we investigated the effect of local administration of ASCs into the knee joints of mice with experimental induced osteoarthritis in which synovial involvement is evident. 
Materials & Methods
Animals 
 C57BL6 mice were obtained from Janvier (Le Genest St. Isle, France). Animals were between 12 and 14 weeks and received a standard diet and tap water ad libitum. All experiments were approved by the local authority Animal Care and 
Use Committee and were performed by personnel certified by the Dutch Ministry of WVC.
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Induction of experimental osteoarthritis   
Experimental CIOA was induced as previously described (21). Briefly, the right knee joint of the mice was injected  with 1 unit collagenase type VII from Clostridium histolyticum (Sigma Aldrich, St. Louis, USA) in 6 μl of physiologic 
saline at day 0 and day 2. Mice were sacrificed at days 14 and 42 after treatment with ASCs. The injected collagenase causes instability of the joints by damaging ligaments and does not directly digest cartilage. This model is characterized by OA-like damage. Clear synovial activation is observed within this model which is related to cartilage destruction(23). 
Adipose Stem Cells
ASCs were isolated from adipose tissue surrounding the inguinal lymph nodes. Next, they were cultured for two weeks according to standard procedures 
in DMEM/F12 (Gibco, New York, USA) supplemented with 1% Penicillin / 
Streptomycin (Invitrogen, Carlsbad, CA, USA), 0.5% Amphotericin B (Invitrogen, 
Carlsbad, CA, USA), 16μM Biotin (Sigma Aldrich, St. Louis, USA), 18μM 
Panthotenic Acid (Sigma Aldrich, St. Louis, USA), 100μM Ascorbic Acid (Sigma Aldrich, St. Louis, USA). After recovery, the cells were tested for 6 different stem cell markers. In accordance with literature, the stem cells stained positive for Sca-
1 (86%), CD44 (81%) and CD105 (69%) (BD Bioscience, Breda, the Netherlands; Biolegend, San Diego, CA, USA and eBioscience, San Diego, CA, USA) and were 
negative for CD11b (0%), cKit (0%) and CD34 (4%) (Biolegend, San Diego, CA, 
USA; BD Bioscience, Breda, the Netherlands and eBioscience, San Diego,CA,USA). 20.000 cells (derived from second passage) in 6 μL mouse serum (Jackson 
Immunoresearch, Newmarket, UK)  with 4% mouse albumin (Sigma Aldrich, St. Louis, USA) were injected intra-articularly into the knee joint. The number of cells that we used was calculated on basis of the number of cells per kg body weight) that is going to be used in the clinical trial in OA patients (5.106 cells/
joint).  Control animals were injected with only mouse serum containing 4% mouse albumin.
Immunodetection of GFP-labeled ASCs
To localize ASCs after intra-articular injection, ASCs were labelled with green 
fluorescent protein (GFP) prior to injection. After standard culture procedures, 
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ASCs were transfected with a lentiviral construct containing GFP under a 
constitutively active PGK promoter. The expression of GFP was confirmed using 
FACS and fluorescence microscopy. ASCs were injected intra-articularly in mice, 7 days after induction of collagenase-induced OA. 24 Hours after injection, knee 
joints were isolated and processed for histology. After deparaffinization and rehydration, sections were incubated for 2 hours at room temperature with 10 mM citrate buffer (0.1M citrate acid, 0.1M sodium acid, (pH 8.0)) to unmask antigenic sites. Next, endogenous peroxidase activity was blocked to avoid 
background staining using 1% H2O2 in methanol. Subsequently, the slides were incubated with a rabbit-anti-GFP antibody (Cell Signaling, Beverly, MA, USA) over night at 4°C. After incubation with a biotinylated goat-anti-rabbit IgG secondary antibody (45 minutes at room temperature) peroxidase labelled avidin-biotin complexes were incubated on the sections using an ABC-kit (Vector Laboratories, Burlingame, CA, USA). Di-amino-benzidine (Sigma Aldrich, St. Louis, USA) was used to localize the peroxidise activity, whereas hematoxylin was used as counterstaining. Finally, the stained sections were mounted in permount (Fisher 
Scientific, Waltham, MA, USA).
Histological analysis of OA progression
Knee joints were dissected and fixed in 4% formalin. After fixation, the joints 
were decalcified in 4% formic acid buffered in PBS and processed for histology. 
Paraffin embedded knee joints were cut in sections of 7μm. Six sections, spaced 140 μm, were mounted on glass slides and stained with safranin O (Saf O) for analysis of cartilage damage and chondrophyte/osteophyte associated ligaments (collateral/cruciate). For scoring of synovial activation, haematoxylin eosin (HE) 
stained sections were used. Cartilage damage starts with surface fibrillation at day 21 and lesions were observed between day 35 and 42 and was scored using 
a modified form of the OARSI cartilage OA histopathology grading system (23). 
Briefly, the depth of the cartilage damage as well as the extent of the damaged surface was scored in a blinded manner at four different locations in the knee joint, i.e. the lateral and medial tibia and femur using an arbitrary score (severity of  cartilage destruction 0 to 6 and the extend of damaged cartilage surface 0 
to 5). The OA score was defined as a multiplication of these two arbitrary scores. Synovial thickness/activation was scored on HE stained sections using an arbitrary score from 0-3 as previous described (21). Synovial thickening 
starts at day 7, is maximal at day 14 but is still significant at day 42.  Briefly, 
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scores ranged from no thickening of the lining layer ( one cell layer) (0) up to the maximal observed thickening (3) of the synovial lining layer (10-12 cell layers). Saf-O stained sections were used to assess size and number of chondrophyte/enthesophytes associated with ligaments. Chondrogenesis starts between day 7 and 14 and transformed into bone between day 35 and 42.  Size of chondrogenisis was scored in each joint by measurement of three sections, each spaced 140 
μm apart. In each section, surface areas of chondrophytes/enthesophytes were measured in cruciate ligaments (CL) and medial collateral ligament (MCL) using an image analysis system (Leica Qwin, Leica Microsystems B.V., Rijswijk, The Netherlands). To assess cartilage formation in the CL, image analysis was used to calculate the surface percentage of the CL positive for proteoglycans. In the MCL 
the cartilaginous and osseous structures that developed were defined as being chondrophytes or enthesophytes by hand. The mean area per knee joint (three sections) was calculated and expressed in µm2.
Immunodetection of NITEGE-epitopes
After deparaffinization and rehydration, knee joint sections were treated with 
citrate buffer and 1% H2O2 in methanol as described above. Thereafter, sections were incubated with anti NITEGE antibodies (Dr. John Mort, Montreal,Canada) 
in phosphate-buffered saline containing 5% milk powder, 3% fetal calf serum 
and 2% BSA. Subsequently, sections were incubated with biotinylated goat-anti-rabbit IgG secondary antibody. After incubation with peroxidase labelled avidin-biotin complexes (Vector Laboratories, Burlingame, CA, USA) di-amino-benzidine (DAB) (Sigma Aldrich, St. Louis, USA) was used to localize the peroxidase activity. Sections were counterstained with hematoxylin for 1 min and embedded in 
Permount (Fisher Scientific, Waltham, MA, USA).
Isolation of murine synovial specimen and preparation of RNA and RT-PCR
At day 14 after ADSC treatment of a day 7 osteoarthritis knee joint, synovial 
specimen were isolated as described previously (9). In short, joint capsule specimens were isolated on medial and lateral sides of the patella with a biopsy 
punch. Synovial specimen were snap frozen in liquid nitrogen and stored for RNA isolation. RNA was isolated from synovium using TRIzol reagent according to the manufacturer’s protocol (Invitrogen). Five μg of total RNA was reverse 
transcribed, and cDNA aliquots were subjected to PCR. RT-PCR was normalized 
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by the transcriptional levels of GAPDH. mRNA levels of various members of 
cytokines (IL-1β, IL-6, IL-10) were measured in synovial specimen at various time-points after induction of collagenase-induced or DMM osteoarthritis and 
were quantified using the ABI/PRISM 7000 Sequence Detection System. 
Statistical analysis
Statistical differences were calculated with the Mann Whitney U test, using Graph Pad Prism 5 (GraphPad Software,  La Jolla, CA). Differences were called 
significant with P-values < 0.05.
Results
Decrease in synovial activation after ASC treatment
A thickened synovial lining layer comprising activated macrophages is prominent in CIOA and has earlier been shown to be involved in mediating cartilage destruction and osteophyte formation (7). Hyperplasia of the synovial lining layer is maximal at day 7 of CIOA and remains high thereafter. 
To test whether ASCs can alter synovial lining thickness, a single injection of ASCs (2•104 cells in 6 μl mouse serum containing 4% MSA) was given into the right knee joint at day 7 after induction of CIOA. Synovial lining thickness was scored after injection of either ASCs or serum only, by two independent observers. Figure 
1A shows that  lining layer thickness was significantly lower at day 42 (31% ) 
but not at day 14 (9% lower) after ASC treatment when compared to control treated mice (Figure 1A). Photomicrographs show that the synovial lining layer 
of ASC-treated mice is significantly less thickened comprising lower numbers of macrophages when compared to control-treated mice (Figure 1C versus control 
B).Interesting at day 14 after ASC treatment, mRNA levels of IL-1β (but not that 
of IL-6 or IL-10) were significantly lower in the OA synovium when compared to control (Figure 1D). 
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Intraarticularly injected ASCs home to the subintimal synovial lining layer 
in mice
As intra-articular injection of ASCs decreases thickness of the synovial lining, we next analyzed whether ASCs directly interact with the synovium using ASCs 
labeled with green fluorescent protein (GFP). In vitro, ASCs were transfected with a lentiviral GFP construct and additionally cultured for 24 hours in chamber 
slides. More than 85% of the ASCs expressed an abundant amount of GFP protein 
as assessed by flow cytometry (data not shown) and fluorescence microscopy (Figure 2A). Next, GFP-transfected ASCs were injected into a day 7 CIOA knee joint. 24 hours and 5 days thereafter knee joints were isolated and processed 
for histology. When knee joint sections were immunostained using specific GFP antibodies, GFP-positive cells were clearly visualized in the crucial ligament area and within the subintimal layer of the synovium at 24 hrs (Figure 2B,C). A larger 
magnification shows that the ASC were lying just below the intima lining layer in 
Figure 1. Decrease in synovial thickening in mice treated with adipose-derived stem 
cells (ASCs).
A, Decreased thickening of the synovium in ASC-treated mice on day 14 and day 42 after 
treatment. The decrease in thickening versus control mice (31%) reached significance on 
day 42. Each data point represents a single mouse; horizontal lines and error bars show 
the mean ± SEM (n = 8–11 mice per group). B and C, Clear reduction in thickening of the lining layer in an ASC-treated mouse (C) compared to a control animal (B) on day 42 after 
treatment. Results are representative of 2 experiments. Original magnification x 250. D, 
Significant reduction in the expression of mRNA for interleukin-1β (IL-1β), but not IL-6 or IL-10, in the osteoarthritic synovium of ASC-treated mice, as compared to controls, on day 14 after treatment. RNA from the synovium of 6 animals per group was used for the 
analysis of gene expression. Bars show the mean.  *=P < 0.05.
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close interaction with synovial macrophages (Figure 2C insert). At 5 days after injection, ASCs were no longer detected in the lining layer (data not shown).
Prevention of dislocation of the OA knee joint and prevention of new 
cartilage formation in the collateral and cruciate ligaments in ASC-treated 
mice
Synovial activation in CIOA strongly contributes to damage of collateral and 
crucial ligaments leading to destabilization and subsequent dislocation of the knee joint. Investigating total knee joint sections, we observed that induction of 
CIOA caused dislocation of the knee joint in the majority (75%) of the mice. A 
single injection of ASC prevented cruciate ligament rupture to only 25% of the mice suggesting that damage to ligaments is protected (data not shown). 
Clinically, new formation of cartilage and bone structures within ligaments impairs good functioning of the joint. During experimental OA, early pathological changes comprise new formation of cartilage (chondrophytes) in collateral 
and cruciate ligaments which subsequently change through ossification into 
Figure 2. Intraarticularly injected adipose-derived stem cells (ASCs) home to 
cruciate ligaments and subintimal layers of the synovium in mice. 
Green fluorescent protein (GFP)–transfected ASCs were injected into mice on day 7 after the induction of collagenase-induced osteoarthritis. Twenty-four hours after the injection of ASCs, mouse knee joints were isolated and processed, and knee joint sections were stained with an anti-GFP antibody. A, Fluorescence microscopy, showing efficient transfection of ASCs with lentiviral GFP. B, GFPpositive cells close to the cruciate ligaments. 
C and D, Localization of clusters of GFP-positive cells in subintimal layers of the synovium. 
D shows a higher-magnification view of the boxed area in C. Original magnification x 1,000 in A; x 250 in B and C; x 400 in D.
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enthosophytes (21). At day 14 after induction of CIOA, chondrogenesis was already observed in collateral ligaments, particularly at the medial site (Figure 3A). At day 42 after OA induction, these structures had completely transformed 
into bone (enthesophytes) due to ossification (Figure 3B).
On day 14 after ASC treatment, chondrogenesis (measured as proteoglycan deposition) was mainly observed in the medial collateral ligaments in the majority of the control OA mice. In contrast, much less chondrophyte formation 
(76% lower) (p=0.08) was observed in the ASC-treated mice (Figure 3E). In line 
with these observations, significantly smaller enthesophytes (size quantified using image analysis) were measured in the medial lateral collateral ligaments 
at day 42 after treatment. The surface area decreased by 89% in ASC-treated 
animals compared to control animals (P < 0.05) (Figures 3C–E).
Figure 3. Prevention of chondrogenesis 
and enthesophyte formation in the medial 
collateral ligament in mice treated with 
adipose-derived stem cells (ASCs). On day 14 and day 42 after treatment, chondrogenesis and the size of newly formed bone structures were determined using a Leica QWin image analysis system. A, Chondrogenesis (arrow) within the mouse medial collateral ligament on day 14 in an untreated control animal. B, Transformation of structures into enthesophytes (arrow) 
through ossification by day 42 in an untreated control animal. C and D, Newly formed enthesophytes in a control animal (C) and an ASC-treated animal (D) on day 42 after 
treatment. Original magnification x 250 in 
A–D. E, Decrease in the surface area containing proteoglycans (chondrogenesis) in ASC-treated animals compared to control animals on day 14 and decrease in the surface area of 
newly formed enthesophytes (by 89%) in ASC-treated animals compared to control animals on day 42. Each data point represents a single 
mouse; horizontal lines and error bars show the mean ± SEM. Results are representative of 
2 experiments (n = 8–11 mice per group).  *= 
P < 0.05.
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In addition to the collateral ligaments, the cruciate ligaments of the OA mouse knee joint showed chondrogenesis/enthesophytes, which were measured using image analysis (Figure 4A). Safranin-O staining showed marked presence of proteoglycans at day 42 particularly at the contact sites of the ligaments with the 
bone. The area that stained positive for proteoglycans was significantly smaller 
(44%) in ASC-treated mice (Figure 4C) than in controls (Figure 4B). Deposition 
of proteoglycans was seen in 35% of the ligaments of the ASC-treated mice 
compared to 63% of the ligaments of the controls (P < 0.05) (Figure 4D).
Synovial activation strongly upregulates enzymes like ADAMTs 4 and 5, members of the aggrecanase family, which are major players  involved in new formation 
and remodelling of cartilage. These enzymes cleave proteoglycans at a specific 
site thereby leaving neoepitopes (ending at the aminoacid sequence NITEGE) 
within the cartilage matrix which can be detected using specific antibodies and immunolocalisation. A strong staining of NITEGE neoepitopes was found within the cartilage containing areas of the cruciate ligaments of the control OA 
Figure 4. Chondrogenesis in the 
mouse cruciate ligaments during 
experimental osteoarthritis.
A, Chondrogenesis in the mouse cruciate 
ligaments delineated as shown, quantified using a Leica QWin image analysis system. 
B and C, Proteoglycan deposition in a control animal (B) and an adipose-
derived stem cell (ASC)–treated animal (C) on day 42 after treatment. Original 
magnification x 250 in A–C. D, Significant decrease in proteoglycan deposition in ASC-treated animals compared to controls on day 42 after treatment. Each 
data point represents a single mouse; horizontal lines and error bars show the 
mean ± SEM (n = 8–9 mice per group). *=P 
< 0.05.
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knee joint. A single injection of ASCs significantly inhibited NITEGE neoepitope expression, suggesting that aggrecanase activity is suppressed by ASC treatment (Figure 5). In vitro, ASCs expressed high levels of mRNA for tissue inhibitors of metalloproteinases (TIMPs), particularly TIMPs 1 and 3, when compared to macrophages, suggesting that they may be involved in inhibiting enzyme activity (data not shown).
Significant inhibition of cartilage destruction in mice with collagenase-
induced OA after intraarticular injection of ASCs into the knee joint
Synovial activation promotes destruction of cartilage during CIOA through combined action of catabolic factors and biomechanical ligamen instability induced by anabolic mediators. At day 42 of CIOA , a prominent cartilage destruction was observed in all four layers of the knee joint. A single injection of ASC into the day 7 OA knee joint inhibited cartilage damage already at day 14. In 
particular, the cartilage damage in the lateral femur was protected (65% lower 
in ASC-treated mice when compared to control mice; p< 0.05 ) (Figure 6A). On day 42 after treatment the mean of the OA scores, indicating cartilage damage, 
for the 4 different locations within the knee joint was still significantly decreased 
(by 35%) in ASC-treated mice compared to controls (P < 0.05) (Figures 6B–D). 
Figure 5. Decreased NITEGE expression in the cruciate ligaments of the knee joints 
of mice with collagenase-induced osteoarthritis treated with adipose-derived stem 
cells (ASCs).The neoepitope NITEGE is expressed upon ADAMTS activity during chondrogenesis/bone formation. The percentage of NITEGE staining regions in the mouse cruciate ligament was determined. A, Reduction of 69% and 35% on days 14 and 42, respectively, in NITEGE staining in mice treated with ASC compared to controls. Bars show the mean ± SEM (n = 8 
mice per group). *= P < 0.05. B and C, Hypertrophic, chondrocyte-like phenotype of cells in the cruciate ligaments of a control animal (B) compared to an ASC-treated animal (C). 
Original magnification x 250.
149
Chapter 7
Lack of a significant effect of a single injection of ASCs at a later time 
point (day 14) on synovial thickness and joint destruction in mice with 
collagenase-induced OA
Next, we studied whether ASC treatment also affects synovial thickness and joint destruction when given at day 14 after induction of CIOA. At that time-point ligaments are  already severely damaged in contrast to day 7 OA. At day 42 after a single injection of ASC into the day 14 OA knee joint, synovial thickness (Figure 6E), enthesophyte formation (Figure 6F) and cartilage destruction (Figure 6G) 
although somewhat lower, were not significantly reduced when compared to controls. 
Figure 6. Inhibition of the development of cartilage destruction in mice treated with 
adipose-derived stem cells (ASCs) soon after the induction of collagenase-induced 
osteoarthritis (OA).ASCs were injected into the mouse knee joints on either day 7 or day 14 after the induction of collagenase-induced OA. Cartilage destruction was scored at 4 different locations in the knee joint, i.e., the lateral tibia (LT), lateral femur (LF), medial femur (MF), and medial tibia (MT). The mean OA score was calculated using the scores for the 4 individual locations. A and B, Reduction in cartilage damage scores on day 14 after treatment (A) and day 42 after treatment (B) in mice treated with ASCs 7 days after the induction of OA (early treatment) 
compared to control mice. The difference was significant for the lateral femur score on day 14 and for the lateral tibia score and mean score on day 42. Bars show the mean ± SEM (n 
= 8 mice per group). *=P < 0.05. C and D, Cartilage damage on day 42 after treatment in a control mouse (C) and a mouse treated with ASCs 7 days after the induction of OA (D). 
Original magnification x 250. E–G, Lack of a significant effect on synovial thickness (E), enthesophyte formation (F), or cartilage damage (G) on day 42 after treatment in mice treated with ASCs 14 days after the induction of OA (late treatment). In E and F, each data 
point represents a single mouse; horizontal lines and error bars show the mean ± SEM. In 
G, bars show the mean ± SEM (n = 8 mice per group).
150
Chapter 7
Discussion
In the present study we find that a single injection of ASC into the knee joint given at an early time-point (day 7) after induction of CIOA, protects against synovial thickening, enthesophyte formation and cartilage destruction. 
Stem cells are used in cellular therapy for a broad spectrum of diseases. Although it is generally believed that the primary therapeutic effect of stem cells occurs 
through tissue differentiation (8,9), they may also act in a paracrine manner 
by the production of soluble anti-inflammatory factors. Previous studies in our lab have shown that thickening of the synovial lining layer is a characteristic feature of CIOA. This layer comprises mainly macrophages exhibiting an activated phenotype. Increased thickness of the lining starts at day 3, reaches its maximum at day 7 and persisted up to day 42 (24). We showed earlier that selective elimination of the lining macrophages prior to induction of CIOA strongly inhibited synovial thickness but also osteophyte formation and cartilage destruction (6, 24).
Synovial macrophages are important producers of chemokines that attract 
monocytes which subsequently differentiate into macrophages or induce 
proliferation of fibroblasts within the lining layer thereby promoting its thickness. During OA, the cartilage layer is damaged and releases cartilage fragments. SLRPs, small proteolycans like biglycan and decorin have been 
shown to stimulate macrophages via TLR4 thereby releasing pro-inflammatory 
cytokines IL-1 (25), TNFα or S100-DAMPs(S100A8/A9) (26) which may further stimulate the activation status of the lining layer. 
Injection of ASCs at day 7 after onset of CIOA inhibited synovial thickness in the OA knee joint at day 42. Localisation of GFP-labelled ASC in the OA knee joint, showed that 24 hours after injection, ASCs were detected within the synovium just below the lining layer. A close interaction between ASC and macrophages within the intimal layer was observed. At day 5 after injection virtually no GFP-labeled cells could be detected anymore (data not shown) suggesting that the 
effects on the synovium are induced within the first days after injection initiating a prolonged long lasting suppressive effect. 
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Chondrogenesis and subsequent formation of enthesophytes within collateral/cruciate ligaments within this model is mediated by synovial macrophages (6, 24) and hampers a good functioning of the joint which may further enhance joint destruction. Macrophage derived factors involved in chondrogenesis include 
growth factors like TGFβ, BMP-2 and -4(6). Production of these growth factors within the synovium was strongly diminished after macrophages were selectively depleted from the lining layer(24). During OA, dysregulated chondrogenesis is observed along the margins of the articular cartilage or within the ligaments and most likely differentiate from chondrogenic precursor cells that reside within periosteum or ligament. Stem cell treatment may suppress production of growth factors by synovial macrophages thereby preventing proliferation of chondrogenic precursor cells. 
Damage of the cruciate ligaments was strongly correlated to dislocation of the knee joint. In the cruciate ligament area, macrophages are also abundantly present and prolonged activation of these cells may further stimulate ligament destruction. Recent studies showed that enzymes like ADAMTs are involved in degeneration of ligament structures(27) and are crucial for destruction of cartilage in experimental OA(28). These enzymes cleave aggrecan thereby inducing neoepitopes (NITEGE) which can be visualized with immunodetection(27). Stem cell treatment strongly inhibited expression of NITEGE neoepitopes suggesting that ADAMTs activity is suppressed.
Cartilage destruction is a characteristic feature of OA which was also inhibited by local ASC treatment. ASC may suppress macrophage activity and thereby the 
production of  catabolic mediators like IL-1β and TNFα. Recently we described 
that “alarmins” S100A8/S100A9, major products of macrophages, are key 
players in mediating cartilage destruction in CIOA(28, 29). These proteins 
stimulate MMP production in macrophages(30) and chondrocytes(29) via TLR4 
signalling. IL-1β is expressed only during the first phase whereas S100 proteins are released throughout the CIOA course and may explain why S100 proteins are 
dominant within this model. Whether ASC treatment has effect on IL-1β, TNFα 
and S100A8/A9 levels in the blood and synovium washouts is momentarily under investigation.
When ASCs were administered intra-articularly at day 14 after onset of CIOA no 
significant protection was found on joint pathology. One explanation may be that 
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collateral/cruciate ligaments are already irreversibly damaged at that time-point 
preventing successful recovery. Mediators like IL-1β and MMPs have predictive value for ligament injury in animal models (31). Stem cells have been shown to produce soluble inhibiting factors like IL-1RA (32) and TIMPs (33) which may partly block induction of the IL-1/MMP mediated ligament destruction (31). However an earlier study has shown that late delivery of autologous MSCs to caprine joints subjected to meniscectomy and complete resection of the anterior 
cruciate ligament still resulted in regeneration of meniscal tissue and significant chondroprotection (34). In our study we only injected a low amount of ASC in the 
knee joint which may be sufficient for inhibiting induction of ligament damage but may be too low for repair of already damaged ligaments. Damaged ligaments can bind MSCs thereby providing the basis for a biological repair of this ligament (35). 
A further explanation that deposition of ASCs may not be effective when given at day 14 after CIOA may be the minor release of cytokines by the synovium at 
that late time-point. Pro-inflammatory cytokines, like IFNγ, IL-6 and TNF-α, have shown to enhance the immunosuppressive potential in ASCs (13, 16, 17, 36). The 
release of pro-inflammatory factors is highest within the synovium during the 
first seven days after onset of CIOA (28) and may drive the anti-inflammatory 
potential of ASCs. In reaction to pro-inflammatory stimuli, ASC increase intracellular enzymes Indolamine 2,3, dioxigenase (IDO), heme-oxygenase-1 (HO-1) and COX-2 leading to enhanced release of CO, biliverdin and PGE2 which are able to suppress activated macrophages thereby preventing OA pathology (13, 37-38). This mechanism may further explain why stem cell treatment is so 
effective in inflammatory diseases like arthritis (16) and ischemic heart disease 
(39). Stimulation of ASCs with pro-inflammatory cytokines prior to delivery to 
the OA joint may further enhance the efficacy of ASC treatment. 
In the present paper we show that ASCs when given at an early phase of experimental OA inhibit synovial lining thickness and protect joint destruction by both anabolic and catabolic mediators. ASCs may therefore be a potent and safe tool for therapeutic approach of a disease from which up till now no cure is available.
153
Chapter 7
Acknowledgements
This study was financially supported by the seventh frame work programme 
ADIPOA; Health-2009-1.4-3 project number 241719. 
154
Chapter 7
References
1. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of 
proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 
2011;7(1):33-42.
2. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, et al. Identification 
of a central role for complement in osteoarthritis. Nat Med. 2011;17(12):1674-9.3. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, et al. 
Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 2003;48(8):2173-7.4. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue 
inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263-7.5. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role 
of synovial macrophages and macrophage-produced mediators in driving inflammatory and 
destructive responses in osteoarthritis. Arthritis Rheum. 2010;62(3):647-57.
6. van Lent PL, Blom AB, van der Kraan P, Holthuysen AE, Vitters E, van Rooijen N, et al. Crucial role of synovial lining macrophages in the promotion of transforming growth factor 
beta-mediated osteophyte formation. Arthritis Rheum. 2004;50(1):103-11.
7. Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction 
during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis 
Rheum. 2007;56(1):147-57.8.  O'Sullivan J, D'Arcy S, Barry FP, Murphy JM, Coleman CM.Mesenchymal 
chondroprogenitor cell origin and therapeutic potential. Stem Cell Res Ther. 2011  18;2(1):8. 
9. Coleman CM, Curtin C, Barry FP, O'Flatharta C, Murphy JM. Mesenchymal stem cells 
and osteoarthritis: remedy or accomplice? Hum Gene Ther. 2010;21(10):1239-50.
10.  Maumus M, Guérit D, Toupet K, Jorgensen C, Noël D. Mesenchymal stem cell-ased 
therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther. 2011 Mar 
18;2(2):14.11. Coleman, CM, Curtin C, Barry FP, O'Flatharta C, Murphy JM. Mesenchymal stem cells 
and osteoarthritis: remedy or accomplice? Hum Gene Ther, 2010; 21(10): 1239-50.
12. Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive Properties of Mesenchymal Stem Cells. Stem Cell Rev. 2011.
13. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of 
host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-9.14. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a 
regulatory-like profile. PLoS One. 2010;5(2):e9252.
15. Pittenger M. Sleuthing the source of regeneration by MSCs. Cell Stem Cell. 2009;5(1):8-10.
16. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 secretion 
by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 
2010;5(12):e14247.
17. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. 
Eur J Immunol. 2008;38(6):1745-55.
155
Chapter 7
18. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory 
effect of human adipose tissue-derived adult stem cells: comparison with bone marrow 
mesenchymal stem cells. Br J Haematol. 2005;129(1):118-29.
19. De Toni F, Poglio S, Youcef AB, Cousin B, Pflumio F, Bourin P, et al. Human adipose-
derived stromal cells efficiently support hematopoiesis in vitro and in vivo: a key step for 
therapeutic studies. Stem Cells Dev. 2011;20(12):2127-38.
20. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C. Mesenchymal stem cells: 
innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5(7):392-9.
21. van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB. Degenerative knee joint lesions in mice after a single intra-articular collagenase injection. A 
new model of osteoarthritis. J Exp Pathol (Oxford). 1990;71(1):19-31.22. Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative- recommendations for histological assessments of osteoarthritis in the mouse. 
Osteoarthritis Cartilage. 2010;18 Suppl 3:S17-23.
23. Blom AB, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. 
Osteoarthritis Cartilage. 2004;12(8):627-35.24. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of 
osteoarthritis. J Rheumatol. 2008;35(12):2306-12.25. van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, et al. Myeloid-related 
proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-
induced arthritis. Ann Rheum Dis. 2008;67(12):1750-8.26. Plaas A, Sandy JD, Liu H, Diaz MA, Schenkman D, Magnus RP, et al. Biochemical 
identification and immunolocalizaton of aggrecan, ADAMTS5 and inter-alpha-trypsin-inhibitor 
in equine degenerative suspensory ligament desmitis. J Orthop Res. 2011;29(6):900-6.27. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 
2005;434(7033):644-8.28. van Lent P, Blom A, Schelbergen R, Sloetjes A, Lafeber F, Lems W, et al. Active 
involvement of "alarmins" S100A8 and S100A9 in regulation of synovial activation and joint 
destruction during mouse and human osteoarthritis. Arthritis Rheum. 2011; doi: 10.1002/art.34315.
29. Schelbergen, R.F., et al., Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on toll-like receptor 4. Arthritis Rheum, 
2011; doi: 10.1002/art.33495.
30 Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W,Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 
4, promoting lethal, endotoxin-induced shock. Nat Med. 2007 Sep;13(9):1042-9. 31 Heard BJ, Achari Y, Chung M, Shrive NG, Frank CB. Early joint tissue changes are highly 
correlated with a set of inflammatory and degradative synovial biomarkers after ACL autograft 
and its sham surgery in an ovine model. J Orthop Res.2011; 29(8):1185-92. 
32 Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 
1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal 
stem cells during lung injury. Proc Natl Acad Sci U S A. 2007 ;104(26):11002-7.33  Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M,Martiat P, Bron D, Lagneaux L. In vitro study of matrix metalloproteinase/tissue inhibitor 
of metalloproteinase production by mesenchymal stromal cells in response to inflammatory 
156
Chapter 7
cytokines: the role of their migration in injured tissues. Cytotherapy. 2009;11(5):559-69.34 Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of 
osteoarthritis. Arthritis Rheum. 2003;48(12):3464-74.
35  Steinert AF, Kunz M, Prager P, Barthel T, Jakob F, Nöth U, Murray MM, Evans CH,  Porter RM. Mesenchymal stem cell characteristics of human anterior cruciate ligament outgrowth 
cells. Tissue Eng Part A. 2011;17(9-10):1375-88.
36. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP, et al. 
Inflammatory conditions affect gene expression and function of human adipose tissue-derived 
mesenchymal stem cells. Clin Exp Immunol. 2010;162(3):474-86.
37. Mitsui H, Aoyama T, Furu M, Ito K, Jin Y, Maruyama T, et al. Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with 
traumatic instability. Arthritis Res Ther. 2011;13(5):R146.
38  Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K. The impact 
of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by 
human mesenchymal stem cells. Blood. 2011;117(18):4826-35.
39. Herrmann JL, Abarbanell AM, Wang Y, Weil BR, Poynter JA, Manukyan MC, et al. Transforming Growth Factor-alpha Enhances Stem Cell-Mediated Postischemic Myocardial 
Protection. Ann Thorac Surg. 2011;92(5):1719-25.
1Chapter 8
158
Chapter 8
Chapter 8
Treatment efficacy of adipose-derived stem cells in 
experimental osteoarthritis is driven by high synovial 
activation and reflected by S100A8/A9 serum levels.
Rik F.P. Schelbergen1, Stephanie C.M. van Dalen1, Menno ter Huurne1, Annet Sloetjes1, Johannes Roth2, Thomas Vogl2, Danièle Noël3, Christian Jorgensen3, Wim B. van den Berg1, Peter M. van der Kraan1, Arjen B. Blom1, Peter L.E.M. van Lent1
1 Experimental Rheumatology, Department of Rheumatology, Radboud university medical center, Nijmegen, The Netherlands
2 Institute of Immunology, University of Münster, Münster, Germany
3 Inserm U844, Hôpital Saint-Eloi, Montpellier, France 
Osteoarthritis & Cartilage, 2014 Aug, 22(8), 1158-66
159
Chapter 8
Abstract
Objective: Synovitis is evident in a substantial subpopulation of patients with osteoarthritis (OA) and is associated with development of pathophysiology. Recently we have shown that adipose-derived stem cells (ASC) inhibit joint destruction in collagenase-induced experimental OA (CIOA). In the current study we explored the role of synovitis and alarmins S100A8/A9 in the immunomodulatory capacity of ASCs in experimental OA.
Method: CIOA, characterized by synovitis, and surgical DMM (destabilization of medial meniscus) OA were treated locally with ASCs. Synovial activation, cartilage damage and osteophyte size were measured on histological sections. Cytokines in synovial washouts and serum were determined using Luminex or enzyme-linked immunosorbent assay (S100A8/A9), mRNA levels with reverse-transcriptase (RT)-qPCR.
Results: Local administration of ASCs at various time-points (days 7 or 14) after DMM induction had no effect on OA pathology. At day 7 of CIOA, already 6 hours 
after ASC injection mRNA expression of pro-inflammatory mediators S100A8/
A9, interleukin-1beta (IL-1β) and KC was down-regulated in the synovium. IL-1β protein, although low, was down-regulated by ASC-treatment of CIOA. S100A8/A9 protein levels were very high at 6 and 48 hours and were decreased by ASC-treatment. The protective action of ASC treatment in CIOA was only found when 
high synovial inflammation was present at the time of deposition which was 
reflected by high serum S100A8/A9 levels. Finally, successful treatment resulted 
in significantly lower levels of serum S100A8/A9.
Conclusion: Our study indicates that synovial activation rapidly drives anti-
inflammatory and protective effects of intra-articularly deposited ASCs in 
experimental OA which is reflected by decreased S100A8/A9 levels.
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Introduction
Osteoarthritis (OA) is primarily a disease of the cartilage. However, synovitis is thought to contribute to aggravation of joint pathology as well (1, 2). Up to 50% of OA patients have synovitis, which was demonstrated by magnetic resonance 
imaging, ultrasonography and arthroscopy (3-5). Histologically, inflammation in the synovial membrane is characterized by high levels of CD68+ macrophages 
expressing an activated phenotype and presence of pro-inflammatory cytokines 
like IL-1β and TNFα (3, 6, 7).
Synovial lining macrophages contribute to joint destruction in murine collagenase-induced osteoarthritis (CIOA). When lining macrophages were selectively depleted from a mouse knee joint prior to induction of CIOA, a strongly diminished thickening of the synovium was observed which coincided with inhibition of cartilage degradation and formation of cartilage/bone within ligaments (8). Synovial macrophages produce both catabolic and anabolic factors that contribute to degradation and new formation of cartilage (9). Major catabolic factors produced by activated macrophages are alarmins or damage associated molecular patterns (DAMPs) S100A8 and S100A9 (10). These are found in large amounts in the serum and synovium of OA patients and we recently showed that S100A8/A9 predict development of cartilage destruction in the Dutch CHECK cohort of early symptomatic OA patients and have catabolic effects on OA chondrocytes via TLR-4 (11, 12).
Mesenchymal stem cells (MSCs) have been shown to exhibit immunosuppressive 
characteristics (13, 14), next to their effect on tissue specific differentiation (15). MSCs can secrete multiple immunosuppressive factors, like IL-10, IL-1 
Receptor Antagonist (IL-1RA), Indoleamine 2,3-DiOxygenase (IDO), TGFβ and 
ProstaGlandin E2 (PGE2) (16) and they can induce anti-inflammatory effects in macrophages (17, 18). Moreover, evidence is gathering that MSCs need an 
inflammatory milieu to deliver immunosuppressive signals (13, 19, 20). Next to bone marrow, adipose tissue also hosts multipotent stem cells. These adipose-derived stem cells (ASCs) share multiple properties with bone marrow-derived MSCs (21), but are more accessible and abundant (5% vs 0.0001-0.001% of nucleated cells). Both types have adipogenic, osteogenic and chondrogenic 
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differentiation potential and display immunosuppressive properties in vitro as well as in vivo (22). 
Recently, we described that local administration of ASCs in the knee joint in early stage CIOA inhibited synovial activation and largely protected against new cartilage/bone formation within collateral and cruciate ligaments (23). Furthermore, cartilage damage was reduced in various layers of the knee joint. We localized GFP-labeled ASCs within the synovial lining layer in close contact to synovial macrophages (23). The immunosuppressive capacity of the ASCs 
may thereby be stimulated by the pro-inflammatory cytokines released by macrophages during the early phase of CIOA.
In the present study we investigated whether the suppressive effect of ASCs on experimental induced osteoarthritis is driven by synovitis. Furthermore, we explored the role of S100A8/A9, major products during synovitis, in this anti-
inflammatory effect of ASCs.
Materials and Methods
Animals
A total of 120 C57BL6J mice were obtained from Janvier. Animals were male and 
between 12 and 14 weeks old (average weight 24.5g SD 0.3), housed in filter-top cages with up to 10 animals per cage and received a standard diet and tap water ad libitum.
Induction of experimental osteoarthritis
We used two different models of experimental OA, CIOA and DMM, because they 
differ in synovial inflammation. Experimental CIOA (which has relatively high 
synovial inflammation) was induced as previously described (24). Briefly, right knee joints of mice were injected with 1U collagenase type VII from Clostridium histolyticum (Sigma-Aldrich) at day 0 and day 2, causing disruption of the ligaments and local instability of the knee joint. To achieve a CIOA with less synovial activation, only one time 1U collagenase was injected. Experimental 
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DMM OA (destabilized medial meniscus, a model where synovial activation is scant) was induced by transection of the medial anterior meniscotibial ligament (25). For the DMM-study 8 mice/group were used on day 7 and 10 mice/group for day 14. For the effects of ASCs on synovium in CIOA, 6 mice/group were used on day 2, 14 and 42, 8 mice/group after 6 hours. For the comparison between high and low synovial activation in CIOA, 8 mice/group were used.
Adipose Stem Cells
ASCs were isolated from adipose tissue surrounding the inguinal lymph nodes of mice and cultured for two weeks according to standard procedures in DMEM/F12 (Gibco) supplemented with 1% penicillin/streptomycin (Invitrogen), 0.5% 
amphotericin B (Invitrogen), 16μM biotin (Sigma-Aldrich), 18μM panthotenic 
acid (Sigma-Aldrich), 100μM ascorbic acid (Sigma-Aldrich). ASCs stained positive for Sca-1, CD44 and CD105 (BD Bioscience; Biolegend and eBioscience) and negative for CD11b, cKit and CD34 (Biolegend; BD Bioscience and eBioscience). 20.000 cells in 6 μL mouse serum (Jackson Immunoresearch) with 4% mouse albumin (Sigma-Aldrich) were injected intra-articularly into the knee joint. Control animals were injected with only mouse serum containing 4% mouse albumin.
Isolation of murine synovial specimens 
At various time points (6 hours, 2, 14 and 42 days) after induction of OA, synovial 
specimens were isolated as described previously (11). Briefly, joint capsule specimens were isolated on the medial and lateral sides of the patella with a biopsy punch. Synovial specimens were snapfrozen in liquid nitrogen and stored for RNA isolation.
In vitro cross-talk between adipose stem cells and activated macrophages
ASCs (passage 2) were stimulated for 24 hours with 10 ng/ml IFNγ and IL-1β and 1 µg/ml recombinant murine S100A8. Bone marrow cells were harvested from C57Bl6J mice and 1x106 were differentiated into macrophages with M-CSF for 6 days and activated with 10 ng/ml LPS for 24 hours. Consequently, these 
macrophages were incubated for 24 hours with IFNγ- and IL-1β- stimulated ASC supernatant. Effect on gene expression of suppressive factors in both ASCs and 
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macrophages was investigated using RT-qPCR.
Preparation of RNA and reverse transcription–qPCR 
RNA from murine synovium was isolated by first disrupting synovial tissue with the MagNA Lyser (Roche) 5 times for 20 seconds and then isolating the RNA using the RNeasy-kit (Qiagen) according to the manufacturers protocol. RNA from cultured ASCs and macrophages was isolated using TRI-reagent (Sigma-Aldrich). RNA was reverse transcribed to cDNA and qPCR was performed with 
specific primers and the SYBR Green Master mix in the ABI Prism 7000 Sequence Detection System (Applied Biosystems/Life Technologies). Expression levels were normalized to GAPDH. Primer sequences were designed on exon-exon transition of murine genes and can be found in Table 1.
Histological analysis of OA progression
Knee joints were dissected and fixed in 4% formalin. After fixation, joints were 
decalcified in 4% formic acid buffered in PBS and processed for histology. Paraffin 
embedded knee joints were cut in sections of 7μm, stained with Safranin O (Saf-O) and counterstained with Fast Green for analysis of cartilage damage and chondrophyte/osteophyte associated ligaments (collateral/cruciate). Cartilage 
damage was scored blinded using a modified form of the Pritzker OARSI OA score, which takes into account the grading and staging components (26). Five sections for each specimen were evaluated by two blinded investigators. Minimal score is 0, indicating no cartilage pathology whatsoever, whereas 30 is the maximum score, indicating highest grade (6) and stage (5). For scoring of synovial activation, Haematoxylin Eosin (HE) staining was used. Synovial thickening/activation was scored using an arbitrary score from 0-3 as previous described (27). Saf-O stained sections were used to measure the size of chondrophytes/osteophytes using an image analysis system (Leica Application Suite, Leica). 
Protein measurement of S100A8/A9 and cytokines in murine synovial 
washouts and serum
S100A8/A9 concentrations were determined in serum or synovial washouts of murine knee joints by a sandwich enzyme-linked immunosorbent assay (ELISA) 
specifically for murine S100A8/A9 as described previously (28). Cytokines (IL-
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1β, IL-6, IL-10, KC, IFNγ) were measured in murine synovial washouts using Luminex multianalyte technology on the Bio-Plex system, in combination with multiplex cytokine kits (Milliplex from Millipore
Measurement of TGFβ-activity 
TGFβ-activity was determined by adding 1:5 dilution of synovial washouts 
overnight to 3T3 fibroblasts transduced with adenoviral CAGA-luciferase (CAGA-luc) with a multiplicity of infection (MOI) of 10 (10 plaque-forming units) per cell, after which luminescence was measured. The plasmid was kindly provided by Dr. Ten Dijke (Department of Molecular Cell Biology, Leiden University Medical Center, The Netherlands). The CAGA-boxes in the vector are transcribed 
by Smad3/4 through active TGFβ, resulting in luciferase activity (29).
Ethical considerations 
All animal experiments were approved by the local authority Animal Care and Use Committee and local ethics committee of the Radboud university medical center 
(RU-DEC 2011-101/2012-247) and were performed by personnel certified by the Dutch Ministry of WVC. 
Statistical analysis
Data were statistically evaluated using the Mann-Whitney U test or student t-test 
using Graph Pad Prism 5 (GraphPad Software). Differences were called significant with P-value < 0.05 (*), < 0.01 (**) or <0.0005(***).
Results
ASC treatment has no effect on development of joint destruction in DMM 
experimental OA with low synovial activation
In a previous study we found that a single injection of ASCs into a mouse knee joint of CIOA inhibited development of cartilage destruction, chondrogenesis in ligaments and osteophyte formation (23). CIOA is characterized by thickening 
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and activation of the synovial layer containing activated macrophages. To investigate further whether synovial macrophage activation may drive the anti-
inflammatory activity of ASCs, ASCs were tested in the DMM model, in which synovial macrophage activation is scant (11). A single injection of 20.000 ASCs was given into the right knee joint either at day 7 or day 14 after induction of DMM. In contrast to CIOA, no effect of ASC treatment was found in DMM on cartilage destruction (Figure 1A), osteophyte formation (Figure 1B) or chondrogenesis in ligaments (Figure 1C). These results suggest that the healing capacity of ASC is related to synovitis.
Intra-articularly applied ASCs rapidly suppress the activation status of the 
synovial lining layer during CIOA 
To investigate the effect of the intra-articularly injected ASCs on the inflammatory status of the synovium, we injected 20.000 ASCs in the knee joint at day 7 after induction of CIOA and isolated synovium 6 hours, 2, 14 and 42 days thereafter. 
Various macrophage derived cytokines (IL-1β, IL-6, TNFα, IL-10, KC, S100A8, 
Figure 1: ASC treatment has no effect on development of joint destruction in a DMM 
model in which synovial activation is scant.DMM OA was induced by transection of the medial anterior meniscotibial ligament and 
20.000 ASCs were injected intra-articularly at day 7 or 14. Mice were sacrificed at day 56 and whole knee joints were prepared for histology. A. No difference was found on mean 
cartilage damage as assessed by the modified Pritzker OARSI score. B. Injection of ASCs on neither day 7 or 14 changed osteophyte size as measured at the margins of the medial femur and tibia by image analysis software. C. Similarly, chondrogenic area in cruciate and medial collateral ligaments was not changed by ASC injection at day 7 or 14 of DMM, measured by redness in Safranin-O stained sections. N=8 mice/group in experiment with ASC injection at day 7, n=10 at day 14.
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S100A9) were measured using RT-qPCR. Pro-inflammatory mediators S100A8, 
S100A9, IL-1β, IL-6 and KC were highest 6 hours after control injection and declined later on, which is in line with earlier studies showing highest 
synovial activation in early stages of CIOA (11). Interestingly, ASCs significantly 
downregulated S100A8, S100A9 (Figure 2A), IL-1β and KC mRNA (Figure 2B) already 6 hours after ASC injection. Although mRNA levels were still lower at day 
14, this did not reach significance. IL-6 mRNA levels were significantly reduced at 
day 14, and lower at day 2, although not significantly (Figure 2B).
Figure 2: Intra-articularly applied ASCs rapidly suppress synovial mRNA-expression 
of pro-inflammatory mediators during collagenase-induced OA ASCs were injected at day 7 of CIOA, and 6 hours, 2, 14 and 42 days thereafter synovial RNA was collected. mRNA levels of alarmins S100A8, A9 (A) and pro-inflammatory cytokines/chemokines IL-1β, IL-6 and KC (B) were measured on RT-qPCR and were significantly lowered after 6 hours (except for IL-6), however not at later timepoints. N=6-8 mice/group (2 synovia pooled at timepoints 2,14,42 days). *=P<0.05, **=P<0.01 as measured by student t-test.
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In addition, protein levels of various cytokines (IL-1β, IL-6, IL-10, KC, IFNγ) and S100A8/A9 were measured in synovial washouts using Luminex or ELISA (for 
S100A8/A9). Low levels of IL-1β (Figure 3B) and very high levels of S100A8/A9 (Figure 3A) were detected 6 hours and 2 days after ASC or control injection. IL-
1β protein levels were found to be lower at day 2, 14 and 42 after ASC treatment (44, 45 and 34% lower, respectively) (Figure 3B). Moreover, S100A8/A9 was 
significantly downregulated on protein level 6 and 48 hours after ASC injection (48 and 58% lower, respectively) (Figure 3A). No effect of ASC treatment was found on protein levels of IL-6 and KC (Figure 3B). These results indicate that the suppressive effect by ASCs is rapidly initiated in the synovium. Apart from lowering catabolic cytokines, ASC treatment may also affect anabolic growth 
factors like TGFβ and BMP-2, crucial during osteophytosis (30). However, 
no effect of ASCs was found on mRNA levels of TGFβ and BMP-2 (data not 
shown). Measuring TGFβ activity in synovial washouts using a CAGA-luc assay, no differences were found at 6 hours, 2, 14 or 42 days after ASC and control treatment (Figure 3C).
Interaction between cytokine stimulated ASCs and macrophages
In various studies it has been shown that pro-inflammatory cytokines, and in 
particular IFNγ, directly stimulate the anti-inflammatory capacity of ASCs (31-
33). First, we confirmed that IFNγ could directly induce anti-inflammatory 
mediators arginase, IL-1RA and iNOS in ASCs on mRNA level (Figure 4A).IL-1β also induced higher levels of arginase and iNOS mRNA in ASCs, whereas S100A8 
did not affect any anti-inflammatory genes in ASCs (Figure 4A). We next studied 
the in vitro effect of IL-1β and IFNγ on the cross talk between ASCs and activated macrophages. To do this, murine bone marrow derived macrophages (BMM) were activated with LPS and consequently stimulated with supernatant of IL-
1β- or IFNγ-stimulated ASCs. The supernatant of IFNγ-stimulated, but not IL-
1β-stimulated ASCs strongly increased IDO mRNA expression in BMM (25-fold 
increase compared to unstimulated ASCs or IFNγ alone), while also upregulating 
iNOS (83- or 6-fold increase compared to unstimulated ASCs or IFNγ alone). Supernatant of unstimulated ASCs already upregulated arginase mRNA levels in 
BMM (8-fold increase). No effect was found on IL-1RA, IL-10 and TGFβ mRNA levels (Figure 4B).
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The efficacy of local ASC treatment in the early phase of OA is related to 
synovial thickness and is reflected by S100A8/A9 levels in the serum 
To investigate whether the efficacy of ASC treatment is related to synovial thickness, we compared CIOA with high and somewhat lower synovial 
inflammation by injecting 1U collagenase either once or twice. The synovial thickening of CIOA on day 42 with one time injection was 65% lower compared to two times injection (2.48 vs 1.5). However, this is still higher than observed 
in the DMM model (synovial activation score at endpoint, day 56: 0.7, data not shown). In the experiment with high synovial activation, day 7 ASC treatment 
Figure 3: Intra-articular ASC-injection reduces synovial protein levels of pro-
inflammatory S100A8/A9 and IL-1β during collagenase-induced OA ASCs (20.000) were injected at day 7 of CIOA, and 6 hours, 2, 14 and 42 days thereafter synovial washouts were collected. Protein levels of S100A8/A9 were measured with a 
specific ELISA (A) and IL-1β, IL-6 and KC proteins levels were measured on Luminex (B). 
S100A8/A9 levels were significantly lowered 6 hours and 2 days after ASC treatment, IL-1β at day 2, 14 and 42. C. TGFβ-activity, measured by CAGA-luc in synovial washouts, was not changed after ASC treatment. N=6 mice/group *=P<0.05, **=P<0.01 as measured by student t-test.
169
Chapter 8
significantly suppressed synovial thickening (32% lower). In addition, osteophyte size was also greatly reduced in the ASC treated group (72% lower) (Figure 5A). In contrast, in the second experiment, no suppressive effect of ASC treatment on synovial thickening, nor on osteophyte size (Figure 5B) was found. 
These data suggest that the inflammatory status of the synovium drives the anti-
inflammatory capacity of the ASC. 
Figure 4: Cytokine 
stimulated ASCs induce 
anti-inflammatory effects in 
activated macrophages ASCs were stimulated with 
pro-inflammatory cytokines IFNγ, IL-1β and S100A8 and the supernatants were used to stimulate activated murine bone-marrow derived macrophages (BMM). A. Direct effects of IFNγ, IL-1β and S100A8 on the mRNA expression of anti-
inflammatory mediators by ASCs, showing upregulation of arginase, IDO, IL-1RA and iNOS. 
B. Supernatants of unstimulated ASCs already upregulated arginase mRNA in BMM, while supernatant of IFNγ-stimulated ASCs upregulated IDO and iNOS mRNA. IL-1RA, IL-10 and TGFβ mRNA levels in BMM were not affected. Values in A are represented as ΔΔCt, corrected for GAPDH and unstimulated. Values in B are represented as –ΔCt, corrected for GAPDH. Results are representative of 2 independent experiments. * = P < 0 . 0 5 , * * = P < 0 . 0 1 , ***=P<0.005 as measured by student t-test.
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During synovitis release of high amounts of pro-inflammatory and catabolic S100A8/A9 may leak from the joint into the bloodstream (11). Serum was isolated at 14 and 42 days after ASC-treatment in the two CIOA experiments differing in synovial activation. In the experiment with high synovial activation, serum levels of S100A8/A9 levels were very high at day 14 (497 ng/ml, 371% of non-arthritic C57Bl6 mice, “naïve”) and at day 42 still clearly above naïve (282 vs 134 ng/ml) (Figure 6A). In the experiment showing less synovial thickening, serum levels of S100A8/A9 levels were much lower at day 14 (272 versus 497 ng/ml) and returned to control levels at day 42 (Figure 6B). Interestingly, 
in the first experiment, local application of ASC at day 7 after OA induction dramatically inhibited S100A8/A9 serum levels (80% at day 14 and 44% at day 42 after treatment) (Figure 6A). In contrast, in the experiment with low synovial 
activation, S100A8/A9 levels were not significantly changed by ASC treatment at day 14 whereas at day 42 a 58% decrease was observed (Figure 6B).
Figure 6: Efficacy of ASC 
treatment can be measured by 
serum levels of S100A8/A9 Systemic S100A8/A9 levels in collagenase-induced OA differing in synovial activation was compared and the effect of ASC treatment at day 7 examined. A. Serum S100A8/A9 levels were very high in OA with higher synovial activation (807 ng/ml at day 14, compared to 134 ng/ml in non-arthritic mice “naïve”) 
and were significantly lowered at day 14 and 42 when ASCs were given intra-articularly at day 7. B. In contrast, S100A8/A9 serum levels were much lower in the experiment with low synovial activation (272 vs 807 ng/ml at day 14). Treatment 
with ASCs did not significantly decrease S100A8/A9 levels at day 14, only at day 42. S100A8/A9 was measured using ELISA. n=8 mice/group, except naive (n=32) *=P<0.05, **=P<0.01 as measured by student t-test
Figure 5 : The efficacy of local ASC treatment in the early phase of collagenase-
induced OA depends on synovial activationTwo collagenase-induced OA experiments differing in synovial thickening/activation (1.7 fold difference) at day 42 were compared on the effect of intra-articular ASC treatment at day 7. Local ASC treatment only reduces synovial activation and osteophyte formation at the medial femur in OA with high synovial activation (A), compared to OA with low synovial activation (B). Right panels show representative histological pictures of hematoxylin-eosin stained knee sections (synovial activation, top panels) or Safranin-O stained knee 
sections on the medial side (osteophyte formation, bottom panels). Magnification, 50x or 
200x, is indicated. *=P-value <0.05, **=P-value<0.01. Significance of osteophyte size was calculated using student t-test, synovial activation with Mann Whitney U. n=6 mice/group
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During synovitis release of high amounts of pro-inflammatory and catabolic S100A8/A9 may leak from the joint into the bloodstream (11). Serum was isolated at 14 and 42 days after ASC-treatment in the two CIOA experiments differing in synovial activation. In the experiment with high synovial activation, serum levels of S100A8/A9 levels were very high at day 14 (497 ng/ml, 371% of non-arthritic C57Bl6 mice, “naïve”) and at day 42 still clearly above naïve (282 vs 134 ng/ml) (Figure 6A). In the experiment showing less synovial thickening, serum levels of S100A8/A9 levels were much lower at day 14 (272 versus 497 ng/ml) and returned to control levels at day 42 (Figure 6B). Interestingly, 
in the first experiment, local application of ASC at day 7 after OA induction dramatically inhibited S100A8/A9 serum levels (80% at day 14 and 44% at day 42 after treatment) (Figure 6A). In contrast, in the experiment with low synovial 
activation, S100A8/A9 levels were not significantly changed by ASC treatment at day 14 whereas at day 42 a 58% decrease was observed (Figure 6B).
Figure 6: Efficacy of ASC 
treatment can be measured by 
serum levels of S100A8/A9 Systemic S100A8/A9 levels in collagenase-induced OA differing in synovial activation was compared and the effect of ASC treatment at day 7 examined. A. Serum S100A8/A9 levels were very high in OA with higher synovial activation (807 ng/ml at day 14, compared to 134 ng/ml in non-arthritic mice “naïve”) 
and were significantly lowered at day 14 and 42 when ASCs were given intra-articularly at day 7. B. In contrast, S100A8/A9 serum levels were much lower in the experiment with low synovial activation (272 vs 807 ng/ml at day 14). Treatment 
with ASCs did not significantly decrease S100A8/A9 levels at day 14, only at day 42. S100A8/A9 was measured using ELISA. n=8 mice/group, except naive (n=32) *=P<0.05, **=P<0.01 as measured by student t-test
Figure 5 : The efficacy of local ASC treatment in the early phase of collagenase-
induced OA depends on synovial activationTwo collagenase-induced OA experiments differing in synovial thickening/activation (1.7 fold difference) at day 42 were compared on the effect of intra-articular ASC treatment at day 7. Local ASC treatment only reduces synovial activation and osteophyte formation at the medial femur in OA with high synovial activation (A), compared to OA with low synovial activation (B). Right panels show representative histological pictures of hematoxylin-eosin stained knee sections (synovial activation, top panels) or Safranin-O stained knee 
sections on the medial side (osteophyte formation, bottom panels). Magnification, 50x or 
200x, is indicated. *=P-value <0.05, **=P-value<0.01. Significance of osteophyte size was calculated using student t-test, synovial activation with Mann Whitney U. n=6 mice/group
Discussion
In the present study we find that synovitis is essential in mediating the immunosuppressive effects of ASCs in experimental OA. S100A8/A9, as marker of this synovitis, could be used as predictor for successful ASC-treatment. Furthermore, locally administered ASCs rapidly suppress the activation status of the synovial lining layer possibly via a suppressive effect on macrophages. 
Thickening of the synovial lining layer is a characteristic feature of CIOA, paralleling large subgroups of OA patients that show synovitis (1). The synovial layer comprises mainly activated macrophages and selective elimination of these macrophages prior to induction of CIOA strongly inhibited synovial thickening, chondrogenesis/osteophyte formation and cartilage destruction (8). However, 
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elimination of lining macrophages in DMM, in which synovitis is scant, has no 
effect on OA pathology. In the present study we find that when ASCs were injected into a DMM OA joint, no effect was found on development of joint destruction. 
Furthermore, ASC treatment is most efficient when given in a CIOA with high, not low synovitis. These data further support the importance of the activated 
synovial lining and macrophages in mediating the anti-inflammatory ASC effect. 
ASCs injected during the first phase of CIOA encounter high levels of pro-
inflammatory cytokines released by activated synovial lining macrophages. 
During early phase CIOA, levels of IL-1β and S100A8/A9 are strongly upregulated 
in the synovium (11). In the present study we find that injection of ASCs into day 
7 CIOA joints caused a rapid downregulation of both IL-1β and S100A8/A9 levels 
and this effect was prolongated up to day 42 after treatment (for IL-1β). Also, 
five days after injection, no ASCs could be detected anymore within the synovium 
(data not shown). Apparently, a short pulse is sufficient for giving a prolonged ameliorating effect. An explanation may be that the ASC imprint on synovial macrophages may result in transformation into suppressive macrophages 
producing lower amounts of IL-1β or S100A8/A9 cytokines.
Although we show clear anti-inflammatory effects of ASCs in CIOA, we cannot rule out that cell-types other than MSCs could also induce immunomodulatory 
capacities. Indeed, we have shown earlier that skin fibroblasts exert anti-
inflammatory effects in collagen-induced arthritis (34). However, we believe that the use of ASCs is superior to other cell-types. First, they have the ability to differentiate into cell-types that can contribute to joint repair, such as chondrocytes and osteoblasts (15). Furthermore, ASCs have an advantage of 
use in osteoarthritis compared to fibroblasts, because the anti-inflammatory effect of the latter is largely attributed to inhibition of T-cell proliferation and activation with T-cells playing no role in OA pathogenesis. Finally, MSCs, to which ASCs belong, are known for their low immunogenicity and can be easily used in therapeutic approaches, without the need of autologous application (35).
It is becoming increasingly accepted that MSCs secrete many factors including growth factors, cytokines, chemokines, metabolites and bioactive lipids which orchestrate multiple interactions with the surrounding microenvironment 
(36). Pro-inflammatory cytokines, like IFNγ, IL-6, TNF-α and DAMPs, present 
during the first phase of CIOA, are capable of inducing an immunosuppressive 
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phenotype in ASCs/MSCs (17, 19, 20, 32). In reaction to these stimuli, ASCs release factors like IDO, COX-2 and PGE2 which are able to suppress activated macrophages, although subtle species differences exist between mouse and man (17, 37). In line with that we show that ASCs are able to induce expression of 
anti-inflammatory mediators arginase and iNOS after IL-1β or IFNγ stimulation 
and upregulate IL-1RA after IFNγ stimulation. Moreover, several in vitro and 
in vivo studies suggest that MSCs can decrease inflammation by changing the macrophage phenotype from M1 (classically activated) to M2 (alternatively activated) (38-40). Previously, we already found that ASCs, when injected into 
the knee joint, interact with synovial lining macrophages (23). We now find 
that supernatant of IFNγ stimulated ASC strongly upregulated arginase, IDO and iNOS in activated macrophages which is characteristic for transformation 
into a M2 signature.We speculate that both IL-1β and IFNγ could stimulate ASCs 
in vivo during (experimental) OA, thereby activating their anti-inflammatory 
phenotype, possibly via macrophages. IL-1β is frequently studied and detected 
in OA synovium (41, 42). Although data on IFNγ in OA is more scarce, it has been shown to be present in OA synovium by immunohistochemistry (41, 43) and 
IFNγ positive CD4 T-cells were found in OA synovium (44, 45). Finally, IFNγ (and 
to a lesser extent IL-1β) could also be used as tool to activate the ASCs ex vivo to 
generate a larger anti-inflammatory potential.
Chondrogenesis within collateral/cruciate ligaments hampers a good functioning of the joint and may further enhance cartilage destruction. In previous studies performed in CIOA, we showed that activated synovial macrophages mediate chondrogenesis/osteophyte formation (9, 46). Macrophage derived factors 
involved in new cartilage formation include growth factors like TGFβ and BMP-2 (9, 47). Production of these growth factors within the synovium was strongly diminished after macrophages were selectively depleted from the lining layer 
(46). However, ASC treatment did not suppress mRNA levels of TGFβ and BMPs or 
active TGFβ within the synovium, suggesting that ASCs mostly act via inhibition 
of pro-inflammatory cytokines (IL-1β) or alarmins S100A8/A9, rather than via growth factors. 
Comparing efficacy of ASC treatment in two CIOA experiments differing in synovial 
activation we found that ASC treatment was anti-inflammatory particularly when injected in joints with high but not with low synovitis, indicating that a 
certain threshold of pro-inflammatory factors is needed for induction of the anti-
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inflammatory effect of ASCs. In line with this is that ASC treatment when given at later phases (day 14 or day 21) after CIOA is also not effective (23) and that treatment of DMM with ASCs is also ineffective (Figure 1). High synovial activation 
in CIOA joints was reflected by high S100A8/A9 levels in the serum (Figure 6). S100A8/A9 produced in the synovium could leak out of the joint cavity thereby 
reflecting inflammatory status in the serum (48). S100A8/A9 serum levels may 
thus be used firstly as a marker for determining synovitis which is a licensing signal for using local ASC treatment. Secondly, local stem cell treatment of CIOA joints lowered levels of S100A8/A9 levels within the serum and may therefore 
also be used as a marker for measuring the efficacy of ASC treatment.
In the present paper we show that intra-articular deposition of ASCs inhibit thickening/activation of the synovial lining layer and protect joint destruction in experimental OA with high synovial activation. ASCs had an immunomodulatory 
effect on the synovium by suppressing catabolic factors like IL-1β and S100A8/A9 
produced by synovial macrophages. In vitro, ASCs upregulated anti-inflammtory factors in activated macrophages. Finally, S100A8/A9 could be used both as marker to determine feasibility of ASC-treatment in experimental OA as well as 
read-out to determine its efficacy. 
ASCs may be a potent and safe tool to combat joint destruction and inflammation in OA patients with high synovial activation.
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Chapter 9: Summary and final considerations
The aims of this thesis were to broaden our knowledge on the role of synovial activation and the resulting DAMPs or alarmins S100A8 and S100A9 in OA and 
to assess efficacy of dampening synovial activation in OA by either inhibiting 
S100A8/A9 or making use of anti-inflammatory ASCs.
S100A8/A9 plays pivotal role in pathology of experimental OA with 
synovial activation
Since very little is known regarding the involvement of alarmins S100A8 and 
S100A9 in osteoarthritis, we started by studying the expression of S100A8 and 
S100A9 during experimental OA (Chapter 2).  To do this, we made use of two 
murine OA models: CIOA is induced by intra-articular injection of collagenase and 
synovial thickening is a common feature of this model (1). In contrast, synovial activation is nearly absent in the DMM model, that is induced by transection of the 
medial anterior meniscotibial ligament (2). We found that S100A8 and S100A9 
were greatly induced during CIOA up to day 21, while other pro-inflammatory 
mediators like IL-1β and TNFα already waned after day 7. In the DMM model, 
S100A8 and S100A9 were expressed at much lower levels compared to CIOA and 
only elevated at day 7. When we induced CIOA in the S100A9 -/- mouse, synovial 
thickening and cartilage destruction were significantly reduced at the end point 
compared to CIOA in wild-types. In sharp contrast, synovitis, already low in DMM, was not further reduced in S100A9 -/- mice and cartilage destruction was 
not different between S100A9 -/- and wild-type mice. 
Next to cartilage damage, osteophyte formation is an important pathological 
feature of OA. Osteophytes are fibro-cartilage capped bony outgrowths that can 
limit joint movement and cause pain. In Chapter 3 we investigated the role of 
DAMPs S100A8 and S100A9 in osteophyte formation during OA. We assessed 
osteophyte development in  S100A9 -/- mice after induction of CIOA and DMM 
OA. At the endpoint of DMM, osteophyte size was not different between knockout 
and wild-type animals. In contrast, osteophyte size was dramatically reduced in 
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S100A9 -/- mice at the endpoint and halfway during CIOA at multiple locations 
in the joint. These results, combined with the observed reduction in cartilage 
damage in Chapter 2, emphasize the importance of synovial activation and the 
resulting S100A8/A9 production in the development of pathology in OA. 
High S100A8/A9 levels in early symptomatic human OA predict 
progression of disease
Next, we zoomed in on the relationship between S100A8/A9 and human OA in 
Chapter 2 and 3. To do this, we used the CHECK cohort of symptomatic early 
OA patients. Synovial mRNA of S100A8 and S100A9 was increased in both early 
symptomatic and end-stage OA compared to healthy synovium as were protein 
levels which was confirmed by immunohistochemistry. This again suggests 
prolonged expression and release of DAMPs S100A8/A9 during OA. Then we 
measured systemic S100A8/A9 in the blood of CHECK participants at baseline 
with ELISA and measured joint destruction (according to Kellgren/Lawrence 
scale) after 2 years (Chapter 2) and osteophyte size after 2 and 5 years (Chapter 
3). Participants that had no joint damage at baseline, but developed joint damage 
after 2 years (Kellgren/Lawrence score ≥1) had significantly higher S100A8/A9 
levels at baseline. In line with this, participants that progressed in osteophyte 
size after 2 or 5 years, also had significantly increased S100A8/A9 levels at entry 
in the CHECK. Interestingly, C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR) or Cartilage Oligomeric Matrix Protein (COMP) could not predict 
osteophyte progression. Together, these results strongly recommend S100A8/
A9 as early biomarker for the development of OA. Patient populations used in 
this study were still fairly small though (n=177 and 56 for joint damage and 
osteophyte size, respectively) and validation in a larger cohort is necessary. 
Possibly, the predictive value of S100A8/A9 for OA pathology will be strongest 
in patients with concurring synovial inflammation as this largely drives S100A8/
A9 production and S100A8/A9 is already being used as biomarker in multiple 
inflammatory diseases (3).
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S100A8/A9 exerts pro-inflammatory and catabolic effects on 
chondrocytes and M1- and M2-macrophages
Endogenous DAMPs, like S100A8 and S100A9, have different functions in- and 
outside of the cell. Inside they often have a homeostatic role, while secreted they 
serve as danger signals, hence the term alarmins. In Chapter 4, we stimulated 
chondrocytes from end-stage OA patients with S100A8 and S100A9 and 
found that pro-inflammatory (cytokines) and catabolic (MMPs) factors were 
significantly upregulated on mRNA expression and protein release. Moreover, 
expression of anabolic genes aggrecan and collagen type II were significantly down-regulated, in combination leading to a shift towards a more catabolic 
chondrocyte. Interestingly, we showed that this catabolic skewing is specific for 
osteoarthritic chondrocytes, not normal chondrocytes and appeared to be TLR4 
dependent, not RAGE or n-glycans. This is in line with studies showing TLR4 as 
receptor for S100A8/A9 in monocytes/macrophages and osteoclasts (4, 5). 
In Chapter 5, we shifted our attention to the effects of S100A8 and S100A9 on 
the OA synovium and cells residing within this tissue. The synovial intima layer 
contains both macrophages and fibroblast-like cells. Fahy et al. recently showed 
that OA synovium contains both pro-inflammatory M1- and anti-inflammatory 
M2-macrophages and we could confirm this in our OA synovial explants (6). 
First, we proved that S100A9 could significantly upregulate pro-inflammatory 
cytokines (MMPs in lesser extent) in total OA synovial explants. Then we focused 
on specific effects on the different cell-types of the synovium. We could not 
find effects of S100A9 on synovial fibroblasts. However, S100A9 had clear pro-
inflammatory effects on both M1- and M2-macrophages, with M2-macrophages 
being slightly less responsive. These results suggest that S100A8/A9, abundantly 
present during synovitis, increases pro-inflammatory and catabolic mediators 
through both M1- and M2-macrophages.
Blocking S100A8/A9 with paquinimod alleviates experimental OA 
pathology
Although OA affects millions of people worldwide and their number is increasing 
due to the increasing age and obesity of the population, still no disease modifying 
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OA drugs have been developed yet. In the last chapters we explored the possibility 
to treat experimental OA by modulating synovitis. In Chapter 6, we used an 
inhibitor of S100A9, the quinoline derivative paquinimod, that specifically inhibits 
the binding of S100A9 with its receptors TLR4 and RAGE (7). This compound has 
already proven to be effective in experimental lupus and encephalomyelitis (8, 
9) and we now show disease modifying effects for the first time in experimental 
OA. Paquinimod administered a few days prior to induction of CIOA significantly 
reduced synovial thickening, osteophyte size and cartilage damage at the end 
point. In line with our studies in the S100A9 -/- mice, blocking S100A9 with 
paquinimod in DMM OA did not have any effects on cartilage damage and only 
slightly on osteophyte formation. Interestingly, we also show that paquinimod 
can block the induction of pro-inflammatory and catabolic mediators by S100A9 
in ex vivo stimulations with human OA synovium. These findings, combined with 
the fact that paquinimod has already proven to be safe and tolerable (8), provide 
us with a feasible option for future treatment of inflammatory type OA.
Adipose-derived stem cells dampen synovial activation and reduce 
pathology in experimental OA
Synovial inflammation can alternatively be blocked by the use of adipose-derived 
pluripotent stem cells (ASCs). These cells like their close relatives, bone marrow 
derived mesenchymal stem cells (BM MSCs), have been shown to have strong anti-
inflammatory characteristics. They can produce numerous anti-inflammatory 
factors and BM MSCs and ASCs have been used in a wide range of inflammatory 
or auto-immune diseases (10, 11). In Chapter 7, we have successfully used 
ASCs in an OA setting. ASCs intra-articularly injected 7 days after induction 
of CIOA significantly reduced synovial thickening, new cartilage and bone 
formation (osteophytes) in ligaments and cartilage damage at the end point. We 
could visualize ASCs no longer than 1 day after injection, in close contact with 
macrophages in the synovial lining layer. As ASC treatment was only successful 
in the presence of inflammation, this suggested involvement of the synovium 
in driving the anti-inflammatory mechanism of the ASCs and in Chapter 8, we 
analyzed changes in expression and production of cytokines in the synovium. 
We found that ASCs could rapidly (already after 6 hours) downregulate pro-
inflammatory cytokines/chemokines and DAMPs S100A8 and S100A9, products 
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of activated macrophages. Next, we showed that synovial activation is essential 
for the efficacy of the ASCs, as CIOA with low synovial inflammation and DMM OA 
could not be treated efficiently with day 7 injection of ASCs. Finally, we measured 
S100A8/A9 during and after treatment of CIOA with ASCs and showed that the 
levels of these DAMPs reflect efficient treatment.
Final considerations
By using sensitive magnetic resonance imaging (MRI) and ultra-sound 
techniques, it has become apparent that inflammation is very common in both 
knee and hand OA (12, 13). OA therapy is currently focused on treating pain 
and relieving symptoms, instead of treating the cause of the disease. Non-
steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids are commonly 
used to dampen inflammation and alleviate pain during OA, but these are 
broad-spectrum approaches and have lots of side effects. We have shown that 
paquinimod, a quinoline-3-carboxamide compound (Q-compound), effectively 
reduces synovial activation, cartilage damage and osteophyte formation in 
experimental OA. Paquinimod inhibits binding of S100A9 to both its receptors 
TLR4 and RAGE (7) and may therefore specifically block synovial activation 
during OA. Moreover, in preclinical studies in systemic lupus erythematosus 
(SLE), paquinimod has proved safe with little side effects (8). Q-compounds have been studied extensively in the treatment of human auto-immune and 
inflammatory diseases (14, 15), while paquinimod is currently in clinical 
development for systemic sclerosis (16). Interestingly, in several animal models 
of auto-immune / inflammatory diseases Q-compounds have a potent effect on 
disease pathology, yet do not suppress adaptive immunity (7, 17). In that light 
Q-compound paquinimod would be suitable for treatment of OA, which has little 
to no involvement of T- and B-cells, without having severe side effects on the 
patient’s immune system. 
A mode of action for paquinimod could be by blocking chemotaxis of myeloid cells. 
Recently, paquinimod has been shown to inhibit recruitment of inflammatory 
Ly6C-high monocytes during sterile peritoneal inflammation (18). Possibly this effect could be through blocking of S100A9, as a relation between S100A9 and 
Ly6C-bearing monocytes has been shown before (19, 20).
185
Chapter 9
Dampening synovial activation locally can be achieved in experimental OA by 
local injection of ASCs, as we have shown in Chapter 7 and 8. A short pulse of ASCs 
already seems sufficient to reduce synovial activation and further aggravation 
of OA development, keeping possible systemic side effects to a minimum. ASCs 
might achieve these effects by inducing anti-inflammatory mediators like IDO, 
COX-2 and PGE2 which are able to suppress activated macrophages (21). We and others have shown that these stem cells interact closely with synovial 
macrophages (Chapter 7, (22)) and several studies suggest that mesenchymal 
stem cells can skew the macrophage phenotype from pro-inflammatory M1 to 
alternatively activated M2-macrophages (23, 24).
ASCs or BM MSCs as anti-inflammatory therapy has been used in several 
experimental inflammatory diseases like arthritis and ischemic heart disease 
(25, 26) and recently also in an experimental osteoarthritis models in the rabbit 
(22). Moreover, ASCs could also exert anti-inflammatory effects on human OA 
chondrocytes and synoviocytes in vitro (27). Together, the anti-inflammatory 
results so far in experimental and human in vitro models show great promise for 
the use of ASCs or BM MSCs as therapy in inflammatory OA.
Overall conclusion
In this thesis we have shown that synovial activation and the resulting DAMPs 
S100A8 and S100A9 are pivotal in the development of OA pathology. Moreover, 
we show promising experimental data that blocking this synovial activation 
either directly with ASCs or with paquinimod, blocking S100A8 and S100A9, 
could be future therapeutic options against inflammatory OA.
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Nederlandse samenvatting
Artrose (OA): een groeiend gezondheidsprobleem
Ouderdomsziektes vormen in de huidige Westerse wereld een steeds groter 
probleem, zowel maatschappelijk als financieel, door de steeds ouder wordende bevolking. Eén van de meest voorkomende ouderdomsziektes is artrose of osteoartritis (afgekort: OA). Meer dan 50% van de bevolking ouder dan 65 heeft een zekere mate van OA die kan worden vastgesteld door een reumatoloog. OA kenmerkt zich door een slijtage van het kraakbeen in gewrichten van met name handen/vingers, ruggenwervel, knie en/of heup. Door het wegvallen van de dempende werking van het kraakbeen ontstaat er direct bot op bot contact wat kan leiden tot gewrichtspijn en verminderde beweeglijkheid van het gewricht. OA kan een zware impact hebben op de kwaliteit van leven, doordat patiënten minder mobiel zijn en daardoor minder kunnen werken en/of deelnemen aan de maatschappij. Tot op heden is het onduidelijk wat de precieze oorzaak van 
OA is, alhoewel verschillende risicofactoren zijn geïdentificeerd, zoals leeftijd, (over)gewicht en een aantal genetische factoren. Bovendien zijn er ook nog geen adequate medicijnen om de ontwikkeling van OA tegen te gaan. Samen met bewegingsadviezen, worden slechts algemene pijn- en ontstekingsremmers gebruikt en wordt uiteindelijk bij verregaande OA een gewrichtsvervangende operatie uitgevoerd.
Ontsteking tijdens OA
De rol van ontsteking bij OA is onderbelicht. Waar vroeger werd gedacht dat OA vooral mechanische slijtage van het kraakbeen was, komt er nu steeds meer bewijs dat ontsteking ook een belangrijke rol bij de initiatie en mogelijk beloop van OA speelt. Ontsteking kan zich voordoen in de binnenbekleding van het gewricht, het 
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synovium, waar zich verschillende ontstekingscellen bevinden. Ondanks dat de mate van deze ontsteking over het algemeen lager is dan bij autoimmuunziektes zoals reumatoïde artritis, wordt bij zeker 50% van de OA patiënten ontsteking in het synovium vastgesteld met behulp van arthroscopie. Verder onderzoek heeft laten zien dat synoviale ontsteking voorspellend is voor kraakbeenschade. Op cellulair en moleculair niveau zijn er ook voldoende aanwijzingen dat ontsteking een rol speelt bij OA. Ontstekingscellen zoals macrofagen worden in grote mate aangetroffen in het synovium van OA patiënten en wanneer macrofagen uit het gewricht worden verwijderd bij muizen, ontwikkelen deze minder ernstige OA. Ontstekingsmediatoren, zoals de cytokines, worden ook in verhoogde concentraties gevonden in het synovium van OA patiënten en verschillende dierstudies laten zien dat deze stoffen een rol spelen bij de ontwikkeling van OA. 
DAMPs en S100-eiwitten tijdens ontsteking
Naast cytokines zijn er ook andere ontstekingsstoffen die vrij kunnen komen bij OA. De zogenaamde alarmines of DAMPs (damage associated molecular patterns) komen vrij bij schade of ontsteking en kunnen andere (ontstekings)cellen waarschuwen en activeren. Net als cytokines zorgen ze dan voor verdere ontsteking, die in het geval van OA nadelig kan zijn voor de kwaliteit van het kraakbeen. Belangrijke DAMPs zijn de eiwitten S100A8 en S100A9. Het zijn eiwitten van de familie van S100-eiwitten, zo’n twintigtal eiwitten die verschillende functies binnen en buiten de cel kunnen hebben. S100A8/S100A9 (afgekort tot S100) kan in grote hoeveelheden worden geproduceerd door ontstekingscellen, zoals macrofagen, maar ook granulocyten en monocyten. Studies waarbij S100 gebruikt is om cellen te stimuleren, laten zien dat deze DAMP een groot scala aan ontstekingsmediatoren kan induceren. S100 is ook verhoogd aangetroffen bij een groot aantal (auto)immuunziektes waarbij ontsteking een essentiële rol speelt, zoals dermatomyositis, SLE (systemic lupus erythematosus), arteriosclerose, psoriasis, de ziekte van Crohn en verschillende vormen van artritis, waaronder de “klassieke” reuma (reumatoïde artritis). Associaties van S100 met OA zijn tot op heden zeer schaars. Een enkele studie laat zien dat S100 aanwezig is tijdens een muismodel van OA, maar geeft verder geen verklaringen of effecten hiervan. 
192
Chapter 10
Doel van het proefschrift
In dit proefschrift hebben we onderzoek gedaan naar de rol van ontsteking en S100 bij OA. We hebben hiervoor gebruikt gemaakt van weefselmateriaal van OA patiënten, een grootschalig cohort (grote groep deelnemers/patiënten met vergelijkbare kenmerken) van patiënten met symptomatische OA en verschillende muismodellen voor OA. Vervolgens hebben we via het gebruik van ontstekingsremmende cel-therapie en het blokkeren van S100 getracht de synoviale ontsteking tijdens OA in de muis te verlagen en daarmee OA ontwikkeling te stoppen.
Ontsteking en S100 dragen bij aan schade bij muismodellen voor OA
In hoofdstuk 2 hebben we eerst de spiegels van S100 in twee verschillende muismodellen voor OA bestudeerd. Collagenase-geïnduceerde osteoartritis (CIOA) (opgewekt door het inspuiten van collagenase direct in het kniegewricht) is een model dat een duidelijke synoviale ontsteking heeft en het chirurgische DMM (waarbij het ligament tussen de meniscus en het scheenbeen wordt doorgesneden en er instabiliteit ontstaat in het kniegewricht) heeft aanzienlijk minder ontsteking. Beide modellen ontwikkelen duidelijke kraakbeenschade, waarbij het ziekteverloop van de CIOA iets sneller is (maximale schade na 42 dagen) dan bij DMM (56 dagen). In het CIOA model vonden we dat S100 
significant verhoogd was tot 21 dagen na de start van het model, terwijl andere 
ontstekingsmediatoren zoals IL-1β en TNFα na één week al sterk verlaagd waren. In het DMM model was het niveau van S100 beduidend lager in vergelijking met CIOA en slechts licht verhoogd op dag 7. Vervolgens hebben we beide modellen opgewekt in muizen die door een genetisch defect geen S100A9 kunnen aanmaken en daardoor eveneens geen stabiel en functioneel S100A8 kunnen produceren. Deze S100-knock-out (k.o.) muizen hadden een sterk verlaagde synoviale ontsteking en kraakbeenschade in het CIOA model, terwijl dit niet verschilde in het DMM model. 
In hoofdstuk 3 hebben we wederom CIOA en DMM geïnduceerd in de S100-k.o. muizen en ons ditmaal geconcentreerd op de formatie van osteofyten. Dit zijn nieuw gevormde kraakbeen/bot structuren op plaatsen in het gewricht waar 
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ze niet thuishoren. Deze structuren limiteren beweging van het gewricht en veroorzaken pijn tijdens OA. Bij het DMM model, met lage synoviale ontsteking, vonden we geen verschillen tussen normale en S100-k.o. muizen. Echter, halverwege (dag 21) en op het eindpunt (dag 42) van het CIOA model was de omvang van de osteofyten in de S100-k.o. muizen drastisch kleiner.
Deze gecombineerde resultaten geven aan dat ontsteking een belangrijke bijdrage levert aan OA-gerelateerde kraakbeenschade en osteofyt-vorming en dat deze ontsteking deels via S100 gereguleerd wordt.
S100 voorspelt mogelijk ontwikkeling van schade bij beginnende OA 
patiënten
Daarnaast hebben we in hoofdstuk 2 en 3 onderzoek gedaan naar de relatie tussen S100 en beginnende OA. Hiervoor hebben we het CHECK (cohort heup en cohort knie) cohort gebruikt. Dit Nederlandse cohort gestart door het reumafonds en verspreid over 14 centra beschikt over uitgebreide data van patiënten met symptomatische OA die nog geen verleden van gewrichtsziekten of andere immunologische aandoeningen hebben, tussen de 45 en 65 jaar zijn, en die voor het eerst bij de huisarts komen met knie- of heupklachten. Deze patiënten zijn tot 5 jaar na de eerste klachten gevolgd. 
Niveaus van zowel S100A8 als S100A9 in het synovium van CHECK patiënten waren duidelijk verhoogd in vergelijking met die van gezond synovium. Verder vonden we dat hoge spiegels van S100 in het bloed van deze patiënten voorspellend waren voor het ontwikkelen van gewrichtsschade na 2 jaar en het verder ontwikkelen van osteofyten na 2 en 5 jaar. Ondanks dat bij hoge bloedwaardes van S100 niet met zekerheid kan worden vastgesteld dat gewrichtsschade ontstaat, geeft een S100 waarde boven de 200 ng/ml wel een 4x verhoogd risico op (verdere) ontwikkeling van osteofyten. In tegenstelling tot S100 waren enkele standaard bloed-parameters voor ontsteking (C-reactief eiwit (CRP), bezinkingssnelheid (BSE) of COMP (cartilage oligomeric matrix protein)) juist niet voorspellend voor verdere osteofyt ontwikkeling. Deze resultaten wijzen er op dat S100 een unieke vroege biomarker zou kunnen zijn voor de voorspelling van OA ontwikkeling.
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S100 heeft catabole en pro-inflammatoire effecten op kraakbeen- en 
ontstekingscellen 
In hoofdstuk 4 en 5 hebben we gekeken naar de effecten van S100 op de verschillende cellen die zich in het gewricht bevinden en die een rol spelen bij de ontwikkeling van OA. Ten eerste hebben we in hoofdstuk 4 de effecten onderzocht van S100 op chondrocyten (kraakbeencellen). Stimulatie van chondrocyten 
afkomstig van OA patiënten met S100A8 of S100A9, veroorzaakte een sterke 
verhoging van allerlei ontstekingsmediatoren (voornamelijk cytokines IL-1β, -6 en -8) op zowel RNA als eiwit niveau. Bovendien resulteerde S100 stimulatie 
in verhoogde spiegels van enzymen die kraakbeen kunnen afbreken, de MMP’s (matrix metalloproteinases), en verlaagde niveaus van groeifactoren, eiwitten die juist voor kraakbeenopbouw zorgen. Tenslotte toonden we in hoofdstuk 4 aan dat S100 veel potenter werkt op OA chondrocyten in vergelijking met normale chondrocyten. Samengevat laten we zien dat S100 vooral op 
chondrocyten van OA patiënten ontstekingsbevorderende (pro-inflammatoire) 
en kraakbeenafbrekende (catabole) effecten heeft.
Het synovium bevat verschillende typen cellen. Bindweefselcellen (=fibroblasten) zitten voornamelijk in de diepere lagen en hebben een relatief lage activiteit. 
Macrofagen, belangrijke cellen van het aspecifieke immuunsysteem, bevinden zich voornamelijk in de binnenste laag van het synovium, grenzend aan de holte en in direct contact met de synoviale vloeistof waarin (ontstekings)mediatoren worden uitgescheiden die kraakbeen en bot kunnen beïnvloeden. Macrofagen 
kunnen worden onderverdeeld in pro- en anti-inflammatoire subtypes genaamd M1- en M2-macrofagen. In hoofdstuk 5 onderzochten we de effecten van S100 stimulatie op intact synovium van OA patiënten en de verschillende celtypen die daarin voorkomen. Eerst stimuleerden we kleine synovium biopten, met S100A8 
en S100A9. Net als bij de chondrocyten, werden ook hier pro-inflammatoire 
cytokines zoals IL-1β, -6 en -8 en catabole MMPs duidelijk verhoogd. S100 had 
echter geen effecten op fibroblasten uit dit OA synovium. Stimulatie van zowel de 
pro- als de anti-inflammatoire M1- en M2-macrofagen met S100 zorgde wél voor 
een toename van pro-inflammatoire cytokines. Uit hoofdstuk 4 en 5 concluderen we dat S100, in grote mate aanwezig tijdens synoviale ontsteking, een pro-
inflammatoir en catabool milieu kan stimuleren in het gewricht tijdens OA.
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S100-remmer paquinimod vermindert OA-schade in de muis
In de laatste drie hoofdstukken hebben we ons gefocust op het remmen van synoviale ontsteking tijdens OA in de muis, als modelsysteem voor de mens. 
In hoofdstuk 6 hebben we gebruik gemaakt van paquinimod, een specifieke remmer van S100A9. Deze stof is eerder met succes getest in muismodellen van verschillende immuunziekten en is bovendien in een aantal kleine patiënten-studies veilig gebleken voor de mens. Wanneer we paquinimod enkele dagen 
voor de inductie van CIOA toedienden aan de muizen, zagen we significante verlagingen van de synoviale ontsteking, osteofyt-grootte en kraakbeenschade na 42 dagen. Paquinimod behandeling van het DMM model, met een lage ontstekingsgraad van het synovium, leverde nagenoeg geen verbetering in de OA ontwikkeling op. Vervolgens lieten we zien dat paquinimod duidelijk pro-
inflammatoire en catabole effecten van S100 op synovium van OA patiënten blokkeerde. Deze resultaten, samen met het feit dat paquinimod tot nu toe nauwelijks bijwerkingen heeft laten zien in patiënten trials, levert een mogelijk interessante therapeutische optie voor OA patiënten met aanzienlijke synoviale ontsteking.
Vetstamcellen verlagen ontsteking en S100 en daarmee OA-schade in de 
muis
In hoofdstukken 7 en 8 tenslotte, hebben we synoviale ontsteking verlaagd door het gebruik van adipose mesenchymale stamcellen (ASCs), stamcellen 
die afkomstig zijn uit vetweefsel. Van deze cellen is bekend dat ze naast de mogelijkheid tot het ontwikkelen naar chondrocyten, vetcellen en botcellen, ook 
potente anti-inflammatoire eigenschappen hebben. ASCs kunnen een scala aan 
anti-inflammatoire mediatoren produceren en zijn al gebruikt in verschillende (auto)immuunziekten. Wanneer we ASCs vroeg na inductie van CIOA lokaal in 
de knie injecteerden, zagen we significant gereduceerde synoviale ontsteking, osteofyt vorming en kraakbeenschade na 42 dagen. Diepgaandere analyse van de moleculaire effecten van ASCs in het synovium, toonden aan dat een lokale 
behandeling met deze cellen al na 6 uur pro-inflammatoire cytokines zoals 
IL-1β en DAMPs S100 verlaagden. Daarna injecteerden we stamcellen in OA muismodellen met verschillende gradaties van synoviale ontsteking en vonden 
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dat ASCs effectiever waren met toenemende ontsteking. Tenslotte vonden we dat S100 spiegels in het bloed na lokale behandeling van het CIOA kniegewricht met ASCs sterk werd verlaagd, hetgeen er op duidt dat bloedspiegels van S100 een succesvolle behandeling weerspiegelen. 
Eindconclusie
In dit proefschrift hebben we aangetoond dat synoviale ontsteking en de resulterende S100 productie essentieel zijn bij de ontwikkeling van kraakbeenschade en osteofyt-vorming tijdens OA. Verder laten veelbelovende data in OA muismodellen zien dat het blokkeren van synoviale ontsteking met 
behulp van anti-inflammatoire adipose stamcellen of met paquinimod (daarbij S100 blokkerend) zeer interessante toekomstige opties zijn voor de behandeling van OA gekenmerkt door veel ontsteking.
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Dankwoord
Dit proefschrift is mede mogelijk gemaakt door:
Peter van Lent. Zonder twijfel ben jij degene aan wie ik de meeste dank verschuldigd ben. Al vanaf het sollicitatiegesprek had ik een goed gevoel bij onze samenwerking en dat was volgens mij wederzijds. Peter, bedankt voor 
de kans die je me geboden hebt, je onaflatende enthousiasme en onmisbare 
wetenschappelijke input. Maar ook voor de gezellige tijden bij de koffie en lunch, in Münster en bij diverse congressen!
Wim. Je gaf me bij de eerste werkbespreking de bijnaam “de jonge Peter van Lent” en sprak meteen je vertrouwen uit over mijn promotie. Bedankt dat ik bij de geoliede machine genaamd Lab Reuma mijn promotie kon behalen en voor de verhelderende inzichten tijdens gezamenlijk overleg. 
Peter van der Kraan. Als co-promoter bedankt voor je goede en kritische inzichten met betrekking tot artrose en osteofyten, maar ook de introducties bij de OARSI meetings en je goede gezelschap bij de Nancy-meeting. Ik kom je vast nog tegen in Oss!
Lab Reuma. Vooraleer ik specifiek collega’s ga bedanken, wil ik eerst de afdeling Experimentele Reumatologie als geheel bedanken voor een geweldige 5,5 jaar, zowel professioneel maar zeker ook sociaal. Ik herinner me talloze geslaagde 
dagjes uit, filmavonden/nachten, spellenavonden, kerstvieringen, borrels… Een geweldige club mensen, het is niet voor niks dat zovelen er lang blijven plakken! 
Annet. Jij was en bent de moedergans in groepje 4 die alle AIO-kuikentjes onder haar hoede neemt, zo ook mij. Zowel praktisch als sociaal kon ik altijd bij je terecht. Zonder jou had ik de promotie niet af kunnen ronden! Ik ben daarom ook super trots dat je straks naast me staat bij de verdediging. 
Wouter de Munter. Bedankt voor je altijd relativerende kijk op de zaken, je hulp bij experimenten en de lol en gezelligheid bij borrels, concertjes en natuurlijk in New York!
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Martijn. Soms was het moeilijk om uit een gesprek met jou te komen, maar dat was zelden een straf. Het ging over goede wetenschappelijke twistpunten, of over de poëzie van de Jeugd van Tegenwoordig. Ik ga de RNAse Fr(i)(ee)day missen!
Wouter Hofkens. Ik heb een goede en gezellige tijd met je gehad samen in U-tje 8, maar ook daarbuiten op bijvoorbeeld Pinkpop en bezoekjes in Sittard. Ik was ook bijzonder vereerd je paranimf te mogen zijn bij de beste verdediging die ik gezien heb (hoewel ik misschien  bevooroordeeld was). Ik hoop je in de toekomst nog vaker te blijven spreken, nu als collega’s bij de hogeschool!
Menno. Naast de soms vermaledijde stamcel en S100, ging het uiteraard vaak 
over voetbal. En niet alleen in U8, maar ook bij de Aesculaaf of de Shamrock. Ik vind het van veel moed getuigen dat je gestopt bent bij reumatologie en vol vertrouwen weer opnieuw als AIO bent gestart bij moleculaire biologie. Succes met je promotie daar!
Arjen. Als relativist en realist van onschatbare waarde voor groepje 4. Ik heb veel aan je gehad, als vraagbaak, hulp bij experimenten, maar ook in gesprekken 
over bijvoorbeeld film en kunst. En ik heb me ontelbare keren verkneukeld aan 
je droge humor, aan de koffietafel of op congres.
Edwin, Stephanie, Irene, Giuliana, Lilyanne. Also you guys (uh, mostly girls) have helped shape the successful and enjoyable atmosphere in group 4. With some Italian class and Brabantse and Achterhoekse energy. Irene, Stephanie, Giuliana: good luck on your own thesis! Edwin: Ik vond het de laatste periode 
zeer prettig samenwerken in U-tje 9, ik heb er vertrouwen in dat je het Ly6C-project naar een hoger plan gaat tillen!
Ben, Renoud. Jullie hebben me destijds wegwijs gemaakt in de wondere wereld van het AIO-schap, op het lab en ver daarbuiten. De Aesculaaf-avonden waren onvergetelijk! Ben: super te zien hoe je het naar je zin hebt bij Saxion en in 
Enschede. Fijn dat ik eens mocht meekijken daar. Renoud: ik was vereerd je bruiloft in de hemel mee te mogen maken en volgens mij is de baan bij Triskelion helemaal op jouw lijf geschreven. 
Richard. Bedankt voor je flexibiliteit op het lab, je stond altijd klaar voor mij en andere AIOs, al was het tot 9 uur ’s avonds. Ik heb veel van je geleerd over Luminex 
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en andere technieken. Alleen jammer dat je zo weinig verstand van voetbal hebt. Ik hoop dat we in de toekomst nog regelmatig gezellig kunnen bijkletsen met een biertje en dat de PSV-vloek voorbij is, nu ik bij Lab Reuma weg ben.
Kim, Mark, Lenny, Tamara, Marta. Collega AIOs van The Human Side, bedankt voor jullie ondersteuning, medische kijk op zaken én gezelligheid als de lichten aan de andere kant uitgingen. Marta, amongst many things, I have always admired your strive for perfection and perseverance. I wish you all the best!
Arjan, Mathijs, Laurie, Wojciech, Debbie, Tom. Als mede AIOs, bedankt voor de goede sfeer, tijdens een goed robbertje Agricola, kwatsend in het Limburgs, dakterrassen schoonmakend, Wolcott-style in New York of onder het genot van een Nespressootje of Tripel Karmeliet.
Marianne. Onmisbaar voor alle administratieve zaken, maar ook in gesprekken over mooie vakantie- en skioorden!
Fons, Marije, Shahla, Esmeralda. Bedankt voor jullie scherpzinnige en nuttige inbreng tijdens werkbesprekingen en discussies.
Liduine. Mijn 15 december buddy! Hopelijk ben je er ook bij op je verjaardag. 
Bedankt voor je goede gesprekken over vakanties, koffie, Vierdaagse en muziek.
Monique, Birgitte. Als koninginnen van het muizenwerk (en meer!) zijn jullie onmisbaar voor een groot aantal artikelen geweest. Super bedankt!
Onno, Miranda, Elly, Henk, Silke, Alsya, Dennis, Eline, Marieke, Jeroen, 
Bartijn, Claire, Bas, Sharon, Jasper, Tim, Judith. Ook jullie allemaal hartelijk bedankt voor de wetenschappelijke hulp en gezellige tijd.
Suzanne, Hanneke, Iris, Terry. Bedankt voor jullie inzet als stagiaires. Hoofdstuk 5 is hiervan het mooie resultaat.
Muizen, CDL-medewerkers. Zonder de hulp van het team van het Centraal Dieren Laboratorium én de muizen zelf was dit proefschrift nooit tot stand gekomen. Voor de dieren helaas met een hoge prijs.
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Thomas, Johannes. All the S100-work wouldn’t have been possible without all the help from you. I have thoroughly enjoyed your hospitality on my visits to Münster as well!
Sander. Als mede kraakbeen-fetisjist ben ik blij en trots dat jij aan mijn zijde staat zometeen, mocht ik écht hulp bij de verdediging nodig hebben.  Maar bovenal als vriend.
Kim, Jeroen, Guido, Linda, Louis, Debby, Maarten, Gijs, Josine. “How am I supposed to live without you”, zongen we veelvuldig op de Singstar avonden en inderdaad, waar zou ik zijn zonder jullie? Niet op Lowlands of op de skihelling in ieder geval. Bedankt voor alle gezelligheid, speciaalbiertjes, spelletjesavonden en oprechte interesse!
Pubquiz Café Beij Ons / De Nieuwe Maan. Dinsdagavond, voor de broodnodige ontspanning: pubquiz! Vaak in kernteam Weurt Up!, maar de reuma-teams 
Macrovaag en Joint Effort, met Arjan als inspirator, mogen ook niet onvermeld gaan. Voor de kennis die verder reikt dan welke liganden aan TLR-4 binden.
Kielpen. In de categorie Soort Vrienden mogen deze gezellige Limburgers niet ontbreken. Een rijke historie die ver terug gaat (soms tot aan het voetbalveldje aan ’t Roermonds Kwartier aan toe) en nog ver gaat reiken. Bedankt voor jullie geduld, begrip en morele steun bij de eindfase. En helaas jongens, in dit boekje staat niet vermeld wat er achter de navel zit.
Peetoom Ger en peettante Henny. Bedankt voor jullie oprechte interesse, ook al was het soms moeilijk te volgen waar ik nu weer voor aan het ‘studeren’ was.
Opa en Oma. Ik hoop dat jullie van de ceremonie genieten. Ik ben super trots dat jullie dit in zo’n gezondheid nog mee mogen maken.
Pap. “Papa, ik lijk steeds meer op jou…” Naast heel veel andere dingen, heb ik van jou de gezonde ambitie gekregen om door te leren en er uit te halen wat er in zit. En ik ben best wel trots wat ik daarmee heb bereikt. Zonder jouw onvoorwaardelijke steun en vertrouwen was ik nooit zover gekomen. Bedankt voor de geweldige springplank en het reddingsvest toen ik dreigde te verdrinken.
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Mam. Leeve mooder. De liefde voor alles wat leeft komt niet van een vreemde en hebben me de biologie in gestuurd. Niet richting de planten en dieren, maar wie weet waar mijn hogeschool carrière me nog brengt. Bedankt voor je enthousiasme, genegenheid, steun en het bieden van een onvoorwaardelijk “thuis”.
Rebecca. En toen was daar de EWRR in Lissabon, waar de vonk definitief oversloeg. Een onvergetelijk congres. Onze weg samen is nog kort, maar wat voelt het al vertrouwd! En ik kan niet wachten om te zien naar welke prachtige 
plekken (letterlijk en figuurlijk) deze weg ons gaat leiden. Je geeft me vrijheid, je geeft me rust. Ik hou van je.
